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Bacille Calmette-Guerin (BCG), the only currently available tuberculosis vaccine, is 
the most widely administered vaccine in the Expanded Programme on Immunisation 
(EPI). Despite this, many gaps in our knowledge of BCG-induced T cell responses 
exist. The primary objective of this study was to comprehensively delineate T cell 
immunity induced by BCG vaccination of newborns and to longitudinally assess 
BCG-specific T cell responses over the first year of life. Comprehensive analysis of 
BCG-specific immunity is needed to guide future, novel vaccination strategies 
against tuberculosis, which may involve a modified BCG prime at birth, and specific 
boost vaccines within the time frames of the EPI. 
Several novel polychromatic flow cytometry reagent panels were designed and 
optimised to analyse specific components of BCG-specific T cell responses. A novel 
whole blood proliferation assay that utilises Ki67 as a marker of antigen-specific in 
vitro lymphoproliferation was also optimised.  
Cross-sectional examination of BCG-specific T cell cytokine expression and memory 
phenotypes from 10-14 week old infants showed that BCG vaccination induces 
distinct T cell subsets that predominantly express Th1 cytokines in multiple 
combinations. Th1 cytokine expressing cells predominantly expressed an effector 
memory phenotype, which may reflect persistence of BCG.  
Longitudinal changes in T cell turnover kinetics, expression of cytotoxic molecules 
and differentiation phenotypes by BCG-specific T cells were examined. BCG-specific 
T cell responses peaked 6 weeks after vaccination and gradually waned over the first 
year of life. Moreover, these specific T cells progressively differentiated towards 
more mature phenotypes over time. These T cell functions were also measured 
directly ex vivo, which showed marked alterations in cytotoxic molecule expression 
and T cell differentiation phenotypes.  
The results suggest that low-level antigen exposure, probably through persistence of 
BCG, or exposure to cross-reactive mycobacteria, results in continuous activation 
and differentiation of specific T cells over the first year of life. Taken together, these 
data and the kinetics of the BCG-induced T cell response suggest that boosting of 
BCG-primed T cells with heterologous tuberculosis vaccines may be ideal after 14 
weeks of age. Our findings therefore have important implications for novel 
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Chapter 1 
Introduction and literature review 
1.1. Introduction 
Nearly one third of the global population is estimated to be infected with 
Mycobacterium tuberculosis (M.tb), the causative agent of tuberculosis (TB) 
disease (Dye et al., 1999). Of the 22 countries with the highest estimated TB 
incidence rates per capita, South Africa is second and in 2007 the Western 
Cape alone had an incidence of 948 TB cases per 100 000 people (Western 
Cape Department of Health, 2007; WHO, 2009). TB case numbers are 
increasing due to the HIV pandemic, the emergence of multi-drug resistant TB 
strains and the variable efficacy of M. bovis bacille Calmette-Guérin (BCG), 
the only licensed TB vaccine currently available. The need for a more 
efficacious TB vaccine or improvement of BCG is urgent.  
M.tb is commonly transmitted through close contact with an individual with 
cavitary pulmonary disease, the most common form of TB disease in adults. 
Unfortunately, BCG is not effective at preventing pulmonary disease in adults 
and therefore has minimal impact on global TB burden. A more efficacious TB 
vaccine or novel vaccination strategies to improve the protective efficacy of 
BCG against pulmonary disease is required to reduce disease transmission. 
Although TB is primarily a pulmonary disease in adults, disseminated TB and 
TB meningitis contributes significantly to TB-related mortality and morbidity of 
children under 5 years of age (Marais et al., 2004). BCG significantly reduces 
the risk of these forms of disease in infants, has a good safety record in 
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1). Because of this, the current BCG vaccine is likely to remain the 
cornerstone of novel vaccination strategies against M.tb (McShane et al., 
2004; Doherty and Andersen 2005; Grode 2005).  
 
 
Figure 1. Global immunisation coverage with BCG at birth, 2009. (WHO/UNICEF, 
1980-2009) 
 
Boosting the BCG-primed response with a novel vaccine is the most common 
strategy aimed at enhancing vaccine-mediated protective efficacy (McShane, 
2005; Lambert et al., 2009; Kaufmann et al., 2010). Despite this, 
comprehensive knowledge of T cell subsets, cytokines and cytotoxic 
molecules that contribute to BCG-specific immunity remains limited 
(Hanekom, 2005). In addition, longitudinal changes in T cell responses 
following primary immunisation of infants with BCG remains unknown. 
Comprehensive understanding of the human host response to BCG is 
essential for measuring immunogenicity and longevity of immune responses 
conferred by novel TB vaccine candidates and for the rational design of new 
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1.2. The immune response to M.tb 
M.tb is acquired through the inhalation of aerosol droplets containing infective 
bacilli when an individual with cavitary pulmonary TB expels infectious aerosol 
droplets by coughing. The body’s first line of defense against M.tb are cells of 
the innate immune system. Once bacilli are inhaled, lung-resident alveolar 
macrophages (Mø), the primary cells involved in the initial uptake of M.tb, and 
immature dendritic cells (DC) in the lung, phagocytose the bacteria (Figure 2) 
(Schlesinger 1993; Schlesinger et al., 1996; Henderson et al., 1997). 
Recognition and phagocytosis of M.tb is mediated via pattern recognition 
receptors (PRR), which recognise pathogen-associated molecular patterns 
(PAMP) of the bacilli (Janeway and Medzhitov, 1998; Aderem and Ulevitch, 
2000). PRRs associated with the recognition and phagocytosis of M.tb include 
complement receptors, scavenger receptors, Toll-like receptors and NOD-like 
receptors (Schlesinger et al., 1996; Ernst 1998; Ferwerda et al., 2005; 
Thoma-Uszynski et al., 2001; Krutzik and Modlin 2004). At this point, bacilli 
may be killed, or may evade host defense mechanisms and begin to multiply 
(Clemens and Horwitz 1995; Loeuillet et al., 2006). Mycobacteria evade host 
defense mechanisms by preventing the maturation of phagosomes that 
contain bacilli, inhibiting the recognition of infected cells by T cells and 
inhibiting Mø killing mechanisms, such as those mediated by reactive nitrogen 
intermediates (RNI) and reactive oxygen intermediates (ROI) (Hmama et al., 
1998; Ruan et al., 1999; Clemens et al., 2000; Noss et al., 2000; Fratti et al., 
2001). Recognition and uptake of bacilli by phagocytic cells trigger the 
expression of chemokines and pro-inflammatory cytokines necessary for the 
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Figure 2. The immune response to M.tb (Hanekom et al., 2007). In the lung M.tb 
bacilli are phagocytosed by DC and Mø. Activated DC migrate to the lymph nodes 
(LN) and prime naïve T cells, which differentiate into effector T cells and undergo 
clonal expansion. Antigen-specific T cells traffic to the lung and activate Mø 
mycobacterial killing mechanisms. Activated Mø express pro-inflammatory cytokines 
and chemokines, which leads to the continuous recruitment of T cells and 
mononuclear cells to the lung, resulting in granuloma formation and containment of 
the pathogen. Breakdown of protective immunity leads to granuloma failure followed 
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DC play a key role in the initiation of adaptive immune responses. DC are 
professional antigen presenting cells, which form the primary link between 
innate and adaptive immunity (Mempel et al., 2004). Once activated through 
pathogen-associated products and danger signals provided by inflammatory 
cytokines, DC begin to mature and process the pathogen into antigenic 
peptides, which are loaded onto major histocompatibility complex (MHC) 
molecules. Simultaneously, DC acquire migratory properties and traffic 
towards lymph nodes to prime naïve T cells (Figure 2) (Schuler and Steinman 
1985; Kripke et al., 1990; Pure et al., 1990; Moll et al., 1993; MacPherson et 
al., 1995; Sozzani et al., 1998). Maturation of DC is also associated with 
reduced antigen capture activity and enhanced capacity to activate T cells 
through the up-regulation of MHC, co-stimulatory and adhesion molecules 
(Viola and Lanzavecchia 1996; Winzler et al., 1997; Rescigno et al., 1997).  
In the lymph node fully mature DC prime naïve T cells by: 1) triggering the T-
cell receptor (TCR) via pathogen-derived antigenic peptides bound to MHC 
molecules (signal 1); 2) providing co-stimulatory signals, for example through 
B7-1 (CD80) and B7-2 (CD86), which interact with CD28 on the T cell (signal 
2) and 3) through the expression of pro-inflammatory cytokines (signal 3) 
(Harding et al., 1992; Curtsinger et al., 1999).  
Two main subsets of T lymphocytes have been described according to the 
expression of co-receptors CD4 and CD8, which contribute to signal 
transduction during antigen recognition (Turka et al., 1991; Julius et al., 1993). 
Exogenously derived antigens, such as M.tb products from the endosome, are 
presented on MHC class II (MHC II) molecules to T cells expressing the CD4 
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(MHC I) molecules for the priming of CD8+ T cells (Bachmann et al., 1996). 
Once activated, T cells undergo clonal expansion and differentiate into 
functionally distinct lineages. Cytokines expressed by DC during priming drive 
the polarisation of naïve helper T (Th) cells into these distinct lineages, which 
were defined primarily according to cytokine expression and function 
(Macatonia et al., 1995). Once differentiated, effector T cells leave the lymph 
nodes to carry out their function at the site of infection, the lung (Mempel et 
al., 2004). In experimental TB models, specific T cells are detected in the lung 
approximately 3 weeks after initial aerosol challenge with M.tb (Gallegos et 
al., 2008; Wolf et al., 2008). Wolf et al. suggest that M.tb may delay the 
initiation of adaptive immune responses to evade host immune effector 
mechanisms. Delaying recruitment of antigen-specific T cells to the site of 
infection allows for bacterial growth to occur and facilitates establishment of a 
chronic infection (Wolf et al., 2008).  
Persistence of M.tb bacilli within Mø, continuous expression of pro-
inflammatory cytokines and chemokines leads to the recruitment and 
accumulation of Mø, T cells and B cells to the site of infection. This localised 
pro-inflammatory response and aggregation of cells into specific architectural 
structures results in the formation of a granuloma, the hallmark of M.tb 
infection (Figure 2). Recruited M.tb-specific T cells participate in granuloma 
formation by activating Mø anti-microbial mechanisms through the production 
of cytokines. T cells also lyse M.tb infected Mø and extracellular bacilli by 
releasing cytotoxic molecules (Ottenhoff and Mutis 1990; Bonecini-Almeida et 
al., 1998; Saunders et al., 2002; Stegelmann et al., 2005). Within the 
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contained resulting in latent infection. Of individuals infected with M.tb 90% 
are able to contain the infection throughout their lifetime. Latently infected 
individuals are immunologically sensitised to M.tb-specific antigens but do not 
display any clinical symptoms of active disease (Brock et al., 2004; Pai et al., 
2008). Latent infection may be determined by using in vitro tests that measure 
T cell interferon (IFN)-γ release in response to M.tb-specific antigens such as 
early secretory antigenic target (ESAT)-6 and culture filtrate protein (CFP)-10 
(Brock et al., 2004; Lee et al., 2006; Mahomed et al., 2006; Connell et al., 
2008). Sensitisation may also be determined by measuring skin induration 
caused by delayed type hypersensitivity in response to purified protein 
derivative (PPD) (Connell et al., 2008). The major disadvantage of the skin 
test (TST) is that it cannot differentiate between T cell responses primed by 
non-pathogenic mycobacteria or M.tb because PPD contains antigens that 
are present in both.  
Of latently infected individuals, less than 10% will develop active disease 
during their lifetime. The factors that lead to reactivation of disease are not 
well defined. However if critical immune regulators required for granuloma 
maintenance, such as tumour necrosis factor (TNF)-α, or if adaptive immune 
responses are compromised, the risk of developing active disease increases 
significantly (Wallace et al., 1997; Keane et al., 2001; Elliott et al., 2004). 
Although latent infection and active disease are described as a single 
condition according to clinical definitions, M.tb infection is likely to represent a 
broad spectrum of in vivo characteristics based on new information of diverse 
granuloma morphology, bacterial load and the metabolic state of bacteria 
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bacteria multiply and granulomas become caeseous facilitating dissemination 
of bacilli (Figure 2) (Fayyazi et al., 2000). At this point the individual becomes 
actively infectious and the cycle begins again. 
 
1.3. The role of CD4+ and CD8+ T cells  
Recruitment of mycobacteria-specific T cells to the site of infection and 
activation of Mø is critical for effective containment of M.tb within granulomas 
(Kaufmann, 2001). M.tb reside predominantly in vacuoles within alveolar Mø 
and survive by inhibiting phagosome maturation and acidification (Frehel et 
al., 1986; Sturgill-Koszycki et al., 1994). Infected Mø are unable to efficiently 
kill bacilli unless activated by effector molecules expressed by activated T 
cells. Multiple lines of evidence from murine and human studies suggest that 
both CD4+ and CD8+ T cells play roles in the adequate containment of M.tb 
as discussed below.  
 
1.3.1. CD4+ T cells 
The contribution of CD4+ T cells to the protective immune response during 
M.tb infection has been well described in humans and in experimental animal 
models of infection (Flynn, 2001; Kaufmann, 2005b). Intravenous challenge of 
mice deficient in MHC II or CD4+ T cells with M.tb leads to significantly 
increased bacterial loads in the lung, spleen and liver, compared with wild-
type controls (Caruso et al., 1999; Saunders et al., 2002). In addition, 
activation of Mø mycobactericidal mechanisms, cytokine production and 
granuloma formation is delayed in these mice (Caruso et al., 1999; Saunders 
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Studies in healthy, latently infected individuals have demonstrated that 
antigen-specific CD4+ T cells are recruited to the lung and participate in 
localised immune responses to mycobacteria-specific antigens (Silver et al., 
2003). Silver et al. instilled a crude mycobacterial antigen, M.tb PPD, via 
bronchoscopic challenge into sub-segmental bronchi of healthy infected 
individuals. Instillation of PPD induced a localised immune response, which 
was compared to saline challenged bronchi segments within the same 
individual. The number of CD4+ T cells increased significantly in challenged 
bronchi segments, and when evaluated in vitro by enzyme linked immunospot 
(ELISpot), these cells expressed IFN-γ in response to mycobacteria-specific 
antigens. In addition to cytokine expression, CD4+ T cells also have the 
capacity to express cytotoxic molecules, which inhibit M.tb growth in vitro. 
CD4+ T cells that express cytotoxic molecules are detectable in healthy TST-
positive individuals and TB patients (Tan et al., 1997; Lalvani et al., 1998a; 
Canaday et al., 2001; Bastian et al., 2008).  
The important role of CD4+ T cells in mycobacteria-specific immunity in 
humans has further been highlighted in human immunodeficiency virus 
(HIV)/TB co-infected individuals (Wallace et al., 1997; Elliott et al., 2004). HIV-
infected persons have a 10% annual risk of developing active TB disease 
compared with a 10% lifetime risk in healthy controls (Selwyn et al., 1989; 
Raviglione et al., 1997; Aaron et al., 2004). In addition, the progressive loss of 
CD4+ T cells during HIV infection is associated with an increased incidence of 
active TB (Markowitz et al., 1997), suggesting that CD4+ T cells play a 
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These findings highlight the essential role CD4+ T cells in mediating M.tb 
protective immunity through their capacity to express key Th1 cytokines that 
promote Mø activation, granuloma formation and maintanence. 
 
1.3.2. CD8+ T cells 
The key functional characteristics of CD8+ T cells that contribute to effective 
M.tb immunity include their capacity to secrete Th1 cytokines, and capacity to 
secrete cytotoxic molecules that mediate lysis of infected target cells 
(Woodworth and Behar, 2006). Although M.tb bacilli reside mainly within Mø 
vacuoles and are thought not to transverse into the cytosol, CD8+ T cell 
responses against mycobacteria-specific antigens have been reported 
(Grotzke and Lewinsohn, 2005). Priming of mycobacteria-specific CD8+ T 
cells occurs through mechanisms of cross-presentation and cross-priming in 
which exogenously derived antigens are loaded onto MHC I molecules 
(Kaufmann and Schaible, 2005; Kaufmann, 2005a; Winau et al., 2006). The 
process of cross-priming requires apoptosis of M.tb infected Mø, which 
release apoptotic blebs containing M.tb derived antigens (Winau et al., 2006). 
Once apoptotic blebs are taken up by bystander DC, antigens transverse into 
the cytosol and are broken down into peptides by proteasomes (Werner et al., 
1996; Wiertz et al., 1996; Pilon et al., 1997). Peptides are translocated into 
the lumen of the endoplasmic reticulum (ER) by transporter associated with 
antigen processing (TAP) and bind to MHC I (Flutter and Gao, 2004). 
Recently, murine studies have shown that cross-priming and activation of 
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Experimental models have shown that CD8+ T cells contribute to control of 
M.tb and participate in long-term containment of the pathogen (Flynn et al., 
1992; Silva et al., 1994; Caruso et al., 1999; Lazarevic et al., 2005; Carranza 
et al., 2006). Lazaveric et al. demonstrated that CD8+ T cells contribute 
substantially to IFN-γ production over the chronic phase of M.tb infection in 
mice. Interestingly, the expression of CD8 effector molecules changed during 
the course of infection. Initially, CD8+ T cells expressed cytotoxic molecules 
but switched to IFN-γ expression as the infection progressed (Lazarevic et al., 
2005). The authors’ hypothesis was that the change in CD8+ T cell effector 
function could possibly be attributed to antigenic load during the course of 
infection.  
CD8+ T cells which recognise M.tb specific ESAT-6 and antigen 85 protein A 
(Ag85A) have been described in human studies (Lalvani et al., 1998; 
Caccamo et al., 2006). Lalvani et al. detected ESAT-6 specific human 
leukocyte antigen (HLA) class I restricted CD8+ T cells in patients with TB. 
ESAT-6 specific CD8+ T cells were capable of IFN-γ production and cytolytic 
activity against infected Mø (Lalvani et al., 1998b). Using MHC pentamers, 
Caccamo et al. detected Ag85A-specific CD8+ T cells in children with TB 
(Caccamo et al., 2006). These Ag85A-specific CD8+ T cells were capable of 
IFN-γ production and perforin expression when stimulated with mycobacteria-
specific antigens.  
These data demonstrate that CD8+ T cells contribute to the immune control of 
M.tb and inducing this subset through vaccination may contribute significantly 
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1.3.3. Non-classical T cell subsets 
This project focuses on conventional CD4+ and CD8+ T cells, however non-
classical T cells such as γδ T cells and CD1 restricted αβ T cells also 
contribute to antimicrobial immunity. 
γδ T cells reside predominantly in epithelial surfaces and are likely to play an 
important role in the initial interaction between host and pathogen. These T 
cells are characterised by a unique TCR comprising a γ  and δ chain and do 
not respond to peptide antigens presented by MHC I or II (Xiong and Raulet, 
2007). A major subset of human γδ T cells express the Vγ9Vδ2 TCR, which 
expand in response to viral and bacterial infections (Havlir et al., 1991; 
Dechanet et al., 1999; Ottones et al., 2000; Poccia et al., 2005). Vγ9Vδ2 T 
cells recognise non-peptide intermediates in the isoprenoid biosynthesis 
pathway. Isoprenoids are molecules that play a role in the cellular metabolism 
of pathogenic bacteria, including M.tb (Eberl et al., 2003; Morita et al., 2007).  
In humans, exposure to mycobacteria-specific antigens either through M.tb 
infection or BCG vaccination leads to the expansion of Vγ9Vδ2 T cells (Havlir 
et al., 1991; Li et al., 1996; Hoft et al., 1998; Shen et al., 2002). Mycobacteria-
specific Vγ9Vδ2 T cells express IFN-γ and target intracellular and extracellular 
bacilli through the expression of cytotoxic molecules such as granulysin 
(Tsukaguchi et al., 1995; Dieli et al., 2001; Worku and Hoft, 2003). 
Importantly, γδ T cells develop a memory-like response and may therefore 
contribute to rapid recall responses at the site of infection (Hoft et al., 1998; 
Shen et al., 2002). In the rhesus monkey, primary immunisation with BCG 
leads to the expansion of Vγ9Vδ2 T cells and accumulation of these cells in 
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mount a rapid recall response after secondary BCG infection and confer 
protective immunity against lethal M.tb challenge (Shen et al., 2002). 
Human and experimental data also support a role for CD-1 restricted T cells in 
the immune response to M.tb. CD1 is a MHC-like molecule that associates 
with β2 -microglobulin and is expressed on DC and monocytes (Zeng et al., 
1997). Five CD1 genes have been identified in humans that encode a family 
of distinct CD1 proteins classified into three groups. Group 1 CD1 molecules 
(CD1a, CD1b and CD1c) present microbial lipid antigens to αβ T cells, while 
the group 2 CD1 molecule, CD1d, presents these antigens to natural killer 
(NK) T cells (Jones et al., 2007). CD1e belongs to group 3, is expressed 
intracellulary and plays a role in CD1b antigen loading (Angenieux et al., 
2005; de la Salle et al., 2005). CD1 molecules bind and present lipid and 
glycolipid antigens derived from M.tb cell membrane components including 
mannosylated lipoarabinomannan, mycolic acids and phosphatidyl 
inositolmannosides (Sieling et al., 1995; de la Salle et al., 2005; Kaufmann 
and Schaible, 2005). In guinea pigs, immunisation with mycobacterial lipids 
induces specific and long-lived CD-1 dependent T cells, which contribute to 
protective immunity (Hiromatsu et al., 2002; Dascher et al., 2003). 
Mycobacteria-specific CD1-restricted T cells are detectable in BCG-
vaccinated and healthy TST reactive donors (Stenger et al., 1998; Ulrichs et 
al., 2003). These cells secrete Th1 cytokines and express cytotoxic molecules 
in response to mycobacterial lipids (Fischer et al., 2004; Stenger et al., 1998; 
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1.4. Helper T cell differentiation  
As described earlier, Th cells differentiate into specific lineages during clonal 
expansion of naïve T cells after primary antigenic stimulation by DC. The 
specific lineages were classified according to cytokine expression. It is 
critically important that the appropriate T cell lineage is primed and expanded 
in response to a given pathogen to successfully contain the infection.  
The polarisation of naïve T cells towards a specific functional profile is 
influenced by a number of factors including co-stimulatory signals, antigen 
dose and the cytokine milieu during priming (Constant et al., 1995; Hosken et 
al., 1995; Kuchroo et al., 1995; O'Garra and Murphy 1996). Cytokines present 
during priming are thought to be the most important regulators of T cell 
polarisation. Cytokines in combination with TCR engagement activate 
signalling pathways and master transcription factors unique to each lineage 
which in turn bind and initiate transcription of specific cytokine gene promoters 
(Jacobson et al., 1995; Kaplan et al., 1996; Lederer et al., 1996; Thierfelder et 
al., 1996; Szabo et al., 2000; Murphy and Reiner 2002).  
The identification of T cell lineages based on expression of signature 
cytokines and function was first described in 1986 by Mosmann and 
colleagues. Initially two subsets of antigen-specific murine Th clones were 
defined, which they designated Th1 and Th2 (Mosmann et al., 1986). Th1 
cells are characterised by the production of IFN-γ, but these cells also 
express interleukin (IL)-2 and lymphotoxin (Lt)-α. Th1 cells are associated 
with cell-mediated immunity, promote the activation of cytotoxic T cells (CTL), 
provide protection against intracellular pathogens and mediate delayed type 
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transducer and activator of transcription (STAT)-4 and the master regulator T 
box transcription factor, T-bet, to promote Th1 development (Figure 3) 
(Jacobson et al., 1995; Szabo et al., 2000). T-bet further sensitises cells to 
Th1 polarising cytokines by up-regulating the IL-12 receptor (IL-12R).  
Th2 cells support B-cell differentiation, promote IgG class switching and are 
required for the control of certain parasites, such as helminths (Coffman et al., 
1988; Turner et al., 2003). Activation of STAT6 by IL-4 leads to the induction 
of transcription factors GATA-3 and cMAF, which bind to genes encoding the 
signature Th2 cytokines, IL-4, IL-5 and IL-13 (Figure 3) (Hoet al., 1996; 
Zheng and Flavell 1997; Kim et al., 1999).  
 
 
Figure 3. T helper differentiation and regulation. Master transcription factors and 
cytokines involved in the differentiation of particular Th lineages. Adapted from 
http://www.citeulike.org/blog/Zephyrus/5402  
 
Since their initial description in the 1980s, additional T cell lineages beyond 
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described based on the expression of IL-17 (Yao et al., 1995). This subset 
plays a role in the modulation of autoimmune diseases and protection to 
extracellular bacteria and fungi (Fujino et al., 2003; Park et al., 2005). Th17 
signature cytokines include IL-17A, IL-17F, granulocyte-macrophage colony-
stimulating factor (GM-CSF), IL-21 and IL-22. Th17 differentiation is driven by 
IL-6 and transforming growth factor (TGF)-β in combination with IL-21 and IL-
1β (Mangan et al., 2006; Veldhoen et al., 2006). These cytokines activate 
STAT3, which induces the expression of Th17 master transcription factors 
retinoic-acid-receptor-related orphan receptor (ROR)-γ and ROR-α (Figure 3) 
(Ivanov et al., 2006; Yang et al., 2008). IL-23, a member of the IL-12 family, is 
required for Th17 stabilisation and maintenance (Stritesky et al., 2008).  
Several CD4+ T cell subsets are involved in regulating effector responses. 
Regulatory T cells (Treg) limit pathogenic immune responses to self- and 
foreign-antigens through contact-dependent and independent mechanisms 
(Takahashi et al., 2000; Nakamura et al., 2001; Chen et al., 2003; Roncarolo 
et al., 2006; Wan and Flavell 2008). Several Treg subsets have been 
described according to their origin and mechanisms of suppression. Two 
major classes of Treg are naturally occurring (nTreg) and inducible (iTreg). 
forkhead box (Fox)-P3 expressing nTreg originate from the thymus and 
mediate their suppressive activity through cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4) or membrane-bound TGF-β (Takahashi et al., 2000; 
Nakamura et al., 2001). iTreg develop from conventional T cells and are 
comprised of IL-10-expressing Tr1 cell, TGFβ-expressing Th3 cells and 
inducible FoxP3+ T cells (Hara et al., 2001; Zheng et al., 2002). The 
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absence of inflammatory cytokines, which up-regulate FoxP3 (Figure 3) 
(Chen et al., 2003).  
The cytokines that drive the polarisation of specific Th subsets negatively 
regulate one another and promote their own lineage. For example, IFN-γ and 
IL-12 inhibit GATA-3, while GATA-3 increases Th2 cytokine expression and 
down-regulates IL-12Rβ2 expression, thus inhibiting Th1 development. TGFβ 
blocks Th1 and Th2 differentiation by inhibiting GATA-3 and T-bet, and 
promotes Treg differentiation by up-regulating FoxP3 (Gorelik et al., 2000; 
Gorelik et al., 2002; Chen et al., 2003). However, combined TGFβ and IL-6 
signalling suppresses FoxP3 and promotes the differentiation of Th17 (Chen 
et al., 2003; Bettelli et al., 2006; Zhou et al., 2007).  
 
1.5. Role of cytokines in TB 
1.5.1. Th1 and pro-inflammatory cytokines 
The importance of Th1 cytokines in primary resistance to M.tb is well 
established. Th1 responses are critical for effective immunity against M.tb 
infections partly through their action on Mø (Flynn et al., 1993; Flynn et al., 
1995; Cooper et al., 1997; Ottenhoff et al., 2003; Dorman et al., 2004; van de 
Vosse et al., 2004). Effective control of M.tb bacillary growth is maintained 
through the induction of nitric oxide (NO) and other RNI within infected Mø. 
IFN-γ knockout (KO) mice have undetectable levels of RNI mRNA and high 
bacterial loads. Despite their initial ability to form granulomas, tissue necrosis 
and dissemination of bacteria to major organs is observed 2 weeks post-M.tb 
challenge (Flynn et al., 1993). Similarly, individuals with genetic mutations that 
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susceptibility to severe mycobacterial disease (Newport et al., 1996; Altare et 
al., 1998; Dorman et al., 2004). 
Similar susceptibilities are seen in TNF-α deficient mice. Neutralization of 
TNF-α leads to reduced RNI expression, increased bacillary loads and re-
activation of latent TB infection (Botha and Ryffel, 2003). TNF-α, a pro-
inflammatory cytokine, synergises with IFN-γ to activate Mø and plays a key 
role in granuloma formation (Bekker et al., 2001; Roach et al., 2002). The 
important role of TNF-α mediated immunity in humans has been 
demonstrated in individuals receiving treatment for inflammatory diseases 
(Stenger, 2005; Saliu et al., 2006). For example, blocking of TNF-α with 
cytokine specific inhibitors in patients with Crohns disease or rheumatoid 
arthritis results in the reactivation of latent M.tb infection (Keane et al., 2001; 
Mohan et al., 2004).  
IL-2, although not exclusively associated with Th1 cytokines, is critical for the 
development of memory CD4+ and CD8+ T cell responses (Dooms, 2006; 
Williams et al., 2006). T cells primed in the absence of IL-2 fail to induce an 
effective recall response (Blattman et al., 2003; Dooms et al., 2007). The 
expression of cytotoxic molecules in CD8+ T cells is also regulated by IL-2 
(Janas et al., 2005; Pipkin et al., 2010).  In conditions of weak IL-2 signalling, 
murine CD8+ T cells fail to acquire efficient killing capacity due to a reduction 
in cytotoxic molecule expression (Pipkin et al., 2010). 
 
1.5.2. Th2 cytokines 
In contrast to the important role of Th1 cytokines, a Th2 response may be 










Chapter 1. Introduction and literature review 
 19	  
1999). For example, Th1 responses to mycobacteria-specific antigens are 
down-modulated in individuals with helminth infections, which may be related 
to a Th2 biased immune response induced by parasitic worms (Elias et al., 
2001). Elias et al. demonstrated that de-worming of individuals prior to BCG 
vaccination results in a significant increase in T cell proliferation and IFN-γ 
expression in response to mycobacteria-specific antigens compared to 
infected individuals (Elias et al., 2001).   
Presence of a Th2 response to mycobacteria-specific antigens during latent 
infection also appears to be predictive of risk of TB disease (Ordway et al., 
2004). Significantly higher frequencies of mycobacteria-specific IL-4 
expressing γδ T cells and CD8+ T cells were detected in health care workers 
(HCW) who develop TB compared to HCW who remain healthy. HCW who 
developed TB also have increased levels of IL-5 (Ordway et al., 2004).  
 
1.5.3. Treg cytokines 
Treg are required for homeostatic control of the immune response but may 
also inhibit immune responses that eliminate pathogens (Belkaid et al., 2002; 
Kursar et al., 2007; Scott-Browne et al., 2007). In TB patients, elevated 
frequencies of Treg are found at the site of infection and in peripheral blood 
compared with healthy TST positive controls (Ribeiro-Rodrigues et al., 2006; 
Chen et al., 2007; Garg et al., 2008; Guyot-Revol et al., 2006).  
TGFβ and IL-10 levels are elevated at the site of disease in TB patients 
compared to controls with other lung diseases (Toossi et al., 1995; Bonecini-
Almeida et al., 2004). Treg exert their immunosuppressive functions through 
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al., 2001; Gorelik et al., 2002), which in turn suppress Th1 activity through 
inhibition of IL-12, IFN-γ and proliferation (Fiorentino et al. 1991; Moore et al., 
2001). Therefore, the accumulation of Treg at the site of infection may 
prevent elimination of mycobacteria and contribute to persistence of M.tb. 
 
1.5.4. Other Th cytokines 
Other cytokines that contribute to protective immunity against M.tb include IL-
17 and IL-23. Studies by Khader et al. have shown that protection in mice 
following ESAT-6 vaccination is dependent on the expression of both these 
cytokines. In vaccinated mice, memory Th17 cells accelerated the 
accumulation of protective Th1 cells in the lung through up-regulation of 
chemokines, CXC chemokine ligand (CXCL)-9, CXCL10, and CXCL11 
(Khader et al., 2007). Therefore, the induction of Th17 through vaccination 
may play a critical role in protective efficacy. However, appropriate regulation 
of this subset and timing of response is required to prevent pathogenic cellular 
responses to TB. Cruz and colleagues have shown that repeated vaccination 
of mice with BCG following M.tb infection leads to a significant increase in 
lung pathology due to excessive inflammation. This increased 
immunopathologic response was associated with persistent IL-17 responses 
in the lung (Cruz et al., 2010).  
 
1.6. Cytotoxic T lymphocytes (CTL) 
CTL confer protection against intracellular pathogens through direct lysis of 
infected target cells and the activation of apoptotic pathways. Lysis of infected 
target cells is mediated by two mechanisms: 1) release of cytotoxic granules 
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granzymes (Grm) and 2) through engagement of death receptors, such as 
Fas-Fas ligand (FasL) (Kagi et al., 1994). Studies by Stenger et al. and 
Canaday et al. suggest that the granule exocytosis pathway more efficiently 
eliminates M.tb infected target cells compared with the death receptor 
pathway. For example, blocking Fas-FasL interaction decreases T cell 
cytolytic function by 25%. However, blocking the granule exocytosis pathway 
reduces cytolytic capacity by >90% (Canaday et al., 2001).  
CTL store cytotoxic and cytolytic effector molecules within specialised 
secretory lysosomes. Upon recognition of target cells, CTL direct granules to 
the immunological synapse where lysosomes fuse with the plasma 
membrane. Cytotoxic molecules are then delivered into the target cell and 
induce both caspase-dependent and independent death pathways.  
 
1.6.1. Granulysin 
Granulysin, a member of the saposin-like family of lipid binding proteins, is 
expressed by numerous cellular subsets including NK cells, NK T cells, CD4+ 
and CD8+ T cells (Clayberger and Krensky, 2003). This cytolytic protein has 
broad lytic activity against numerous pathogens including Gram-positive and -
negative bacteria, fungi, and parasites (Stenger et al., 1998; Ochoa et al., 
2001; Ma et al., 2002). Importantly, early studies by Stenger et al. 
demonstrated that granulysin can kill extracellular M.tb directly and 
intracellular M.tb in combination with perforin (Stenger et al., 1998). In 
patients with chronic TB infection granulysin and perforin expression at the 
site of infection, the granuloma, is impaired compared with distal lung 










Chapter 1. Introduction and literature review 
 22	  
contribute to efficient containment of M.tb during latent infection (Andersson et 
al., 2007). 
Granulysin disrupts cell membrane integrity directly and can cause 
mitochondrial damage, which leads to cytochrome c release and the 
activation of caspase 3 (Kaspar et al., 2001; Okada et al., 2003). In addition, 
this molecule induces monocytes to express cytokines and chemokines, such 
as CC chemokine ligand (CCL)-5 and may therefore play a role in cellular 
recruitment during inflammation (Deng et al., 2005). 
 
1.6.2. Granzymes 
Grm are a group of serine proteases. Five human Grm have been described 
(Grm A, B, H, K, M), which differ on the basis of killing mechanisms, cellular 
expression and biological function (Sower et al., 1996; Russell and Ley 2002; 
Lieberman 2003; Chattopadhyay et al., 2009; Harari et al., 2009; Pardo et al., 
2009).  
Grm induce cell death through multiple mechanisms including direct activation 
of pro-caspases or targeting molecules that lead to mitochondrial and DNA 
damage. Grm entry into target cells occurs via reparative endocytosis or 
receptor mediated endocytosis. However, perforin is required for the efficient 
activation of Grm mediated death pathways (Froelich et al., 1996; Trapani et 
al., 2003; Veugelers et al., 2004). 
The most well characterised serine proteases are GrmA and B. The molecular 
pathways of cell death induced by these two Grm are distinct. GrmA induces 
cell death through caspase independent mechanisms, which involves the 










Chapter 1. Introduction and literature review 
 23	  
(Beresford et al., 1999; Lieberman, 2003). In the absence of a delivery agent 
such as perforin, GrmA induces the secretion of pro-inflammatory cytokines 
from fibroblasts, epithelial cells and monocytes (Sower et al., 1996; Beresford 
et al., 1999; Lieberman and Fan 2003; Metkar et al., 2008).  
GrmB activates caspase-dependent cell death pathways and caspase-
independent mitochondrial death pathways. GrmB activates caspase-
activated DNAse (CAD) by cleaving its associated inhibitor (ICAD) directly or 
indirectly by activating caspase 3, resulting in DNA fragmentation and 
apoptosis (Thomas et al., 2000; Sharif-Askari et al., 2001).  
GrmB also cleaves BH3-interacting domain death agonist (BID), which 
disrupts the mitochondrial outer membrane and leads to the activation of a 
number of pro-apoptotic factors (Yang et al., 1998; Kuwana et al., 2002). 
Studies using CTL from KO mice have demonstrated that cell death delivery 
is greatly impaired in the absence of GrmB compared to other granzymes 
(Heusel et al., 1994). This data suggests that GrmB is one of the main effector 
molecules in granule exocytosis mediated cell death. 
 
1.6.3. Perforin 
Perforin is a 66kDa protein that binds to phospholipid membranes in a calcium 
dependent manner (Masson and Tschopp, 1985). Early studies demonstrated 
that perforin is capable of forming pore-like structures on the plasma 
membrane of target cells (Masson and Tschopp 1985; Podack et al., 1985; 
Young et al., 1986). In addition, delivery of granzymes in combination with 
perforin is required for maximum CTL activity (Kagi et al., 1994). Thus it was 
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target cells to allow delivery of serine proteases. However, more recent 
studies have shown that Grm are internalized into target cells in a perforin 
independent manner (Trapani et al., 2003; Veugelers et al., 2004; Shi et al., 
2005). In addition, secreted Grm are bound to a serglycin carrier protein, 
therefore pores formed by perforin on target cells may not be sufficiently large 
enough to allow entry of these macromolecule complexes (Raja et al., 2002) 
The revised hypothesis suggests that although perforin is not required for Grm 
entry into cells, both molecules need to be co-endocytosed for the release of 
Grm from endosomes into the cytosol or for nuclear translocation (Shi et al., 
2005).  
As mentioned previously, granulysin in combination with perforin kills 
intracellular M.tb and perforin expression is impaired at the site of infection 
during chronic TB (Stenger et al., 1998; Andersson et al., 2007).  
 
1.7. Immunological memory 
1.7.1. Phases of the T cell response 
In order for a vaccine to be effective it must not only prime an appropriate T 
cell response but also establish a pool of long-lived memory T cells. Memory 
T cells are antigen experienced T cells, which persist in an antigen and TCR 
independent manner (Sallusto et al., 2004). These cells are present at higher 
frequencies and respond rapidly upon pathogen re-encounter, compared with 
naïve T cells. The heightened and accelerated immune responses conferred 
by memory T cells mediate rapid clearance of the targeted pathogen before 
extensive damage is inflicted to the host (Steinbrink et al., 2002).  
Memory T cells are established after a number of distinct “phases” following 
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After priming in the lymph nodes, antigen specific T cells enter a clonal 
expansion phase driven by IL-2. Primed T cell “clones” differentiate into 
antigen-specific Th cells and CTL, leave the lymph nodes and circulate in the 
periphery or home to infection sites to carry out their effector functions. Once 
the antigen or pathogen has been cleared, T cells undergo a contraction or 
death phase in which >90% of the cells undergo apoptosis. The remaining 
pool of T cells develop into long-lived memory T cells (Figure 4) (Kaech et al., 
2002; Schluns KS, 2003). 
 
Figure 4. Phases of the T cell response (Badovinac and Harty, 2003). Following 
acute infection or vaccination, primed naïve T cells enter a clonal expansion phase 
and differentiate into effector T cells. Once the targeted antigen or pathogen has 
been cleared, >90% of T cells undergo apoptosis during the contraction phase. The 
remaining pool of T cells develop into long-live memory T cells. 
 
Survival and transition of effector T cells into memory T cells following 
contraction is mediated through IL-7R signalling, which up-regulates the 
expression anti-apoptotic molecules such as Bcl-2 and Bcl-XL (Kaech et al., 
2003; Li et al., 2003). Although several memory subsets have been described, 
a subset referred to as central memory T cells (TCM) are often considered to 
be “true” long-lived memory T cells as this population persists for longer in 
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Zaph et al., 2004a). The delineation of specific memory subsets based on T 
cell function and phenotype will be discussed in greater detail in the following 
section. The selective survival of TCM compared with other memory T cell 
subsets is mediated by transcription factor FoxO3a, which regulates pro-
apoptotic and anti-proliferative genes. TCM express significantly higher levels 
of the transcriptionally inactive forms of FoxO3a compared to TEM 
(Birkenkamp and Coffer, 2003; Riou et al., 2007). Another characteristic 
feature of TCM cells is that they undergo homeostatic turnover. This 
mechanism of self-renewal and survival is primarily mediated through the 
common gamma chain (γc) cytokines, IL-15 and IL-7 (Zhang et al., 1998; 
Lantz et al., 2000; Judge et al., 2002; Carrio et al., 2007; Osborne et al., 
2007).  
The generation of long-lived memory T cells is primarily observed following 
acute infection or after antigen clearance and may not develop in scenarios of 
prolonged antigen persistence. In humans, T cells displaying qualities of long-
lived memory cells are detectable in peripheral blood many years after 
primary immunisation with vaccine antigens that are efficiently cleared, such 
as tetanus toxoid (TT) and the attenuated strain of the yellow fever virus 
(Cellerai et al., 2007; Miller et al., 2008). However, specific T cells generated 
under conditions of antigen persistence fail to acquire a characteristic long-
lived phenotype (Appay et al., 2002b). For example, HIV-specific and 
cytomegalovirus (CMV)-specific T cells are largely skewed towards a highly 
differentiated effector phenotype and do not express markers associated with 
long-lived potential such as BCL-2 and the IL-7R (Champagne et al., 2001; 
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et al., 2010). The same observation has been made in experimental models of 
chronic infection. Following chronic lymphocytic choriomeningitis virus 
(LCMV) infection, murine CD8+ T cells isolated after viraemic control express 
low levels of IL-7R, IL-15R and show reduced homeostatic proliferation and 
survival capacity (Wherry et al., 2004). In combination with data from acute 
viral infection models, the authors suggest that T cells require a rest period 
after antigen-stimulation for efficient transition into long-lived antigen-
independent T cells. 
 
1.7.2. Phenotypic markers for the identification of memory T cell 
subsets 
Memory cells are categorised into a number of subsets based on anatomical 
location, phenotype and function (Sallusto et al., 1999; Wherry et al., 2003). A 
number of markers expressed on the cell membrane including chemokine 
receptors and antigens involved in the regulation of T cell activation and 
survival have been useful for discrimination of specific T cell memory subsets 
(Hamann et al., 1997; Kaech et al., 2003; Gourley et al., 2004; Cellerai et al., 
2007; Miller et al., 2008). The most commonly used markers in humans 
include CC chemokine receptor (CCR)-7, leukocyte selectin (L-selectin, 
CD62L), CD45RA, CD27 and CD28 (Michie et al., 1992; Sallusto et al., 1999; 
Tomiyama et al., 2004; Fritsch et al., 2005).  
CCR7 is a chemokine receptor for CCL-19 and CCL-21, which are 
constitutively expressed by stromal cells in secondary lymphoid organs (Gunn 
et al., 1998; Cyster 1999). CD62L is a cell adhesion molecule that mediates 
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Thus, CCR7 and CD62L play an essential role in facilitating the homing and 
entry of naïve and memory T cells into lymph nodes.  
CD45 is an important regulatory component of TCR signal transduction and 
therefore essential for effective T cell activation (Mustelin et al., 1989; 
Koretzky et al., 1990). Combined analysis of the CD45 isoforms, CD45RA and 
CD45RO, distinguishes naïve from antigen-experienced T cells (Ralph et al., 
1987). Loss of CD45RA and acquisition of CD45RO expression is observed 
during the transition of naïve T cells into memory T cells. However, a subset 
of antigen-experienced T cells has been shown to express CD45RA 
(Johannisson and Festin 1995; Caccamo et al., 2006). 
The co-stimulatory molecules, CD27 and CD28, enhance cell cycling and 
promote T cell survival by maintaining the expression of the IL-7R and by up-
regulating the expression of anti-apoptotic molecules (Hendriks et al., 2000; 
Okkenhaug et al., 2001; Carr et al., 2006). In addition, the expression of CD27 
and CD28 provides information about the function and progressive 
differentiation of T cells driven by antigen encounter. T cells with an early 
differentiation phenotype express both molecules and have high proliferative 
potential. T cells progress through an intermediate differentiation stage 
associated with the loss of CD27 on CD4+ T cells and CD28 on CD8+ T cells. 
Highly differentiated T cells lack the expression of both CD27 and CD28 and 
express high levels of cytolytic molecules (Appay et al., 2002a; Tomiyama et 
al., 2004). The accumulation of highly differentiated T cells is typically 
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1.7.3. Memory T cell subsets and pathways of differentiation 
Two main subsets of memory T cells were first described in human blood 
based on CCR7 and CD62L expression (Sallusto et al., 1999). TCM cells are 
identified by the expression of lymph node homing receptors, CCR7 and/or 
CD62L, but also express CD27 and CD28 (Wherry et al., 2003). TCM cells 
reside mainly in draining lymph nodes and once presented with antigen 
proliferate rapidly and differentiate into effector T cells with cytokine producing 
properties (Wherry et al., 2003). Because proliferative capacity is a key 
feature for this subset and cytokine expression is relatively delayed compared 
to TEM, longer term T cell assays such as the cultured ELISPOT assay and 
proliferation assays are required to accurately measure this population 
(Combadiere et al., 2004; Reece et al., 2004; Hanekom et al., 2008). 
TEM cells are identified by the loss of CCR7 expression and down-regulation 
of CD62L and/or CD27 (Wherry et al., 2003; Schiott et al., 2004). TEM patrol 
sites where pathogens may first be encountered and have an increased 
capacity to home to inflamed tissue through the expression of chemokine 
receptors such as CCR2 and CCR5 (Sallusto et al., 2004; Hansen et al., 
2009). These cells have limited proliferative potential but are highly functional 
and release cytokines and cytotoxic molecules rapidly once presented with 
antigen.  
Terminally differentiated memory T cells lack CCR7 and CD62L expression 
but express CD45RA and are proposed to be derived from effector T cells or 
TEM. This subset also expresses CD57, a marker associated with a state of 
replicative senescence (Brenchley et al., 2003). This subset is thought to be 
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and short telomere lengths (Hamann et al., 1999; Fritsch et al., 2005). 
Terminally differentiated T cells may express effector molecules but have lost 
the ability to proliferate and are likely to undergo apoptosis after pathogen 
clearance. 
A number of models describing the differentiation pathways of TEM and TCM 
have been proposed. Based on observations of acute infection of mice with 
LCMV or the intracellular bacterium, Listeria monocytogenes (L. 
monocytogenes), a linear model of differentiation was originally proposed by 
Wherry and colleagues (Wherry et al., 2003). Wherry et al. demonstrated that 
the differentiation of memory CD8+ T cells is a continuous linear process from 
effector T cell to TEM to TCM. Following expansion, effector T cells either 
underwent apoptosis following pathogen clearance or became TEM, which 
gave rise to TCM (Figure 5A).  
This study also showed that the conversion from TEM to TCM was imprinted 
during priming of naive T cells and that TCM convert into effectors and TEM 
upon secondary infection. A similar linear model of differentiation for CD4+ T 
cells was also described (Swain 1994; Hu et al., 2001). Swain et al. 
demonstrated that after adoptive transfer, Th1 and Th2 effector T cells 
generated in vitro displayed a long-lived memory phenotype when recovered 
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Figure 5. Models of memory T cell differentiation (Ahmed et al., 2009). A. In the 
linear differentiation model, effector T cells are generated following stimulation of 
naive T cells with antigen. Effector T cells either become terminally differentiated T 
cells, which die by apoptosis soon after antigen clearance, or differentiate into TEM 
which differentiate into long-lived TCM. B. The branched differentiation model 
suggests that following priming, asymmetric T cell division gives rise to two daughter 
cell subsets with different differentiation fates: one subset gives rise to long-lived TCM 
cells and the other TEM and effector T cells.  
 
Non-linear or bifurcated differentiation pathways have also been described for 
both CD4+ and CD8+ memory T cell development. Recent studies by Chang 
et al. suggest that asymmetric division of naïve T cells, pre-determined during 
priming, gives rise to daughter cells, which either display properties of short-
lived effector T cells (TEM) or are long-lived memory precursors (TCM) (Figure 
5B) (Chang et al., 2007).  
Whatever the differentiation pathway, it is well established that cells fated 
toward an effector lineage express IFN-γR, T-bet and GrmB and memory 
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expression. Adoptive transfer experiments demonstrated that both lineages 
confer protection to naïve hosts upon challenge, however memory precursors 
confer protection over a longer period. A branched differentiation model in 
which memory CD4+ T cells do not have to progress through a fully 
differentiated effector phase has also been proposed (Song et al., 2005). 
Based on the analysis of chemokine receptors, Song et al. described the 
development of functional effector and memory CD4+ T cells at multiple 
points along the classical pathway from naïve to memory T cell differentiation.  
Although the differentiation and linear relationship between distinct memory T 
cell subsets remains uncertain, it is clear that the induction of long-lived 
memory T cells may be key for establishing vaccine-mediated protection.  
 
1.8. BCG and novel TB vaccine strategies 
BCG, an attenuated strain of M. bovis, remains the only licensed TB vaccine 
currently available. BCG vaccination is effective at preventing severe forms of 
childhood TB, such as TB meningitis and miliary TB, but has variable efficacy 
against pulmonary disease (Colditz et al., 1995; van Rie et al., 1999; Trunz et 
al., 2006). The reasons for this variable efficacy have not been well defined 
but a number of hypotheses have been proposed. These include host genetic 
differences, differences between BCG vaccine strains and interference by 
environmental mycobacteria or other pathogens (Elias et al., 2001; Black et 
al., 2002; Castillo-Rodal et al., 2006). Because BCG is not effective at 
preventing pulmonary disease in adults it has minimal effect on global TB 
burden. Therefore, a number of novel TB vaccines are currently being 
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numbers. These include pre-exposure vaccines, which aim to replace BCG, or 
boost BCG primed responses. Since BCG prevents severe forms of TB and 
over 80% of infants worldwide have been immunised with this vaccine, it is 
likely that BCG will be retained until a new, safe TB vaccine with improved 
benefits is available. Consequently, one of the approaches for the design of 
novel vaccination strategies is to include BCG in a heterologous prime-boost 
regimen or to replace the current BCG with an improved BCG (Lambert et al., 
2009; Kaufmann et al., 2010).  
A rational strategy for the improvement of BCG has been to introduce or over-
express key mycobacteria-specific antigens or to insert non-mycobacterial 
genes (Eddine A.N 2005; Grode 2005; Hoft et al., 2008). For example, 
recombinant BCG (rBCG)-30 expresses the 30-kDa major secretory protein of 
M.tb, Ag85B. rBCGΔureC:Hly+ is an example of a rBCG containing non-
mycobacterial genes. rBCGΔureC:Hly+ secretes listeriolysin, a pore forming 
toxin produced by L. monocytogenes and maintains an acidic phagosomal pH 
for optimal listeriolysin activity. Listeriolysin expression facilitates escape of 
BCG from the phagolysosome into the cytoplasm and thus facilitates efficient 
priming of CD8+ T cells (Horwitz and Harth 2003; Grode 2005; Sun et al., 
2009).  
A second strategy is to boost BCG-primed responses with a heterologous 
vaccine (McShane et al., 2004; McShane 2005; Abel et al., 2010). Several 
studies in animals and humans have demonstrated that boosting BCG-
specific responses with a non-replicating viral vector vaccine can be achieved 
safely and rapidly (Beveridge et al., 2007; Hawkridge et al., 2008; Abel et al., 
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recombinant vaccinia vector expressing Ag85A and AERAS-402, a non-
replicating Adeno virus serotype-35 (Ad35) vector expressing Ag85A, Ag85B, 
and TB10.4 (Kaufmann et al., 2010). Recently, a novel subunit vaccine that 
combines Ag85B, ESAT-6 and Rv2660c was shown to efficiently boost BCG-
primed T cell responses in mice (Aagaard et al., 2011). This booster vaccine 
significantly reduced lung bacterial loads during late-stage M.tb infection 
compared with mice that received BCG only (Aagaard et al., 2011). In addition 
to vaccine candidates outlined above, a number of other vaccine candidates, 
including attenuated mycobacteria such as M. vaccae, are currently 
undergoing clinical trials (Lambert et al., 2009; Kaufmann et al., 2010). Most 
of these vaccines aim to boost BCG-primed responses however the kinetics 
of BCG-specific T cell responses following primary immunisation of infants 
remains unknown. Previous work in chronic viral infection models suggest that 
primary immune responses should be boosted after the peak effector phase 
and following the transition of effector T cell into a stable memory population 
(Wherry et al., 2003; Wherry et al., 2004; Wrammert et al., 2009). Boosting 
during the effector phase of the T cell response may lead to T cell exhaustion 
and death. Therefore, a major limitation in the optimal implementation of novel 
TB vaccines is the lack of kinetic data on BCG-specific responses, which 
hampers the design of appropriate prime-boost immunisation regimens. 
 
1.9. T cell responses following BCG vaccination of infants 
Almost 9 decades after BCG was first administered, BCG-specific T cell 
effector responses remain poorly characterised and the memory phenotypes 
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Infants are more susceptible to infectious diseases, which is predominantly 
attributed to limitations of both innate and adaptive effector mechanisms of 
the neonatal immune system (Harris et al., 1992; Goriely et al., 2001). For 
example, neonatal DC remain phenotypically immature and express lower 
quantities of IL-12 in response to stimulation with lipopolysaccharide (LPS), 
CD40 ligation or polyinosinic–polycytidylic acid compared with adult DC 
(Goriely et al., 2001). Thus, this lack of maturity translates to diminished 
capacity to prime T cells and polarisation of Th1 responses (Harris et al., 
1992; Goriely et al., 2001; Langrish et al., 2002). Despite this, adult like IFN-γ 
responses following BCG vaccination of infants have been reported 
(Vekemans et al., 2001; Ota et al., 2002). Studies have shown that 
vaccination of infants induces specific CD4+ and CD8+ T cells capable of 
IFN-γ recall responses to mycobacteria-specific antigens (Marchant et al., 
1999; Smith et al., 1999; Vekemans et al., 2001; Hussey et al., 2002; Ota 
2002; Davids et al., 2006; Murra  et al., 2006). In the studies conducted by 
Vekemans et al and Davids et al, analysis of peripheral blood mononuclear 
cells (PBMC) by four colour flow cytometry revealed that mycobacteria-
specific CD4+ T cells are a source of IFN-γ (Vekemans et al., 2001; Davids et 
al., 2006). BCG vaccination also up-regulates the expression of cytotoxic 
molecules. Specific CD8+ T cells from 10-14 week old BCG vaccinated 
infants’ up-regulate Grm, perforin and lyse M.tb infected target cells (Hussey 
et al., 2002; Murray et al., 2006). BCG vaccination of neonates has also been 
shown to induce the production of IL-5, IL-13 and IL-10, which are detectable 
by enzyme-linked immunosorbent assay (ELISA) at low levels in plasma 
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antigens (Marchant et al., 1999; Vekemans et al., 2001; Ota 2002).  
Despite the studies described above, comprehensive knowledge of BCG-
specific T cell responses and kinetics following vaccination of infants remains 
limited. This can be attributed to a number of factors: Firstly, since soluble 
cytokine production was pre-dominantly assessed in plasma or supernatant 
following incubation of whole blood, intracellular cytokine expression and the 
phenotypic profiles of antigen-specific T cells could not be discerned. 
Secondly, T cell profiling was restricted to four colour flow cytometry which 
limits the ability to gauge the potential complexity of T cell mediated immune 
responses. Thirdly, IFN-γ expression was selected as the primary measure of 
immunogenicity; however, measuring a single component of the immune 
response may underestimate the magnitude and complexity of BCG-induced 
immunity. Lastly, our understanding of BCG-specific T cell immunity in infants 
is largely based on cross-sectional studies. To model the kinetics of T cell 
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1.10. Objectives 
The primary objective of this thesis is to comprehensively delineate T cell 
immunity induced by BCG vaccination of newborns and to longitudinally asses 
BCG-specific T cell responses over the first year of life. This entails 
developing and optimising several novel polychromatic flow cytometry (PFC) 
reagent panels to allow for detailed dissection of various components of the 
immune response including T cell cytokine and cytotoxic molecule expression, 
T cell memory subsets and differentiation phenotypes. A novel whole blood 
proliferation assay will also be optimised to be implemented in future studies 
to monitor antigen-specific T cell proliferation and cytokine expression 
following vaccination of infants. Optimised reagent panels will first be used for 
cross-sectional analysis of a 10-14 week old infant cohort to determine which 
functional and phenotypic markers are expressed on BCG-specific T cells. 
Longitudinal changes in T cell turnover kinetics, expression of cytotoxic 
molecules and differentiation phenotypes will then be examined directly ex 
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Chapter 2 
Materials and methods 
2.1. Recruitment of study participants 
2.1.1. Adult participants 
Pilot studies for the initial development and optimisation of PFC reagent 
panels were completed using adult whole blood. Healthy TST positive and 
negative donors were recruited at the Institute of Infectious Disease and 
Molecular Medicine (IIDMM) at the University of Cape Town (UCT). Blood 
was collected by qualified phlebotomists within the guidelines of written 
consent. This protocol was approved by the UCT research ethics committee 
(REC REF: 038/2003). 
 
2.1.2. Infant participants - Cross-sectional studies 
The aim of the cross-sectional studies was to determine which functional and 
phenotypic markers are expressed on specific T cells after BCG vaccination 
of infants. Healthy, 10-14 week old infants routinely vaccinated at birth with 
intradermal BCG (Danish strain 1331; Statens Serum Institut), were recruited 
at South African TB Vaccine Initiative (SATVI) clinical sites in Worcester and 
surrounding areas. Peripheral venous blood was collected by qualified nurses 
within the guidelines of written consent and HIV pre- and post-test counselling 
was provided. This protocol was approved by the UCT research ethics 
committee (REC REF: 016/2001) and written informed consent was provided 
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2.1.3. Cross-sectional studies exclusion criteria 
1. Infants who had not received BCG within 48 hours of birth, as is routine. 
2. Infants <10 weeks or >14 weeks of age 
3. Infants who were HIV positive 
4. Infants with acute or chronic disease at the time a blood draw was 
scheduled 
5. Infants on TB prophylaxis or treatment  
 
2.1.4. Infant participants- Longitudinal study 
Participants were recruited in the Worcester district. Mothers were verbally 
informed about this study by SATVI study nurses after delivery at Eben 
Donges Hospital and the Worcester Community Health Centre maternity 
units. Only mothers who had undergone screening for HIV infection by the 
state-run programme to prevent maternal to child transmission (MTCT) of HIV 
and who were HIV negative were approached. Mothers that expressed 
interest in participating in the study were visited at home where informed 
consent was obtained from her or another appropriate legal guardian, and a 
follow-up phlebotomy schedule was assigned.  
At specified scheduled time points, infants visited the Maria Pieterse clinic site 
in Worcester. All had been routinely vaccinated at birth with intradermal BCG 
(Danish strain 1331; Statens Serum Institut). At each visit the infant’s medical 
history was taken and a general examination was performed prior to 
phlebotomy procedures. Peripheral venous blood was collected within the 
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listed below. This protocol was approved by the UCT research ethics 
committee (REC REF: 323/2006) and by the Western Cape Department of 
Health (19/18/RP01/2008).  
 
2.1.5. Longitudinal study exclusion criteria 
1. Infants who had not received BCG within 48 hours of birth, as is routine. 
2. Infants with a birth weight of <2.5kg, as these infants immune systems 
may be relatively “immature” and the maximum amount of blood we 
could safely draw at each time point may be insufficient to allow 
completion of all assays. 
3. Infants with chronic disease within the first three weeks of life, e.g., 
congenital heart disease and chronic lung disease. (Chronic disease that 
developed after three weeks of age, e.g., asthma, was not an exclusion 
criterion.) 
4. Acute disease in the first month of life, such as newborn respiratory 
disease and sepsis. 
5. Infants whose mothers were HIV positive, as HIV exposure or infection of 
infants may affect the BCG-induced immune response. 
6. Infants whose mothers had not been screened for HIV infection by the 
state-run program to prevent MTCT of HIV. 
7. Clinically significant anaemia. This was detected by the examination of 
the infant during each visit. If the study personnel suspected anaemia, a 
finger prick haemoglobin examination was done. A Hb<9.5 g/dL led to 
exclusion of the infant from that blood draw and the infant was referred 
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8. Acute disease at the time a blood draw was scheduled.  
9. Missed scheduled appointments on more than two occasions. 
10. TB prophylaxis or treatment at any point during the one-year follow-up 
period. 
11. M.tb infected infants. M.tb infection was determined at each time point by 
measuring T cell proliferation following a 6 day whole blood culture with 
ESAT6/CFP10 fusion protein. 
 
2.2. Longitudinal study design 
To determine the kinetics of BCG-specific T cell responses following 
vaccination, infants were followed up from 3 weeks of age to 52 weeks of age. 
Blood specimens were drawn from each infant at only three to four of the 
following seven time-points (ages): 3, 6, 10, 14, 27, 40 or 52 weeks. This 
schedule was chosen to coincide with the standard Expanded Programme on 
Immunisation (EPI) schedule (Table 1). 
Table 1. EPI vaccine schedule in South Africa during the study follow-up 
period (2008 – 2009). 
At birth 6 weeks 10 weeks 14 weeks 6 months 9 months >12 months 
BCG       
OPV OPV OPV OPV    OPV (18 months) 
  DTP-HibV DTP-HibV DTP-HibV  DTP-HibV  
(18 months) 
     MV MV (18 months) 
       
OPV - Oral polio vaccine 
DTP-HibV - Diphtheria, tetanus, pertussis, haemophilus influenza type B combined 
vaccine 
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Infants were allocated to a limited number of time points as it was unlikely that 
parents would allow infant phlebotomy seven times during the year. Also, the 
volume of blood that can be safely drawn from infants cannot exceed 3mL/kg 
over an 8 week period. The randomised allocation of infant participants to 
specific phlebotomy schedules is discussed in section 2.7.2 of this chapter. 
 
2.3. Assays 
2.3.1. Whole blood intracellular cytokine (WB-ICC) assay  
Co-stimulants anti-CD28 and anti-CD49d (both from BD Biosciences) at a 
final concentration of 1µg/ml each, were included with antigens, as pilot 
experiments had shown enhancement of the specific cytokine response of T 
cells. Whole blood was incubated with the following antigens (final 
concentrations): 1.8 x 106cfu/mL Danish BCG (Danish strain 1331; Statens 
Serum Institut) or 20ug/mL M.tb PPD (Statens Serum Institut; Batch RT48). 
Whole blood incubated with co-stimulants only served as the negative control. 
Positive controls included: 5ug/mL phytohaemagglutinin (PHA; Sigma-Aldrich) 
or 10µg/ml Staphylococcal enterotoxin B (SEB; Sigma-Aldrich). Prepared 
antigens were stored overnight at 4°C and transported on ice packs the 
following morning to the clinic sites.  
At the clinic, whole blood was collected into heparinised syringes by veni-
puncture. Immediately following phlebotomy, 1mL of whole blood was added 
drop-wise directly into the Sarstedt tubes containing prepared antigens, after 
these had been brought to room temperature. Whole blood was added to 
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transferred into a portable incubator set to 37°C for transport to the Cape 
Town SATVI lab site. The portable incubator, adapted to plug into a vehicles 
lighter outlet, maintains whole blood samples at an optimal temperature of 
37°C during transport. At the SATVI lab site, samples were transferred into a 
programmable waterbath set to 37°C. 
After 7 hours of incubation from the initial bleed time, 100 µL of plasma was 
removed from each sample and immediately stored at -80°C. These samples 
were collected for later analysis of soluble cytokines by multi-plex bead array. 
After collection of plasma, Brefeldin A (Sigma-Aldrich) was added at a final 
concentration of 10µg/mL, to trap cytokines intracellularly. Tubes were 
vortexed and transferred immediately into a 37°C waterbath and stimulated 
for an additional 5 hours. After a total stimulation time of 12 hours, the 
waterbath temperature was reduced to 21°C to down-regulate stimulation. 
Cells were harvested the following morning within 10 hours of temperature 
reduction. 
To harvest cells, whole blood was incubated with 2mM EDTA (Sigma-Aldrich) 
for 15 minutes at room temperature. To lyse red blood cells and fix white 
blood cells, 1mL whole blood was transferred into 15 ml Sterillin tubes 
containing 9mL, BD FACS lysing solution (BD Biosciences) and incubated at 
room temperature for 10 minutes. Cells were centrifuged at 300 x g for 10 
minutes at room temperature. Supernatants were decanted and the remaining 
cells were resuspended in a cryo-preservation solution consisting of 500µL 
1% human AB serum (Western Cape Blood Transfusion Service) in RPMI 
1640 (Lonza BioWhittaker) and 500µL 20% DMSO (Sigma-Aldrich) in fetal 
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(Corning) and placed in Mr. Frosty’s (Merck) containing iso-propanol (Sigma-
Aldrich) which allows for step-wise freezing at a rate of -1°C/min. Mr Frosty’s 
remained at -80°C for 24 hours prior to transfer of cells into liquid nitrogen. 
 
2.3.2. Cytotoxicity assay 
Whole blood (125µL diluted 1:5 in warm RPMI 1640) was incubated with 1 x 
105cfu/mL BCG, 1ug/mL PHA (positive control) or medium only (NIL, negative 
control) in 24-well culture plates at 37°C in 5% CO2.  On day 3, 250uL plasma 
was removed from each sample and immediately stored at -80°C for later 
analysis of soluble cytokines by multi-plex bead array. After collection of 
plasma, whole blood was incubated with 2mM EDTA for 15 minutes at room 
temperature to harvest cells. To lyse red blood cells and fix white blood cells, 
1mL of whole blood was transferred into 15 mL Sterilin tubes containing BD 
FACS lysing solution and incubated at room temperature for 10 minutes. Cells 
were pelleted at 300 x g for 10 minutes at room temperature and cryo-
preserved as described for the WB-ICC assay. 
 
2.4. Antibodies 
The development and optimisation of each PFC reagent panel designed to 
address the aims of this thesis is outlined in chapter 3. Conjugated antibodies 
selected for the analysis of T cell functional and phenotypic profiles are 
tabulated in chapter 3 or listed under the materials and methods section of 
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2.5. Staining Protocols 
A “one step” and “two step” staining method were optimised to assess the 
functional and phenotypic profiles of T cells, respectively. 
 
2.5.1. One step staining method 
Cryo-preserved cells were rapidly thawed in a waterbath set to 37°C. Thawed 
cells were transferred into Falcon tubes containing 1mL of 1 x PBS 
(BioWhittaker) and pelleted at 300 x g for 10 minutes at 4°C. Cells were 
resuspended in 1mL 1 x BD Perm/Wash solution (BD Biosciences), vortexed 
and incubated for 10 minutes at room temperature to permeabilise cells. 
Permeabilised cells were pelleted and supernatants decanted prior to 
staining. The remaining volume after decanting was approximately 60µL. 
Cells were incubated with fluorescent-conjugated antibodies for 1 hour in the 
dark at 4°C. Stained cells were washed in 1mL BD Perm/Wash buffer, 
resuspended in 100µL BD Perm/Wash buffer and acquired immediately on a 
LSR II flow cytometer (BD Biosciences). 
 
2.5.2. Two step staining method using BD Perm/Wash buffer 
To assess memory T cell phenotypes a two step staining method was used. 
This method allows for staining of all surface markers first, followed by 
staining of intracellular cytokines. 
Cryo-preserved cells were rapidly thawed in a waterbath set to 37°C. Thawed 
cells were transferred into falcon tubes, containing 1mL 1 x PBS and pelleted 
at 300 x g for 10 minutes at 4°C. Cells were resuspended in 1mL BD 










Chapter 2. Materials and methods 
	   46	  
permeabilise cells. Cells were pelleted, decanted and stained for all surface 
markers for 1 hour in the dark at 4°C. Stained cells were washed twice in 1mL 
BD Perm/Wash buffer and then stained for 1 hour at 4°C with antibodies 
against intracellular cytokines. Stained cells were washed in 1mL BD 
Perm/Wash, pelleted and resuspended in 100µL of BD Perm/Wash buffer. 
Cells were acquired immediately on a LSR II flow cytometer. 
 
 
2.6. Data acquisition 
All flow cytometric data was acquired on a BD LSR II equipped to detect 13 
individual fluorescent signals excited by 405nm violet, 488nm blue and 633 
red lasers. Mirror and filter configurations are tabulated in Appendix A. 
Compensation corrections and data analysis was completed using FACSDiva 
(BD Biosciences) or FlowJo (Tree Star Inc, Ashland, OR). Histograms and 
bivariant dotplots were selected to display data with 0 and negative log 
scaling (bi-exponential scaling) (Tung et al., 2004). 
 
2.7. Statistical considerations 
Statistical analysis and graphical representation was done using Prism 
(GraphPad, San Diego, CA, USA). Statistical significance (p values) was 
calculated using non-parametric statistical tests, as most data were not 
normally distributed. A p value of less than 0.05 was considered significant. 
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2.7.1. Sample size calculations for the cross-sectional studies 
Sample size calculations were based on data from pilot experiments that 
recorded the peripheral blood frequency of BCG-specific CD4+ T cells (IFN-γ-
expressing CD4+ T cells after 12 hours stimulation of whole blood), measured 
at 10-14 weeks of age, in children vaccinated with BCG at birth. The mean 
frequency was 0.30% with a standard deviation of 0.27%. When the sample 
size in 29, a two-sided 95.0% confidence interval for the single mean will 
extend 0.100 from the observed mean, assuming that the standard deviation 
is known to be 0.270 and the confidence interval is based on the large sample 
z statistic. 
 
2.7.2. Sample size calculations for the longitudinal study 
Sample size calculations were based on pilot data from the cross-sectional 
studies that recorded the peripheral blood frequency of BCG-specific CD4+ T 
cells (IFN-γ-expressing CD4+ T cells after 12 hours stimulation of whole 
blood), measured at 10 weeks of age, in 33 children vaccinated with BCG at 
birth. The mean frequency was 0.54% with a standard deviation of 0.29%. 
Assuming that the standard deviation of the frequency measurements at 1 
month and at 1 year will both be 0.29%, and assuming a within-subject 
correlation between 1-month and 1-year frequencies of 0.75 (i.e. 56% of the 
variability in the 1-year frequencies can be accounted for by their linear 
association with the 1-month frequencies), the standard deviation for the 
difference in the mean frequencies at 1 month and 1 year is 0.205%. To 
detect a relative change of 20% in CD4+ T cell frequencies from 1 month to 1 
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based on a 1 month frequency of 0.54%.  Using a paired t-test to detect a 
difference of 0.108%, with 80% power and at a two-sided 5% level of 
significance, when the standard deviation of the differences is 0.205%, a 
sample size of 32 subjects per time point is required. To reduce the frequency 
of bleeds, infants were assigned to 2 of the first 4 bleed time points and 2 of 
the last 3 time points. Since infants were only allocated to half the number of 
visits, the sample size was doubled to 64 and an additional two recruited to 
obtain round numbers. The total sample size was therefore 66 infants. The 
sample size could be increased to 90 infants, to compensate for loss to follow-
up, acute disease, or unanticipated sample loss, etc, which may have resulted 
in obtaining fewer than the proposed 33 infant for each time point.  
There were 6 possible schedules of 2 out of the first 4 visits and 3 possible 
schedules of 2 out of the later 3 visits. Half the number of infants were 
allocated to consecutive visits than to other schedules among the earlier 
visits. The allocation of infant participants to specific phlebotomy schedules is 
listed in Appendix B. Details of participant specific follow-up time points (time 
given in weeks), including volumes of blood drawn at specific time points are 











Chapter 3. Optimisation of polychromatic flow cytometry reagent panels for the 




Optimisation of polychromatic flow cytometry reagent panels 
for the characterisation of BCG-specific T cell subsets and 
functional profiles 
3.1. Introduction 
Characterising the human host response induced by BCG vaccination is 
challenging due to the highly complex nature of the T cell compartment. 
Previous studies have relied on assays such as the IFN-γ ELISPOT, ELISA or 
intracellular cytokine staining (ICS) combined with four colour flow cytometry 
to measure mycobacteria-specific immunity (Vekemans et al., 2001; Ota et 
al., 2002; Vekemans et al., 2004; Davids et al., 2006; Murray et al., 2006). 
However, these assays do not accurately reflect the complexity of vaccine-
specific responses, which encompass multiple cellular subsets with numerous 
effector functions (De Rosa et al., 2004; Cellerai et al., 2007; Miller et al., 
2008). Further, measuring the production of a single effector molecule, such 
as IFN-γ, and collecting limited data on the immunophenotype of antigen-
specific cells, limits the rate at which we acquire knowledge on vaccine 
induced responses.  
The field of PFC has progressed rapidly due to the development of flow 
cytometers equipped with multiple lasers and advanced detection systems 
and the availability of numerous novel fluorescent dyes (Roederer et al., 1996; 
Perfetto et al., 2004; Chattopadhyay et al., 2006a). PFC, which is based on 
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parameters or characteristics on a single cell level. PFC is the only 
technological platform currently available that allows complex analysis of 
multiple T cell subsets and functions.  
At the initiation of this project, comprehensive knowledge of BCG-specific 
immunity in infants was very limited, and PFC reagent panels specifically 
designed to measure BCG-induced T cell function and phenotypes had not 
been developed. This chapter focuses on the steps undertaken to develop 
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3.2. Aims  
To address the objectives of this study, four reagent panels, each aimed at 
assessing specific components of T cell mediated immune responses relevant 
to mycobacterial immunity, were optimised. These included panels 
measuring: i) T cell cytokine expression profiles ii) memory phenotypes of T 
cell subsets iii) expression of cytotoxic molecules and T cell differentiation 
stage and iv) T cell proliferative capacity. Reagent panels were designed and 
optimised by completing the following sub-aims: 
1. Identify relevant cellular markers for measurement of BCG-specific T 
cell immunity. 
2. Optimise reagent panels by: 
a. Titrating antibodies. 
b. Optimising staining reagents and protocols. 
c. Assess false-positives and any potential antibody interactions 
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3.3. Materials and methods 
3.3.1. Study participants and phlebotomy 
Optimisation of reagent panels was performed on whole blood from healthy 
adults. Study participants were recruited as described in chapter 2 (section 
2.1.1) and blood was collected by qualified phlebotomists within the guidelines 
of written consent.  
 
3.3.2. Immuno-fluorescence staining 
All samples used for optimisation experiments were stained using the “one 
step staining method” described in chapter 2 (section 2.5.1.), unless stated 
otherwise. 
 
3.2.3. Titration of antibodies 
Each commercially obtained antibody conjugate was individually titrated by 
serial dilution to determine staining performance and optimal antibody titre. 
Conditions such as temperature, light exposure and different staining buffers 
may influence staining and antibody performance; therefore titrations were 
completed under the same conditions as experimental staining. Twice the 
volume recommended by the manufacturer was selected as the starting titer 
to ensure antigen saturation. At least eight and up to twelve two-fold serial 
dilutions were completed per antibody. Data were analysed using histograms 
and dotplots to determine background staining (noise), separation and 
saturation titers and signal-to-noise ratios. A separation titer is defined as the 
dilution at which optimal resolution between unstained (noise) and stained 
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which 100% staining of the targeted antigen is achieved. A ‘signal-to-noise’ 
ratio of the median fluorescent intensity (MFI) of the positive population 
divided by that of the negative population was calculated for each dilution. 
When appropriate, biological negative controls were included in titration 
experiments to determine the level of non-specific antibody binding or noise 
and to guide analysis of titration data. The MFI and the frequency of the 
positive population were plotted against antibody volume (µL). The optimal 
antibody volume typically lies on the plateau or peak area of both plots, i.e. a 
dilution that results in the maximum frequency of positively stained cells and 
in the largest separation (highest signal-to-noise ratio) between stained and 
unstained cells. Final dilutions for each antibody were selected by assessing 
all of the experimental outcomes listed above. 
 
3.3.4. Effects of fixation on phenotypic marker resolution 
Because all whole blood samples used in this study were fixed prior to 
staining with antibodies, the effects of fixation on the resolution of surface 
markers was evaluated. For freshly stained samples, 1mL of adult whole 
blood was added directly to 5mL erythrocyte lysis (EL) buffer that does not 
contain a fixative (RNeasy kit, Southern Cross Biotechnology), vortexed and 
incubated on ice for 20 minutes. For fixed samples, 1mL of whole blood was 
added directly to 9mL FACS lysing solution, vortexed and incubated at room 
temperature for 15 minutes. 
After lysis, cells were pelleted and stained with a combination of the following 
antibodies: CD3-Pacific Blue, CD4-Alexa Fluor 700, CD8-PerCP-Cy5.5, 
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All antibodies were obtained from BD Biosciences (BD Biosciences) except 
for CCR7-APC (R&D Systems). 
 
3.3.5. Optimisation of staining protocols for phenotypic surface marker 
analysis 
Three different staining protocols (outlined below) were evaluated in parallel. 
Each protocol was tested on whole blood incubated with BCG for a total of 12 
hours as described previously in chapter 2 (section 2.3.1.).  
Samples were stained with: CD3-Pacific Blue, CD8-PerCP-Cy5.5, CD45RA -
PE-Cy7, CD27-PE, CCR7-APC, IFN-γ-Alexa Fluor 700 and IL-2-FITC. All 
antibodies were obtained from BD Biosciences. 
 
i. One step staining method 
Refer to the “one step staining method” in chapter 2 (section 2.5.1.) 
 
ii. Two step staining method using BD Pharmingen stain buffer and BD 
Perm/Wash buffer 
Cryo-preserved cells were rapidly thawed in a waterbath set to 37°C. Thawed 
cells were transferred into Falcon tubes containing 1mL of 1 x PBS and 
pelleted at 300 x g for 10 minutes at 4°C. Cells were resuspended in 1ml BD 
Pharmingen stain buffer (BD Biosciences) vortexed, pelleted and the 
supernatants decanted prior to staining. Cells were stained with antibodies 
against all surface markers for 1 hour in the dark at 4°C. Stained cells were 
washed in 1mL BD staining buffer and resuspended in BD Perm/Wash for 10 
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cytokines in the dark for 1 hour at 4°C. Cells were washed, pelleted and 
resuspended in 100µL of BD Perm/Wash buffer prior to acquisition.  
 
iii. Two step staining method using BD Perm/Wash buffer 
Refer to the “two step staining method” in chapter 2 (section 2.5.2.) 
 
3.3.6. FMO 
In FMO experiments one reagent is omitted at a time to assess potential false 
positives or other issues arising from antibody interactions in large panels. A 
whole blood sample stained with all antibodies from a single panel was 
compared with a series of samples stained with the same panel excluding 
each individual antibody (Perfetto et al., 2004). FMO controls were completed 
for all reagent panels under the same experimental conditions planned for the 
final analysis of infant samples, e.g., FMO controls for the cytotoxicity panel 
were tested on whole blood stimulated with BCG for 3 days. Gating strategies 
were based on data obtained from samples stained with the full reagent 
panel, before being applied to FMO control data. 
 
3.3.7. Determining which activation markers allow detection of antigen-
specific T cells in a 3 day assay 
The expression of CD69, HLA-DR and Ki67 were evaluated as potential 
markers of antigen-specific T cells following a 3 day culture of whole blood 
with BCG. Markers of activation were screened on samples collected from six 
healthy BCG-vaccinated infants (age range, 3 - 40 weeks). Markers were 
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previously in chapter 2 (section 2.3.2). Samples were stained with: CD3-
Pacific Blue, GrmB-Alexa Fluor 700, CD69-PE-Cy7, HLA-DR-PerCP and 
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3.4.1. Selecting cellular markers for the analysis of BCG-specific T cell 
responses 
Development of each reagent panel began with selecting markers relevant to 
mycobacteria-specific immunity and to the objectives of this study. Specific 
marker combinations were selected to: 1) identify T cell lineages; 2) indentify 
T cell memory and differentiation phenotypes and 3) T cell functional capacity 
(proliferative capacity, expression of cytokines and cytotoxic molecules). 
Markers included for analysis within each final reagent panel are listed in 
section 3.4.8 at the end of this chapter. Several markers were screened 
initially but excluded from final reagent panels due to poor discrimination 
between positive and negative populations, reduced specificity or protocol 
limitations. These included: CD62L, CD154, CD137, CD69, HLA-DR and 
CD127. The rationale for excluding each marker is given in the discussion 
section of this chapter or in other relevant chapters.  
 
3.4.2. Assigning fluorochrome conjugates to markers 
 
After selecting antigens of interest, fluorescent conjugates were assigned to 
each marker. Allocation of fluorochrome-conjugates was guided by several 
selection criteria including: instrument configuration (Appendix A), 
commercial availability of antibodies, antigen expression levels, fluorochrome 
staining index and the amount of spectral overlap contributed by each 
fluorochrome (Baumgarth and Roederer, 2000). Antigens which were 
expressed on a small population of cells (rare), or which had low expression 
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tandem fluorochromes and APC (Maecker and Trotter, 2008). Dimmer 
fluorochromes, such as the violet dyes AmCyan and Pacific Blue were 
assigned to highly expressed markers such as the lineage markers CD4 and 
CD3. These markers have distinct negative and positive populations (bimodal 
distribution) that are usually well resolved with dimmer dyes. Fluorochromes 
were also selected based on emission wavelengths and potential spectral 
overlap between detectors. Fluorochrome emission wavelengths often overlap 
and “spillover” into other channels. A high percentage of spillover may 
decrease sensitivity in some channels as a result of data spread (Maecker et 
al., 2004). Fluorochrome-conjugates assigned to specific markers for each 
final reagent panel are listed at the end of this chapter in section 3.4.8.  
 
3.4.3. Optimal antibody titers 
All antibodies were titrated to ensure optimal reagent performance. The 
titration of Ki67-PE for the cytotoxicity reagent panel is shown in Figure 1A-C 
as a representative example. Titration data were analysed by dotplots (Figure 
1A) and histograms (Figure 1B) to determine the frequencies and MFI of 
stained and unstained cells. Figure 1C shows the titration curve of antibody 
volume in relation to the MFI and percentage of Ki67 expressing CD3+ T 
cells. A plateau was established between 0.2µL to 0.4µL in which no 
significant increase in the percentage of Ki67+CD3+ T cells was observed. 
Resolution between stained and unstained cells diminished significantly at 
titers below 0.025µL (Figure 1A). Although the highest signal-to-noise ratio 
was observed at 0.4µl, 0.2µl was chosen as the optimal volume for this 
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C), allowed good discrimination between stained and unstained cells (Figure 
1B), and non-specific binding/noise was minimal (NIL, Figure 1A). Optimal 
titers for all antibody-conjugates in each final reagent panel are listed in 
section 3.4.8 of this chapter.  
 
 
Figure 1. Titration of Ki67 PE. The frequency of Ki67+CD3+ and Ki67-CD3+ T cells 
in whole blood after 3-day culture with medium only (NIL) or BCG displayed as (A) 
pseudocolour dotplots and (B) histograms. The values above each dotplot indicate 
final antibody volume. (C) Frequencies of Ki67+CD3+ T cells after background (NIL) 
subtraction and signal-to-noise ratios in relation to antibody volume  
 
3.4.4. Effects of fixation on phenotypic marker staining 
To determine the effects of paraformaldehyde fixation on phenotypic marker 
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antibodies and compared to whole blood stained post-fixation with FACS 
lysing solution.  
Reliable resolution between negative and positive staining populations was 
maintained for CD45RA, CCR7 and CD27 after fixation and results were 
comparable to freshly stained samples (Figure 2A and B).  
 
 
Figure 2. The effect of fixation with FACS lysing solution on CD45RA, CCR7 
and CD27 staining. Histogram overlays of CD4+ (purple shading) and CD8+ T cells 
(blue shading) illustrating the resolution of memory markers in (A) fresh and (B) fixed 
whole blood.  
 
Conjugates which exhibited reduced staining intensity due to fixation were 
excluded from panels, when suitable fixation-resistant antibodies could not be 
found. An example of such a conjugate was the CD127-PE antibody from BD 
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Figure 3. The effect of fixation with FACS lysing solution on CD127 staining. 
Histograms showing CD127 expression on CD4+ (green shading) and CD8+ T cells 
(blue shading) after staining (A) fresh and (B) fixed whole blood. 
 
 
3.4.5. Optimising of staining protocols for the analysis of phenotypic 
surface markers 
Three staining protocols were tested to determine the effect of 
permeabilisation and staining techniques on the resolution of surface markers 
and on antibody performance. Experiments were run in parallel and the levels 
of CCR7, CD45RA and CD27 expression compared. The discrimination of 
CCR7-negative and positive populations was more clear when using a two-
step staining method with BD Perm/Wash solution for both CD3+CD8- and 
CD3+CD8+ T cells (Figure 4A and B).  Discrimination between negative and 
positive CCR7 populations was lost on CD3+CD8- T cells with the other two 
staining protocols and a difference in CD45RA staining was observed using 
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maintained for CD3, CD4, CD8, CD27 and CD28 (data not shown) for all 
other staining/permeabilisation protocols tested. The two step staining method 
using BD Perm/Wash buffer was selected as the optimal protocol for the 
analysis of phenotypic surface markers (phenotypic profile panel). 
 
 
Figure 4. Optimisation of staining protocols for the analysis of phenotypic 
surface markers. CCR7 and CD45RA staining in (A) CD3+CD8- and (B) 
CD3+CD8+ T cells shown as dotplots and histograms using 3 different staining 
protocols. 
 
3.4.6. FMO  
FMO controls were used to assess potential false positives related to 
fluorochrome interactions, spectral overlap or tandem-dye degradation 
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channels because the primary fluorochrome is omitted from the panel. For this 
study FMO controls were run for all fluorochrome-conjugates and not only 
tandem dyes or channels requiring high sensitivity. FMO controls for the 
cytotoxicity reagent panel are shown in Figure 5. This panel is shown as a 
representative example as it was the most complex panel optimised within the 
study. Detailed results from the cytotoxicity panels FMO controls are listed in 
Table 1. Secondary fluorescence due to spillover remained low in all channels 
for the cytotoxicity reagent panel (values highlighted in grey, Table 1) and all 
other panels designed for this study (data not shown). The highest secondary 
fluorescence was detected in the PerCP-Cy5.5 channel (Table 1). Since this 
fluorochrome was assigned to a highly expressed marker, CD28 (Figure 5), 
the amount of background fluorescence detected in this channel was 
negligible compared to the positively stained population. Importantly, the 
frequency of each positive population remained consistent between each 
FMO control and were comparable to control samples stained with the full 9-
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Figure 5. Cytotoxicity panel FMO controls. The label above each dotplot indicates 
the fluorescent conjugated antibody excluded from the full reagent panel. All dotplots 
are gated on CD3+ T cells except the first dotplot (FM Pacific Blue), which is gated 
on lymphocytes. Below each FMO control dotplot is a dotplot showing BCG 
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 Table 1. FM
O
 results for the cytotoxicity panel. 
 
Pacific PerCP- Alexa Fluor Alexa Fluor 
FM QOot 605 APC-H7 QOot 655 PE APC 
Blue Cy5.5 488 700 
Pacific Blue 0.0258 51.6 27.4 81.4 74.9 6.93 5.65 2.25 7.08 
QOot 605 37.7 0.00521 32.9 96.5 89.3 2.34 4.72 2.45 2.63 
APC-H7 35.8 61 .5 0.0159 96.3 89 2.32 4.9 2.45 2.71 
QOot 655 34.9 61 .6 32.8 0.0138 88.8 2.5 4.7 2.67 2.35 
PerCP-Cy5.5 36.4 61.5 32.6 96.3 0.848 2.37 4.78 2.53 2.33 
Alexa Fluor 488 35.3 61.5 32.4 96.4 88 0.125 4.7 2.51 2.31 
Alexa Fluor 700 33.1 62.5 31.8 96.6 89.7 2.29 0.0174 2.35 2.71 
PE 35.5 61.4 32.7 96.4 87.3 2.39 4.74 0.0591 2.56 
APC 35.1 61.2 32.8 96.5 89.6 2.8 4.73 2.63 0.0178 
Full reagent panel 
BCG stimulated I 
35.6 61.5 32.9 96.4 88.7 2.41 4.59 2.52 2.72 
WB 
The values shaded in grey indicate the amout of backgrond fluorescence within a specific channel when the antibody 
detected in that channel is omitted. Values are reported as a frequency of CD3+ T cells except for 'FM Pacific Blue' which 
shows the percentage of spillover as a frequency of the lymphocyte population. Frequencies obtained from BCG 
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3.4.7. Determining which activation markers allow detection of antigen-
specific T cells in a 3 day assay 
One of the aims of this study was to characterise BCG-specific cytotoxic 
molecule expression during the first year of life. Detection of de novo 
expression of cytotoxic molecules within antigen-specific CTL by flow 
cytometry is challenging due to the high levels of pre-formed granules 
containing these molecules (Appay et al., 2002c). To resolve this, the 
expression of activation antigens CD69, HLA-DR and Ki67 were evaluated as 
potential markers of antigen-specific T cells after stimulation of whole blood 
with BCG. Representative dotplots in Figure 6A show the expression of 
CD69, HLA-DR and Ki67 by CD3+ T cells under different stimulatory 
conditions. Background HLA-DR expression on unstimulated cells (NIL; 
median, 1.92%) was consistently higher compared with CD69 (median, 
0.051%) and Ki67 (median, 0.69%). After stimulation of whole blood with 
BCG, the expression of all markers increased significantly above background 
levels (NIL) (Figure 6A and B); however after background (NIL) subtraction 
the frequency of Ki67+CD3+ T cells was higher in four of the six donors 
compared to CD69+CD3+ and HLA-DR+CD3+ T cells (data not shown). 
Therefore, Ki67 consistently identified a greater frequency of antigen-specific 
T cells following background (NIL) subtraction. Ki67 expression also identified 
a greater percentage of BCG-specific GrmB+ T cells in four of the six donors 
(Figure 7A and B). These data show that Ki67 is more sensitive than CD69 
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Figure 6. Activation markers HLA-DR, CD69 and Ki67 are up-regulated after 
incubation of whole blood with BCG. (A) Representative example showing the 
frequencies of HLA-DR, CD69 and Ki67 expressing CD3+ T cells after incubation of 
whole blood with medium only (NIL), BCG or PHA over 3 days. (B) Expression of 
activation markers in whole blood from 6 donors after 3-day culture with medium only 
(NIL) or BCG. Each colour represents an individual donor. Differences were 
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Figure 7. CD69, HLA-DR and Ki67 identify a subset of BCG-specific GrmB+ T 
cells. (A) Representative example showing the frequencies of GrmB+ T cells co-
expressing HLA-DR, CD69 and Ki67 after incubation of whole blood with medium 
only (NIL), BCG or PHA over 3 days. Dotplots are gated on CD3+ lymphocytes. (B) 
Frequencies of GrmB+ T cells detected by CD69 or HLA-DR or Ki67 expression in 6 
donors. Each colour represents an individual donor. The horizontal line indicates the 
median. 
 
3.4.8. Final PFC reagent panels 
When this project was initiated, the availability of fluorochrome-conjugates 
was still limited. To assess all markers of interest, two reagent panels were 
developed to analyse T cell cytokines profiles and an additional two to 
analyse memory T cell phenotypes. Table 2A-F lists markers included for 
analysis within each final reagent panel and optimal antibody volumes for 










Chapter 3. Optimisation of polychromatic flow cytometry reagent panels for the 
characterisation of BCG-specific T cell subsets and functional profiles 
 
 69 
Table 2. Markers and fluorochrome conjugates included in final reagent 
panels and optimal antibody titers. 
Antibody Fluorochrome Clone Optimal volume per reaction (µL) 
A. Cytokine Profile Panel 1 
CD3 Amcyan SK7 5  
CD4 Alexa Fluor 700 RPA-T4 1  
CD8 PerCP-Cy5.5 SK1 10  
TNF-α PE-Cy7 MAb11 5  
IL-2 Alexa 610 PE 5344.111 5  
IFN-γ FITC 25723.11 5  
IL-10 APC JES3-19F1 1  
    
B. Cytokine Profile Panel 2 
CD3 Amcyan SK7 5  
CD4 Alexa Fluor 700 RPA-T4 1  
CD8 PerCP-Cy5.5 SK1 10  
TNF-α PE-Cy7 MAb11 5  
IL-2 Alexa 610 PE 5344.111 5  
IL-4 FITC MP4-25D2 2  
IFN-γ PE 25723.11 10  











Chapter 3. Optimisation of polychromatic flow cytometry reagent panels for the 
characterisation of BCG-specific T cell subsets and functional profiles 
 
 70 
Table 2 (continued). Markers and fluorochrome conjugates included in final 
reagent panels and optimal antibody titers. 
Antibody Fluorochrome Clone Optimal volume per reaction (µL) 
C. Phenotypic Profile Panel 1 
CD3 Pacific Blue UCHT1 1  
CD4 PerCP-Cy5.5 SK3 10  
IL-2 FITC 5344.111 5  
IFN-γ Alexa Fluor 700 B27 1  
CD45RA PE-Cy7 L48 5  
CCR7 APC 150503 10  
CD27 PE M-T271 5  
    
D. Phenotypic Profile Panel 2 
CD3 Pacific Blue UCHT1 1  
CD8 PerCP-Cy5.5 SK1 10  
IL-2 FITC 5344.111 5  
IFN-γ Alexa Fluor 700 B27 1  
CD45RA PE-Cy7 L48 5  
CCR7 APC 150503 10  
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Table 2 (continued). Markers and fluorochrome conjugates included in final 
reagent panels and optimal antibody titers. 
Antibody Fluorochrome Clone Optimal volume per test (µL) 
E. Cytotoxicity Panel 
CD3 Pacific Blue UCHT1 1  
CD4 Qdot 605 S3.5 0.5  
CD8 APC-H7 SK1 0.6  
CD28 PerCP-Cy5.5 L293 7  
CD27 Qdot 655 CLB27/1 0.1  
Perforin APC δG9 5  
Granulysin Alexa Fluor 488 RB1 5  
GrmB Alexa Fluor 700 GB11 1  
Ki67 PE B56 0.1  
 
F. Lymphoproliferation Panel 
CD3 QDot605 UCHT1 1  
CD8 PerCP-Cy5.5 SK1 5  
Ki67 PE B56 0.2  
IFN-γ Alexa Fluor 700 B27 1  
TNF-α PE-Cy7 MAb11 3  
IL-2 APC MQ1-17H12 0.5  
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The goal of the experiments outlined in this chapter was to develop and 
optimise PFC reagent panels to comprehensively characterise BCG-induced 
T cell immunity in infants. Panel development began with the selection of T 
cell effector molecules and phenotypic markers relevant to the aims of this 
study. Markers were selected to allow for: the delineation of T cell subsets 
(CD3, CD4 and CD8), identification of memory T cell populations or T cell 
differentiation stage (CCR7, CD45RA, CD27, CD28), antigen specificity or 
proliferative potential (Ki67) and functional capacity (numerous cytokines and 
cytotoxic molecules). A number of markers and fluorochrome combinations 
were screened during the development and optimisation of reagent panels 
and many were excluded from final reagent panels due to protocol limitations 
or poor performance. For example, CD62L is useful for the identification of 
long-lived memory T cell subsets (Sallusto et al., 1999; Cellerai et al., 2007; 
Miller et al., 2008). However, this marker exhibited diminished resolution 
between positive and negative populations after activation of T cells to such 
an extent that discrimination between the two populations was challenging. 
Protocol limitations led to the exclusion of markers such as CD127, which 
could not be detected on fixed samples and CD154, a marker of antigen-
specificity, which requires antibody addition during cell culture for optimal 
performance (Chattopadhyay et al., 2006b).  
After selecting antigens of interest, fluorescent conjugates were assigned to 
each marker based on antigen density, fluorochrome brightness and spectral 










Chapter 3. Optimisation of polychromatic flow cytometry reagent panels for the 
characterisation of BCG-specific T cell subsets and functional profiles 
 
 73 
Titration of antibodies is critical for interpretable and reliable data and to 
ensure optimal staining performance. Excessive antibody concentrations 
increase non-specific binding, leading to a reduction in signal-to-noise ratios 
and reduce the dynamic range of detection. Conversely, too low a 
concentration results in diminished resolution between negative and positive 
populations and may not sufficiently stain the highest antigen expression 
level. Since batch-to-batch variations are common among tandem conjugates 
and Qdots, these dyes were re-titrated when different lots were received (Wu 
et al., 2007; Hulspas et al., 2009). Tandem dyes are a group of dyes in which 
two fluorescent molecules are covalently linked; one fluorescent molecule 
(donor) is excited and transfers energy to the second fluorescent molecule 
(acceptor), which emits light (Baumgarth and Roederer, 2000). Tandem dye 
variability is related to changes in acceptor to donor ratios during the 
manufacturing process (Baumgarth and Roederer, 2000; Hulspas et al., 
2009). QDots are nanometer sized crystalline clusters synthesised from a 
variety of semiconductor materials. QDot preparation methods may alter 
particle size, shape or introduce small surface defects resulting in the 
synthesis of particles with different optical properties (Wu et al., 2007). 
Therefore, whenever possible, tandem dye conjugates and QDots from the 
same lot were used for the analysis of infant samples.  
FMO controls were used to assess potential staining artefacts and the amount 
of background fluorescence expected in each channel (Maecker et al., 2004; 
Perfetto et al., 2004; Tung et al., 2004). When tandem dyes are included in 
reagent panels, artefacts are of particular concern as these conjugates are 
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fixatives containing paraformaldehyde (Hulspas et al., 2009). FMO controls 
are also useful for determining the extent of data spread between channels 
(Maecker et al., 2004). Although fluorochromes were carefully selected to limit 
this, data spread was observed in some reagent panels and gating strategies 
were adjusted accordingly to accommodate for this error.  
Staining protocols and reagents used for ICS may alter the epitope structure 
of certain proteins and influence the performance of antibodies (Lee et al., 
1999; Berhanu et al., 2003; Kivisakk et al., 2003). All samples processed 
within this study were fixed prior to cryo-preservation with an erythrocyte 
lysing buffer containing paraformaldehyde. Fixing cells stabilises cellular 
membranes and prevents linkage between intracellular and extracellular 
proteins (Pollice et al., 1992). However, paraformaldehyde alters three-
dimensional protein conformations resulting in modified epitope structures and 
therefore the ability of an antibody to recognise its target antigen (Pollice et 
al., 1992; Macey and McCathy, 1993; McCarthy et al., 1994). This is a 
potential explanation for the lack of CD127 staining when using the BD 
Biosciences antibody on fixed whole blood samples. In this study, the anti-
CCR7 antibody was particularly sensitive to variations in staining conditions 
compared to other surface markers. The reason for this variability remains 
unclear as the components of commercially obtained reagents are not 
disclosed by manufacturers. 
The development of PFC has finally provided immunologists with an 
appropriate tool that allows dissection of complex immune responses. PFC 
has several advantages over conventional four colour flow cytometry in that it 
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obtain detailed information from a single sample. This reduces assay 
variability and maximises data accumulated from small sample volumes, such 
as the paediatric samples used in this study. The disadvantages of this 
technology are predominantly due to higher reagent costs and the length of 
time required to optimise large reagent panels and analyse complex data 
sets. This chapter outlines the optimisation processes required for the 
development of PFC panels specifically designed to measure multiple aspects 
of T cell mediated immunity after BCG vaccination of infants. Although 
thorough evaluation of panels is required to obtain accurate and reliable data, 
the advantages of using this technology far outweigh the amount of time and 
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Chapter 4 
BCG vaccination of human newborns induces T cells with 
complex cytokine and phenotypic profiles 
4.1. Introduction 
Our knowledge of immunity induced by BCG vaccination is incomplete, 
particularly after human newborn vaccination. However, infants will be targets 
of novel and more efficacious TB vaccines in the future (Hoft, 2008) and a 
better understanding of the immune response induced by newborn BCG 
vaccination is likely to facilitate development of improved vaccines.  
Experimental evidence suggests that both CD4+ and CD8+ T cells are 
important for protection against M.tb (Flory et al., 1992; Flynn et al., 1992; 
Caruso et al., 1999; Lazarevic et al., 2005). In humans, the role of CD4+ T 
cells has been highlighted by an increased risk of disease after infection with 
M.tb when CD4+ T cell numbers decline in HIV infected persons (Elliott et al., 
2004). CD4+ and CD8+ T cells contribute to anti-mycobacterial immunity 
through the production of the Th1 cytokine, IFN-γ. Numerous studies have 
demonstrated that BCG vaccination of newborns induces CD4+ and CD8+ 
IFN-γ expressing T cells (Vekemans et al., 2001; Black GF, 2002; Davids et 
al., 2006; Murray et al., 2006). IFN-γ expression has been the primary focus of 
these studies as production of this cytokine is typically measured to monitor 
M. tb-specific immune responses (Meier et al., 2005; Dogra, 2006).  
Although IFN-γ plays a crucial role for the effective control of this pathogen 
(Ottenhoff et al., 2003; Dorman et al., 2004), T cells are capable of expressing 
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The pro-inflammatory cytokine, TNF-α, synergizes with IFN-γ to activate 
macrophage anti-mycobacterial activity and plays a key role in granuloma 
formation and maintenance. (Bekker et al., 2001; Roach et al., 2002). The role 
of TNF-α has been underscored by high rates of reactivation of latent TB 
following treatment of rheumatoid arthritis patients with specific inhibitors of 
this cytokine (Stenger, 2005; Saliu et al., 2006). IL-2 drives the optimal 
development of memory T cell populations and is required for T cell 
proliferative capacity (Dooms et al., 2007). Previous studies have also shown 
that BCG vaccination of infants induces TNF-α, which is detectable in plasma 
by ELISA (Davids et al., 2006). However, the expression of all Th1 cytokines, 
on a single cell basis, has not been delineated. 
Although BCG vaccination of infants has been shown to induce low levels of 
Th2 cytokines, detection was in plasma (Marchant et al., 1999; Hussey et al., 
2002; Ota, 2002) and cell-associated expression has not reported. In contrast 
to Th1 cytokine responses, Th2 cytokines are thought to be associated with 
suboptimal anti-mycobacterial T cell mediated immunity. Individuals who 
develop active TB have increased levels of soluble IL-5 detectable in plasma 
and increased frequencies of IL-4-expressing γδ and CD8+ T cells (Ordway et 
al., 2005).  
IL-10 expression was also assessed since this cytokine is likely to be an 
important regulator of effector T cell responses against M. tb (Boussiotis et al., 
2000) and IL-10 expression is induced by newborn BCG vaccination 
(Marchant et al., 1999; Vekemans et al., 2001; Ota et al., 2002). 
The memory phenotype of T cells induced by BCG vaccination of newborns 
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their functional capacity, such as cytokine production or proliferative potential, 
and according to expression of specific surface markers (Sallusto et al., 1999; 
Kaech, 2003; Sallusto et al., 2004; Fritsch et al., 2005; Song et al., 2005). 
Commonly used surface markers include chemokine and co-stimulatory 
receptors, receptors involved in differentiation and markers of activation 
(Appay et al., 2002a; Cellerai et al., 2007; Miller et al., 2008). The original 
classification of human CD4+ and CD8+ T cells into TEM and TCM 
subpopulations was defined according to CD45RA and CCR7 expression 
(Sallusto et al., 1999). TCM cells express CCR7, but not CD45RA, and 
represent a long-lived population, which expand rapidly in lymph nodes upon 
subsequent antigen encounter (Sallusto et al., 2004; Huster, 2006). 
Expression of IL-2, which is critical for the development and survival of 
memory T cells (Dooms et al., 2004), is pre-dominantly associated with TCM 
(Sallusto et al., 1999). In contrast, TEM lack both CCR7 and CD45RA 
expression, have limited proliferative capacity but immediate effector functions 
such as IFN-γ production and cytolytic capacity (Sallusto et al., 1999; Sallusto 
et al., 2004). A third subset, terminally differentiated memory cells (TEMRA), 
express CD45RA, lack CCR7 expression and are the most differentiated 
subpopulation. TEMRA express less or no IL-2, and less IFN-γ compared with 
TEM, and are more likely to undergo apoptosis after encountering antigen 
(Geginat et al., 2003; Fritsch et al., 2005). Naïve, or T cells that have not 
encountered antigen, characteristically express both CD45RA and CCR7 
(Sallusto et al., 1999; Geginat et al., 2003; Fritsch et al., 2005) A combination 
of markers other than CCR7 and CD45RA may also differentiate memory 
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classification of CD4+ T cell populations based on expression of CCR7 and 
the TNFR family member CD27 (Fritsch et al., 2005).  TCM were defined as 
CD27+ and CCR7+, TEM as CD27+ and CCR7–, and TEMRA as CD27– and 
CCR7–. 
In this chapter the cytokine and memory phenotype of BCG-specific T cells 
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4.2. Aims 
Although several investigators have characterised BCG-specific T cell 
responses in infants, these studies used assays that could measure a limited 
number of cytokines or phenotypic markers at a time and thus underestimated 
the complexity of the response. The primary objective of this study was to 
determine which functional and phenotypic markers are expressed on BCG-
specific T cells after BCG vaccination of infants. A short-term ICS assay was 
used to cross-sectionally examine BCG-specific T cell mediated immunity in 
blood from 10-14 week old infants, routinely vaccinated with BCG at birth. 
To achieve this, two cross-sectional analysis were designed to address the 
following aims: 
1. Comprehensively assess BCG-specific CD4+ and CD8+ Th1 and Th2 
intracellular cytokine expression (cross-sectional study 1).  
2. Assess the levels of secreted Th1 and Th2 cytokines in plasma after 
incubation of whole blood with BCG (cross-sectional study 1). 
3. To determine the memory phenotypes of BCG-specific CD4+ and 
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4.3. Materials and methods 
4.3.1. Study participants and phlebotomy 
Infants were recruited as described in chapter 2 (section 2.1.2). Twenty-nine 
infants were recruited into the first cross-sectional study to assess BCG-
specific T cell cytokine expression and 29 into a second study characterising 
T cell memory phenotypes. Blood was collected by qualified phlebotomists 
within the guidelines of written consent. 
 
4.3.2. Antibodies  
The following monoclonal antibodies were used characterise BCG-specific T 
cell responses: 
 
i. Intracellular cytokine panel 
CD3-Amcyan, CD4-Alexa Fluor 700, CD8 PerCPCy5.5, IFN-γ-FITC or IFN-γ-
PE, IL-4-FITC, IL-2-Alexa Fluor 610 PE, TNF-α-PE-Cy7 and IL-10-APC.  
 
ii. Memory phenotype panel 
CD3-Pacific Blue, CD4-PerCPCy5.5 or CD8-PerCPCy5.5, IFN-γ-Alexa Fluor 
700, IL-2-FITC, CD27-PE, CD45RA-PE-Cy7 and CCR7-APC. 
 
All antibodies were obtained from BD Biosciences except for CD3-Amcyan 
and IL-2-Alexa Fluor 610 PE, which were custom conjugated by H. T. 
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4.3.3. Whole blood intracellular cytokine (WB-ICC) assay 
Whole blood was stimulated with specific antigens for a total of 12 hours as 
described previously in chapter 2 (section 2.3.1.).  
 
4.3.4. Plasma cytokine detection (multi-plex bead assay) 
To assess soluble Th1 and Th2 cytokines in plasma, plasma was collected 
from whole blood cultured with BCG for 7 hours, and cryopreserved. Levels of 
IFN-γ, TNF-α, IL-12p70, IL-2, IL-4, IL-5, IL-10 and IL-13 were measured in 
thawed plasma with multiplex beads following the manufacturer’s instructions 
(Bio-Rad Laboratories), and read on a luminometer (Luminex). The range of 
detection for all cytokines was 1.95–32,000pg/mL. An optimal plasma dilution 
of 1:4 was determined in pilot experiments. Background cytokine levels 
measured in plasma harvested from whole blood incubated with co-stimulants 
only were subtracted from BCG-stimulated blood. 
 
4.3.5. Immuno-fluorescence staining and flow cytometric analysis 
i. Intracellular cytokine panel 
Stimulated whole blood was stained with fluorochrome-conjugated antibodies 
using a one step staining method as described in chapter 2 (section 2.5.1). 
Cytokine profiles of T cells were analysed using FACSDiva based on the 
following gating strategy: T cells were first defined based on expression of 
CD3. CD3+ T cell lineages were differentiated according to CD4 and CD8 
expression. Expression of all cytokines were assessed in CD4+ and CD8+ T 
cell populations. To determine co-expression of Th1 cytokines, IFN-γ 
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and TNF-α were assessed within IFN-γ positive (+) and IFN-γ negative (-) 
populations.   
Cut-offs to determine positive cytokine expression in CD4+ and CD8+ T cells 
from blood incubated with BCG were set using cells incubated with co-
stimulants only (NIL, negative control). Negative control (background) values 
for cytokine expression were not subtracted from BCG-induced responses, as 
the median backgrounds was low for all CD4+ T cells (0.001%; range, 
0.000%-0.01%) and for CD8+ T cells (0.000%; range, 0.000%-0.01%). The 
sensitivity of the LSR II used in this study was 0.01%. Therefore, cytokine 
responses above 0.01% were considered reliable. At least 266 610 (median = 
508 509) CD4+ cells and 86 421 (median = 188 498) CD8+ cells were 
acquired for each condition. Angled cut-off lines were necessary for some 
fluorochromes because of increased variance (data spread) after instrument 
compensation. SEB was an excellent positive control for induction of all 
cytokines, except IL-4. HICK-2 cells (BD Biosciences), processed as per 
manufacturer’s protocol were used as a positive control for IL-4.  
 
ii. Memory phenotype panel 
Stimulated whole blood was stained with fluorescent-conjugated antibodies 
using a two step staining method as described chapter 2 (section 2.5.2). 
Phenotypic profiles of BCG specific T cells were analysed using FACSDiva 
according to the following gating strategy: T cell populations were first 
identified in a SSC vs. CD3 dotplot (Figure 1A). T cell lineages were 
differentiated according to expression of CD4 or CD8 (Figure 1A). CD4+ and 
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cells. IFN-γ+, IFN-γ+IL-2+ and IL-2+ T cell subsets were each analysed for 
the expression of CD45RA. (Figure 1B) CD45RA+ and CD45RA- populations 
were then delineated according to CCR7 and CD27 expression (Figure 1). T 
cell phenotyping was carried out on samples which had at least 50 cytokine 
positive events. 
Cut-offs to determine positive cytokine expression in CD4+ and CD8+ T cells 
from blood incubated with BCG were set using cells incubated with co-
stimulants only (NIL, negative control) as previously described. Negative 
control (background) values were not subtracted from BCG-induced cytokine 
responses as the endpoint of this analysis was the phenotype of cytokine 










Chapter 4. BCG vaccination of human newborns induces T cells with complex cytokine and 
phenotypic profiles 
 
  85 
 
Figure 1. Phenotypic profiling of CD4+ Th1 cytokine expressing T cells in 
whole blood incubated with BCG for 12 hours. (A) Gating strategy to identify T 
cells by CD3 expression and T cell lineages by CD4 or CD8 expression. CD45RA 
expression on (B) IFN-γ+ (C) IFN-γ+IL-2+ and (D) IL-2+ subsets were analysed for 
the expression of CD45RA. CD45RA+ and CD45RA- populations were delineated 
according to CD27 and CCR7 expression. Cytokine expressing T cells (in colour; 
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4.4. Results 
4.4.1. Newborn vaccination with BCG induces complex Th1 CD4+ and 
CD8+ T cell responses 
Intracellular expression of three Th1 cytokines thought to be critical for 
protective immunity against mycobacteria, IFN-γ, IL-2 and TNF-α, were 
evaluated by incubating blood from 29 BCG-vaccinated infants with BCG for 
12 hours. The median frequencies of CD4+ T cells expressing either IFN-γ or 
IL-2 or TNF-α were similar (Figure 2). Lower frequencies of CD8+ T cells 
expressed IFN-γ, IL-2, or TNF-α, compared with CD4+ T cells (Figure 2). 
 
 
Figure 2. Individual Th1 cytokine expression of BCG-specific T cells. Frequency 
of CD4+ (☐) and of CD8+ (r) T cells expressing individual Th1 cytokines following 
incubation of whole blood with BCG for 12 hours, in 29 infants. Responses above 
0.01% were considered reliable. The horizontal line indicates the median and the 
whiskers the interquartile range. Differences were calculated using the Wilcoxon 
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A strong positive correlation between the frequencies of IFN-γ- or IL-2- or 
TNF-α-expressing CD4+ and CD8+ T cells was observed (r = 0.770, r = 
0.879, r = 0.760, respectively, all p < 0.0001).  
Analysis of simultaneous expression of IFN-γ, IL-2, and TNF-α on a single cell 
level revealed seven distinct Th1 cytokine-expressing CD4+ T cell populations 
(Figure 3A). Among CD8+ T cells, the dominant population expressed IFN-γ 
only and three other populations were discernable (Figure 3B). IFN-γ 
production is typically measured to diagnose latent infection (Mahomed et al., 
2006; Janssens et al., 2007) or to describe human immune responses to TB 
vaccines (McShane et al., 2004). Importantly, a proportion of CD4+ T cells 
expressing IL-2 and/or TNF-α did not co-express IFN-γ (Figure 3A). Similarly, 
among CD8+ T cells, a proportion of IL-2-expressing T cells did not co-
express IFN-γ (Figure 3B).  
 
 
Figure 3. Th1 cytokine subsets induced by BCG vaccination. Frequency of BCG-
specific (A) CD4+ and (B) CD8+ T cells T cells expressing different combinations of 
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Total Th1 cell responses were dominated by IFN-γ expression (Figure 4A 
and B) and the frequency of IFN-γ expressing T cells correlated significantly 
with the total Th1 response (Figure 4C and D). However, measuring IFN-γ 
alone did not detect all Th1 cytokine-expressing T cells.  
Taken together, these data show that BCG vaccination of newborns induces 
multiple Th1 cell subsets defined by expression of distinct cytokine 
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Figure 4. CD4+ and CD8+ T cells pre-dominantly express IFN-γ. (A) Comparison 
of frequency of CD4+ and of CD8+ T cells expressing IFN-γ+ only (n) T cells IFN-γ- 
expressing IL-2 and/or TNF-α (☐), in 29 BCG-vaccinated infants. (B) Representative 
intracellular staining of Th1 cytokines in BCG-specific CD4+ T cells and CD8+ T cells, 
from a single 10-week old infant. Relationship between the frequency of (C) CD4+ 
and (D) CD8+ T cells expressing IFN-γ alone, and cells expressing any Th1 cytokine. 
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4.4.2. BCG-specific IL-10 and IL-4 intracellular cytokine expression 
The frequency of T cells expressing IL-10 or IL-4 following incubation of whole 
blood with BCG was low (Figure 5). Few donors had responses above 0.01%, 
but IL-10 and IL-4 production were consistently above the background 
expression levels found in NIL controls (Figure 5A and D). CD4+ T cell 
expression of both cytokines was marginally higher than that of CD8+ T cells 
(data not shown). Intracellular IL-4 could be readily be detected in HICK-2 
cytokine-expressing cells, which served as positive control (Figure 5C).  
These data show that intracellular IL-4 and IL-10 expression are not reliably 
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Figure 5. IL-10 and IL-4 frequencies were below the detection limit of this 
assay. Expression of (A) IL-10 or (C) IL-4 in CD4+ T cells in whole blood from a 
single, vaccinated infant. Frequency of CD4+ T cells expressing (B) IL-10 or (D) IL-4 
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4.4.3. Th1 and Th2 cytokines are detectable in plasma following incubation 
of whole blood with BCG 
All three Th1 cytokines and IL-12p70 could also be detected in plasma 
(Figure 6). There was a significant correlation between plasma levels of IFN-
γ, IL-2, and TNF-α and frequencies of CD4+ T cells producing these cytokines 
(Table 1). Plasma IFN-γ and IL-2 also correlated with frequencies of CD8+ T 
cells producing IFN-γ and IL-2, respectively (Table 1). 
IL-4, IL-10 and IL-13 were detected at low levels in plasma (Figure 7) and IL-
13 correlated with IL-4 levels (r=0.5924, p<0.001). IL-5 was also measured, 
however levels of this cytokine were below the detection range of the assay. 
 
 
Figure 6. Th1 cytokines detected in plasma. Levels IFN-γ, IL-2, TNF-α and IL-
12p70 detected by bead array in plasma from whole blood incubated with BCG for 7 
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Table 1. Association between Th1 cytokine levels in plasma, and frequencies 
of CD4+ or CD8+ T cells expressing these cytokines, after incubation of whole 
blood with BCG.   
 
CD4+ T cells expressing 
cytokine 
CD8+ T cells expressing 
cytokine 
 r p r p 
Plasma IFN-γ 0.6793 <0.0001 0.6305 0.0004 
Plasma IL-2 0.6441 0.0003 0.6013 0.0009 
Plasma TNF-α 0.4034 0.01 0.3187 0.1052 




Figure 7. Th2 cytokines detected in plasma. Levels of the Th2 cytokines IL-4, IL-
13, and IL-10, detected by bead array in plasma from whole blood incubated with 
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These data show that Th1 cytokines are detectable in plasma after short-term 
incubation of whole blood with BCG and correlate with intracellular cytokine 
expression. BCG vaccination of newborns also induces low levels of Th2 
cytokines, which can be detected in plasma.  
 
4.4.4. BCG vaccination of newborns induces Th1 CD4+ and CD8+ T 
cells with a predominantly TEM phenotype 
Studies in infectious disease and vaccine models have shown that distinct 
memory subsets of antigen-experienced T cells may be associated with long-
lived protection (Combadiere et al., 2004; Zaph et al., 2004b). Therefore the 
phenotypic profiles of BCG-induced T cells were examined. Antigen-specific T 
cells were defined based on IL-2 and/or IFN-γ expression (Figure 2). BCG 
vaccination induced a heterogeneous Th1 CD4+ and CD8+ T cell response 
as described previously (data not shown). Five distinct T cell phenotypes were 
discerned among specific CD4+ T cells, based on expression of CD45RA, 
CCR7 and CD27 (Figure 8). The most common phenotype of both IFN-γ and 
IL-2 expressing CD4+ T cells was CD45RA-CCR7-CD27+ (Figure 9), a 
phenotype that has been reported to be characteristic of TEM. The second 
most common phenotype among IFN-γ expressing CD4+ T cells was 
CD45RA-CCR7-CD27-, also characteristic of TEM (Figure 9). Among IL-2 
expressing CD4+ T cells, the latter population was significantly less frequent 
(Figure 9). IL-2+ cells were more likely to be CD45RA+CCR7-CD27+, 
CD45RA+CCR7+CD27+ and CD45RA-CCR7+CD27+ compared with IFN-γ 
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and IL-2 were predominantly CD45RA–CCR7–CD27+ or CD45RA–
CCR7+CD27+ (Figure 9).  
 
Figure 8. Phenotypic analysis of BCG-specific CD4+ T cells. Antigen-specific 
CD4+ T cells were identified as (A) IFN-γ+, (B) IL-2+ and (C) IFN-γ +IL-2+. Cytokine 
subsets were phenotyped according to CD45RA, CCR7 and CD27 expression. The 
plots illustrate the distribution of cytokine expressing cells (in colour; foreground) in 
relation to the entire CD4+ T cell population (grey; background, also shown in (D). 
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As a comparison, the expression of phenotypic markers among cytokine-
negative CD4+ T cells are depicted in Figure 9C. 
 
 
Figure 9. BCG specific CD4+ T cell memory subsets. Frequency of different 
subsets of BCG-specific CD4+ T cells, based on expression of CD45RA, CCR7 and 
CD27 among (A) IFN-γ+ and IL-2+ and (B) IFN-γ+IL-2+ expressing CD4+ T cells. (C) 
shows the frequency of these cells among cytokine-negative, i.e., mostly 
mycobacteria-non-specific, CD4+ T cells. The horizontal line represents the median 
and the whiskers the interquartile range. Differences were calculated using the 
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CD4+IL-2+ T cells expressed significantly higher levels of CCR7 and CD45RA 
compared to CD4+ T cells expressing IFN-γ (Figure 10). No significant 
difference in CD27 expression was observed (data not shown). 
 
 
Figure 10. (A) CD45RA and (B) CCR7 expression of BCG specific CD4+ T cells. 
The horizontal line represents the median. Differences were calculated using the 
Kruskal-Wallis test followed by the Wilcoxon matched pairs test. Ns, not significant. 
 
 
Phenotyping of BCG-specific CD8+ T cells was reliable only for IFN-γ 
expressing cells as the number of events available for analysis of other CD8+ 
T cell cytokine subsets were too low. CD8+IFN-γ+ T cells also displayed a 
pre-dominant CD45RA-CCR7-CD27+ effector phenotype (Figure 11A). The 
expression of phenotypic markers among cytokine-negative CD8+ T cells are 
depicted in Figure 11B. 
Collectively, these data show that the majority of specific T cells induced by 
BCG vaccination of newborns have a TEM phenotype, and that IL-2 expression 
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Figure 11. BCG-specific CD8+ T cell memory subsets. Frequency of BCG-specific 
CD8+ T cell subsets based on expression of CD45RA, CCR7 and CD27 among (A) 
IFN-γ+ and (B) cytokine negative CD8+ T cells. The horizontal line represents the 
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4.5. Discussion 
Recent advances in flow cytometry have led to more comprehensive 
characterisation of antigen-specific T cell effector functions at the single cell 
level (Perfetto et al., 2004). In this study, PFC analysis revealed that BCG 
vaccination of newborns induces a diverse set of T cells delineated by distinct 
cytokine expression profiles. Prior to the work completed in this project, the 
polyfunctional (co-expression of multiple cytokines) nature of BCG-specific T 
cells after newborn vaccination had not been described.  
As has been demonstrated previously, BCG-specific T cells produced mainly 
Th1 cytokines. However, an important observation was that Th1 cytokines 
were co-expressed in multiple combinations with a considerable number of 
IFN-γ negative CD4+ T cells expressing IL-2 and TNF-α.  Similarly, a 
proportion of CD8+ T cells produced IL-2 in the absence of IFN-γ. This is an 
important observation as the most commonly used measure of mycobacteria-
induced immunity is IFN-γ production, be this to diagnose latent infection via 
IFN-γ release assays (Mahomed et al., 2006; Janssens et al., 2007) or to 
describe human immune responses to novel tuberculosis vaccines (McShane 
et al., 2004) or BCG (Hussey et al., 2002; Davids et al., 2006). Consequently, 
the measurement of a single component of the immune response, such as 
IFN-γ expression has underestimated the magnitude and complexity of BCG-
induced immunity. Additionally, experimental data suggest that measuring 
IFN-γ alone may not correlate with vaccination-induced protection against 
tuberculosis (Hovav et al., 2003; Hope et al., 2005; Majlessi et al., 2006). 
These findings strongly support measurement of multiple relevant cytokines 










Chapter 4. BCG vaccination of human newborns induces T cells with complex cytokine and 
phenotypic profiles 
 
  100 
BCG-induced CD8+ T cells expressing Th1 cytokines were also readily 
detectable confirming previous observations that BCG is capable of inducing 
CD8+ T cell responses (Smith et al., 1999; Murray et al., 2006). Murine 
studies suggest that CD8+ T cells play an important role in control of M. tb 
infection and contribute substantially to total IFN-γ production (Lazarevic et 
al., 2005). Although BCG-induced CD8+ T cell responses have been 
described before (Smith et al., 1999; Murray et al., 2006), the data presented 
here show that the response is characterised by both IFN-γ and IL-2 
producing subsets. BCG-specific CD8+ T cells expressed significantly less 
Th1 cytokines than CD4+ T cells. Antigen load has been shown to be a 
determinant of CD8 T activation following mycobacterial infection (Russel et 
al., 2007; Ryan et al., 2009). Therefore, low Th1 CD8+ T cell responses 
following BCG vaccination of infants may be attributed to reduced antigen 
load at the site of T cell priming (Ryan et al., 2009). The low levels of TNF-α 
expression by CD8+ T cells observed here contrast with previous published 
data. Smith, et al., detected similar frequencies of CD8+ T cells expressing 
TNF-α and IFN-γ  following incubation of PBMC with BCG for 6 days (Smith et 
al., 1999). The contrasting low frequency of TNF-α expression observed in 
this study could be due to differences in assays, as cytokine expression was 
measured 12 hours after incubation of whole blood with BCG. In longer term 
assays such as those performed by Smith, et al., TNF-α production may be 
derived from newly differentiated effector T cells, whereas short term assays 
measure cytokine producing potential directly ex vivo (Schwendemann et al., 
2005; Hanekom et al., 2008). The results presented here also contrast with 
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express TNF-α in short-term intracellular cytokine assays (de Castro Cunha 
et al., 2005; Betts et al., 2006), implying that BCG-specific CD8+ T cells in 
newborns express little TNF-α. 
PFC is a highly sensitive technique that allows analysis of rare events such as 
those measured within this study. Despite this, IL-4 and IL-10 could not be 
reliably detected intracellularly. Although IL-4 and IL-10 responses were 
below the reliable detection limit of the ICS assay, CD4+ T cell expression of 
these cytokines was in most infants greater than background frequencies. 
Soluble IL-4, IL-10 and IL-13 were however detectable in plasma by a 
sensitive multi-plex bead array. Expression of Th2 cytokines has been 
associated with a sub-optimal immune response to mycobacteria (Hernandez-
Pando et al., 1996; Wedlock et al., 2003). For example, Ordway, et al., 
showed that long-term control of latent M.tb infection in humans appeared to 
be associated with optimal Th1 cytokine production and absence of 
detectable Th2 cytokine production (Ordway et al., 2004). This study showed 
that high percentages of IL-4 expressing CD8+ and γδ T cells in latently 
infected individuals were associated with ultimate development of TB disease. 
IL-4 expressing cells were detected after incubation of PBMC for 6 days, 
which contrasted with the 12-hour assay completed in this study. Longer-term 
assays may be required to detect these cells in the setting of BCG vaccination 
of the newborn. Intracellular expression of IL-10 could also be detected in this 
cohort, but was low. These cells are likely to represent induced Treg cells, 
which are expected to be present at low frequencies. Treg cells control 
conventional effector immune responses, are induced by infections (Grazia 
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levels of Th2 cytokine production was low in comparison to the dominant Th1 
response, indicating that the Th2 cytokines potentially play a immuno-
regulatory roll. 
The data presented here clearly demonstrate the advantages of complex 
multiparameter analysis for deciphering vaccine-induced immune responses. 
The value of this type of analysis over more traditional techniques is that the 
quality of the immune response can be assessed. However, this technology is 
expensive and not readily available. It is therefore important to note that the 
measurement of intracellular IFN-γ alone appears to be a good surrogate 
measurement of the total Th1 response, as the frequency of CD4+ or CD8+ T 
cells expressing this cytokine alone correlated well with the frequency of total 
Th1 response. Also, when flow cytometry is not available, plasma levels of 
IFN-γ or IL-2 may serve as surrogates of T cell cytokine production. Plasma 
levels of Th1 cytokines correlated strongly with intracellular expression 
despite the fact that non-T cells also have the ability to make these cytokines 
(Esin et al., 2004; Feinberg et al., 2004). Importantly, TNF was a poor 
correlate and may not be a good surrogate. This poor correlation may be 
attributed to high quantities of TNF secreted by innate cells in response to 
BCG. 
The heterogeneous nature of T cells based on cytokine expression profiles 
has been described in various models of infection and vaccination (Harari et 
al., 2004a; Harari et al., 2005; Beveridge et al., 2007; Precopio et al., 2007). 
Exploring the quality of T cell responses may be highly relevant as the 
induction of polyfunctional T cells, either through infection or vaccination, have 
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al., 2007). In models of chronic viral infection these cells have shown to be 
superior in controlling viral replication (Kannanganat et al., 2007a; 
Kannanganat et al., 2007b). For example, in HIV infection the presence of 
polyfunctional HIV-specific T cell populations is associated with better clinical 
outcome (Betts, 2006; Kannanganat et al., 2007b). In the mouse model of 
Leishmania major (L. major) infection, polyfunctional T cell induction is also 
associated with lower parasite burden (Darrah et al., 2007). These data 
suggest that measurement of these cells may also be important following 
BCG vaccination. 
The memory phenotype of BCG-induced T cells after vaccination of infants 
has not been described. In this study, five phenotypically distinct subsets 
within BCG-specific Th1 cells were identified based on CD45RA, CCR7 and 
CD27 expression. A predominant CD45RA-CCR7-CD27+ effector phenotype 
was displayed by BCG-specific CD4+ and CD8+ T cells, irrespective of 
whether these cells produced IFN-γ or IL-2. This observation is of interest as 
CCR7- effector phenotypes are characteristic of antigen-specific T cells seen 
in chronic viral infections (Appay et al., 2002a; Harari et al., 2004a; Harari et 
al., 2004b). In contrast, antigen-specific T cells retain or re-express CCR7 and 
display a predominantly TCM phenotype in vaccine models of cleared antigen 
such as TT and hepatitis B surface antigen (HBs) (Cellerai et al., 2007; 
Stubbe et al., 2008). The predominantly CCR7- phenotype observed in 10-14 
week old BCG vaccinated infants may arise due to a number of factors. 
Firstly, exposure of infants to cross-reactive environmental mycobacteria or 
persistence of BCG following vaccination may contribute to activation of T 
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this study is a direct ex vivo measurement of antigen-specific cells and may 
not represent the entire BCG-specific memory response. For example, short-
term assays are likely to measure TEM responses as this subset displays 
immediate effector functions. However longer term assays are required to 
measure TCM proliferation and cytokine expression (Combadiere et al., 2004; 
Hanekom et al., 2008). Thirdly, BCG-specific CCR7+ T cells may reside pre-
dominantly in secondary lymphoid organs and would only be detectable when 
re-circulating through the peripheral blood. Lastly, although classification of 
memory T cell subsets according to CD45RA, CCR7 and CD27 expression is 
informative, these markers may not always accurately reflect the long-lived 
potential of T cells in vivo. In humans, long-term memory T cells specific for 
vaccinia virus have been shown to have a pre-dominantly TEM (CD45RA-
CCR7-CD27+) phenotype years after smallpox vaccination (Combadiere et 
al., 2004) and not the classical TCM phenotype.  
A significant proportion of BCG-specific CD4+ and CD8+ T cells had a 
phenotype traditionally regarded as naïve, i.e., CD45RA+CCR7+CD27+. In a 
recent study of children with tuberculosis, Caccamo et al. also described this 
population, identified as specific by MHC I pentamers of antigen-85A 
(Caccamo et al., 2006). The CD45RA+CCR7+ populations observed here 
might be indicative of an early antigen-specific population that has not yet lost 
CD45RA expression.  
Distinct differences in phenotypes were observed amongst CD4+ IFN-γ and 
IL-2 expressing cells. IL-2 expressing cells were significantly more likely to 
express CCR7 compared with IFN-γ expressing cells. Therefore, a subset of 
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to that previously described for purified human TCM populations, which are 
likely to express IL-2 (Sallusto et al., 1999). TCM persist in vivo in the absence 
of antigen, conferring long-term protection to the host (Sallusto et al., 1999; 
Sallusto et al., 2004; Zaph et al., 2004b). In the experimental L. major model 
of infection, TCM (defined by CD62L expression) conferred protection by 
proliferating and differentiating into effector CD4+ T cells capable of IFN-γ 
production (Zaph et al., 2004b). Like M. tb, L. major is an intracellular 
pathogen and protection against L. major infection is associated with the 
development of a Th1 cytokine response (Sacks and Noben-Trauth, 2002). 
The IL-2 expressing TCM subset observed following BCG vaccination of 
infants may confer long-term protection by maintaining memory cells capable 
of differentiating into Th1 effector cells upon antigen encounter (Zaph et al., 
2004a; Bouneaud et al., 2005). 
Collectively, these data indicate that BCG vaccination of newborns elicits 
polyfunctional Th1 cells, which predominantly express a TEM phenotype. BCG 
vaccination also induces low level expression of type 2 cytokines and IL-10, 
that may play an immuno-regulatory role. The kinetics of BCG-specific T cell 
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Chapter 5 
Longitudinal characterisation of CD4+ and CD8+ T cells 
directly ex vivo. 
5.1. Introduction 
Characterising functional and phenotypic changes in T cells over the first year 
of life is important for understanding factors that influence the development of 
the immune system during infancy. T cells develop in the thymus from 
common hematopoietic lymphoid progenitors that migrate from the bone 
marrow. The main goals of lymphopoiesis are to generate a T cell repertoire 
with broad TCR diversity and to generate a sufficiently large enough clonal 
pool size of naïve T cells with a particular specificity. In the thymus naïve T 
cell diversity is established through numerous re-arrangements of gene 
segments encoding the variable portions of the TCR α and β chains 
(Shortman and Wu, 1996). Once naïve T cells exit the thymus, clonal 
population sizes are established through post-thymic proliferation (Hassan 
and Reen, 2001). Survival and maintenance of a stable peripheral T cell 
population is maintained through homeostatic proliferation driven by common 
γc cytokines, IL-7 and IL-15 (Lantz et al., 2000; Geginat et al., 2001; Bradley 
LM 2005; Fry and Mackall 2005).  
Naïve T cells undergo functional and phenotypic changes, which are driven by 
numerous encounters with foreign antigens. Consequently, a progressive shift 
in the composition of the peripheral T cell pool from a naïve phenotype 
towards an antigen-experienced phenotype is observed from infancy to 
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addition, antigen exposure drives in vivo turnover of T cells which can be 
monitored by methodologies including Ki67 expression by T cells directly ex 
vivo or using in vivo DNA labels such as deuterated glucose or water. 
(Sachsenberg et al., 1998; Hellerstein et al., 1999; Miller et al., 2008; van 
Gent et al., 2009). 
Age-related changes in memory T cell distribution has been demonstrated in 
a number of longitudinal studies analysing a large number of surface 
molecules including CD27, CD28, CCR7 and CD45RO expression (Tsegaye 
et al., 2003; Saule et al., 2006; van Gent et al., 2009). In this chapter, 
maturation of T cells over the first year of life was determined by assessing 
CD27 and CD28 expression. According to this model of differentiation, early 
differentiated antigen-experienced and naïve T cells defined by CD27 and 
CD28 co-expression, progress through an intermediate differentiation stage 
associated with the loss of CD27 on CD4+ T cells and CD28 on CD8+ T cells. 
Fully differentiated T cells lack expression of both CD27 and CD28 (Appay et 
al., 2002a; Kovaiou et al., 2005). Numerous studies have shown an 
association between distinct stages of T cell differentiation and functional 
capacity, such as proliferation and the expression of effector molecules. For 
example, T cells that express a highly differentiated or mature phenotype 
express cytotoxic molecules but show diminished proliferative capacity 
(Appay et al., 2002a; Appay et al., 2002c; Tomiyama et al., 2004). Given that 
cytotoxic molecules are stored in pre-formed granules within antigen-
experienced T cells, these molecules could be analysed directly ex vivo 
without activating T cells with specific antigens (Appay et al., 2002c).  
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over, expression of differentiation markers and expression of cytotoxic 
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5.2. Aims 
Neonatal T cells predominantly express a naïve phenotype, however 
homeostatic mechanisms required for T cell survival and exposure of infants 
to foreign antigens contributes to functional and phenotypic changes within 
the peripheral T cell compartment. Characterising these changes over the first 
year of life, when infants are continuously exposed to foreign antigens through 
vaccination and environmental exposure, is important for understanding the 
development of the immune system. To assess longitudinal changes within 
the whole T cell compartment, the following aims were addressed:  
1. Determine ex vivo T cell turnover kinetics over the first year of life. 
2. Characterise changes in T cell cytotoxic molecule expression directly 
ex vivo during the first year of life. 
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5.3. Materials and methods 
5.3.1. Study participants and phlebotomy 
The infants studied in this chapter were selected from the longitudinal cohort 
described in chapter 2, for which direct ex vivo samples had been collected. 
Direct ex vivo assessment of T cells was completed on samples collected 
from 47 infants. Cross-sectional and longitudinal analyses were done. 
 
5.3.2. Sample processing and antibodies 
Fresh whole blood was lysed and fixed with FACS lysing solution directly ex 
vivo, cryo-preserved and stained with the optimised “Cytotoxic Panel” shown 
in chapter 3 using the “one step staining method” described in chapter 2 
(section 2.5.1.). Samples for all time points from each individual were stained 
and acquired in a single batch to reduce variability. 
 
5.3.3. Data analysis 
T cells were identified using a SSC vs. CD3 dotplot. Cell doublets were 
excluded using forward scatter-area versus forward scatter-height 
parameters. Samples collected for the longitudinal study were cryo-preserved 
for lengthy periods of time (>1 year for some samples), which may result in 
the accumulation of cellular debris. Debris or dead cells tend to auto-fluoresce 
in the 490nm-560nm range and are identifiable as a diagonal line between the 
FITC and PE channel. When necessary, dead cells/debris were identified and 
excluded by gating using a Ki67-PE vs. granulysin-Alexa Fluor 488 dotplot. 
CD4+ and CD4- T cells were identified using a CD4 vs. Ki67 dotplot. CD8+ T 
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GrmB dotplot. A skewed gate was used to select CD8+ T cells due to data 
spread between the APC-H7 and Alexa Fluor 700 channels (Figure 1A). 
Boolean gating analysis was carried out once positive gates were established 
for functional parameters (Figure 1B and C). Single-stained mouse  beads 
were used to calculate compensations for every run. Data were analysed with 
FlowJo software v 9.0.1, Pestle v 1.6.2 and Spice v 5.1 software (provided by 
M. Roederer, National Institutes of Health, Bethesda, MD). Statistical 
analyses were performed using GraphPad Prism v 4.0.  
 
Figure 1. Flow cytometric analysis of T cell cytotoxic molecule expression and 
differentiation phenotypes. (A) Gating strategy from a representative 6-week old 
infant. Representative dotplots showing boolean analysis of Ki67, GrmB, granulysin, 
perforin and differentiation markers CD27 and CD28 on (B) CD4+ and (C) CD8+ T 
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5.4. Results 
5.4.1. Longitudinal analysis of CD4+ and CD8+ T cell turnover  
In vivo CD4+ and CD8+ T cell turnover was investigated by measuring the 
expression of Ki67 by T cells directly ex vivo. Cross-sectional analysis 
showed that Ki67 expression by CD4+ T cell peaked at 6 weeks of age 
(median, 6.85%) and remained at a relatively steady plateau over the first 
year of life (p=0.2463, Kruskal-Wallis; Figure 2A and B). The turnover 
kinetics and magnitude of CD8+ T cells differed to that observed for CD4+ T 
cells. At 3 weeks after vaccination, Ki67 expression on CD8+ T cells was 
similar to that observed in CD4+ T cells, but at all other time points more 
CD8+ T cells expressed Ki67 than CD4+ T cells. The frequency of 
Ki67+CD8+ T cells was higher at 6 weeks of age and thereafter compared 
with 3 weeks. The frequency of Ki67+CD8+ T cells peaked at 14 weeks 
(median, 16.06%) and thereafter gradually declined with age (Figure 2B and 
C). To corroborate the results obtained by cross-sectional analysis, results 
from individual infants were investigate longitudinally. Consistent with cross-
sectional observations, longitudinal analysis of Ki67 expression in CD4+ and 
CD8+ T cells showed that a subset of T cells consistently express Ki67 over 
the first year of life and confirmed that the turnover kinetics of CD8+ T cells 
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Figure 2. T cell turnover over the first year of life. (A) Representative dotplots 
showing longitudinal changes in the frequency of CD4+ (blue; foreground) and CD8+ 
(green; foreground) T cells expressing Ki67 in whole blood directly ex vivo. Dotplots 
are gated on CD3+ lymphocytes (red; background). This example is from a 
representative BCG-vaccinated infant at 10 weeks (wks), 14wks and 27wks of age. 
Values in each dotplot represent the frequency of  Ki67+ T cells within the CD4+ 
(upper) and CD8+ (lower) T cell population. Cross-sectional analysis of Ki67 
expression in (B) CD4+ and (C) CD8+ T cells. The horizontal line indicates the 
median and the whiskers the interquartile range. Differences were calculated using 
the Kruskal-Wallis test followed by a Mann Whitney U test. Longitudinal changes in 
Ki67 expression in (D) CD4+ and (E) CD8+ T cells for individual infants. Each line 
represents a different infant. Statistical analyses were not performed on longitudinal 
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These findings show that T cells remain in a constant state of in vivo 
proliferation throughout the first year of life and that turnover kinetics differ 
between CD4+ and CD8+ T cell. 
 
5.4.2. Longitudinal analysis of T cell cytotoxic molecule expression 
directly ex vivo 
Expression of cytotoxic molecules GrmB, granulysin and perforin was 
assessed cross-sectionally in CD4+ and CD8+ T cells. At 3 weeks of age both 
CD4+ and CD8+ T cells expressed low levels of all 3 cytotoxic molecules 
(Figure 3A-D). A gradual increase in the frequency of CD4+ T cells 
expressing GrmB, granulysin and perforin was observed from 3 to 52 weeks 
of age (Figure 3A and C). Frequencies of GrmB expressing CD4+ T cells 
were significantly higher at 14 weeks of age and all other time points 
thereafter compared to 3 weeks. Frequencies of perforin and granulysin 
expressing CD4+ T cells were significantly higher at 27 weeks of age and 
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Figure 3. Cross-sectional analysis of T cell cytotoxic molecule expression 
directly ex vivo. Representative dotplots showing longitudinal changes in Ki67, 
GrmB, granulysin and perforin expression in (A) CD4+ and (B) CD8+ T cells. Whole 
blood was analysed directly ex vivo following lysis of red blood cells. Dotplots are 
from a representative BCG-vaccinated infant at 3 weeks (wks), 27wks and 52wks of 
age. Values in each boolean gate represent the frequency of CD4+ or CD8+ T cells 
expressing Ki67 or cytotoxic molecules. Kinetic changes in GrmB, granulysin and 
perforin expression in (C) CD4+ and (D) CD8+ T cells. The horizontal line indicates 
the median and the whiskers the interquartile range. Differences were calculated 
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An increase in the frequency of CD8+ T cells expressing cytotoxic molecules 
was also observed over time (Figure 3B and D). This increased expression 
was more pronounced than that observed for CD4+ T cells and the median 
frequency of CD8+ T cells expressing cytotoxic molecules was higher at all 
time points compared with CD4+ T cells (Figure 3A-D). Frequencies of GrmB 
and granulysin expressing CD8+ T cells were significantly higher at 6 weeks 
of age and thereafter compared with 3 weeks, perforin expressing CD8+ T 
cells were significantly higher at 14 weeks of age and thereafter (Figure 3D).  
Longitudinal analysis showed a continuous increase in the frequency of CD4+ 
and CD8+ T cells expressing cytotoxic molecules over the first year of life and 




Figure 4. Longitudinal changes in T cell cytotoxic molecule expression directly 
ex vivo. Longitudinal changes in GrmB, granulysin and perforin expression in (A) 
CD4+ and (B) CD8+ T cells for individual infants. Each line represents a different 
infant. Statistical analyses were not performed on these data. Please refer to the 
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These data show that the frequencies of CD4+ and CD8+ T cells expressing 
cytotoxic molecules increases with age. 
 
5.4.3. Qualitative changes in the total T cell compartment and in Ki67+ 
T cells 
To determine changes in the quality of the T cell response, the proportions of 
T cells expressing cytotoxic molecules was monitored over time. Cross-
sectional analysis showed that at 3 weeks, <10% of CD4+ T cells within the 
total CD4+ T cells compartment expressed cytotoxic molecules or Ki67 and 
remained low over the first year of life (Figure 5A). A similar trend was 
observed for Ki67+CD4+ T cells: only a small fraction of cycling CD4+ T cell 
expressing cytotoxic molecules. The majority of Ki67+CD4+ T cells expressed 
GrmB. (Figure 5B) By contrast, the proportion of CD8+ T cells expressing 
cytotoxic molecules within the total CD8+ T cell compartment gradually 
increased over the first year of life (Figure 5C). At 52 weeks, >25% of CD8+ T 
cells co-expressed three (3+) or (2+) cytotoxic molecules. The majority of 
CD8+ T cells expressed GrmB and the proportion of T cells expressing 
perforin or granulysin was similar. Perforin was always co-expressed with 
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Figure 5. Changes in the proportion of T cells expressing cytotoxic molecules 
over the first year of life. Pie charts representing the proportions of T cells 
expressing a given number of markers within (A) the total CD4+ T cell compartment, 
(B) Ki67+CD4+ T cells, (C) total CD8+ T cells compartment and (D) Ki67+CD8+ T 
cells. Responses are grouped and colour-coded according to the number of markers 
expressed. The contribution of each marker to each pie slice is depicted by the outer, 
colour-coded arcs. 
 
A similar trend was observed for Ki67+CD8+ T cells. The proportion of cycling 
CD8+ T cells expressing cytotoxic molecules progressively increased over the 
follow-up period (Figure 5D). At 52 weeks >50% of Ki67+CD8+ T cells 
expressed cytotoxic molecules. The majority of Ki67+CD8+ T cells expressed 
GrmB and/or granulysin (Figure 5D). Longitudinal data were consistent with 
results obtained by cross-sectional analysis (data no shown). 
These data show that cytotoxic granule expression is predominantly restricted 
to CD8+ T cells and that the proportion of CD8+ T cells that express cytotoxic 
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5.4.4. Changes in T cell differentiation phenotype  
Differentiation stage of CD4+ and CD8+ T cells was defined according to the 
expression of CD27 and CD28. CD27+CD28+ (early differentiation stage) T 
cells were the pre-dominant CD4+ T cell subset in infants between 3 (median, 
93.05%) and 6 weeks (median, 69.23%) of age (Figure 6A and B). From 10 
weeks of age, most CD4+ T cells expressed an intermediate phenotype 
(CD27-CD28+; median, 88.56%) and retained this phenotype during the 
entire follow-up period (Figure 6A). Changes in the differentiation phenotype 
of CD4+ T cells undergoing cycling (Ki67+) were similar to those observed for 
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Figure 6. Changes in CD4+ T cell differentiation phenotype. Longitudinal 
changes in the differentiation phenotypes of CD4+ T cells based on CD27 and CD28 
expression within the (A) total CD4+ T cell compartment and for (C) Ki67+CD4+ T 
cells. Dotplots are from a representative BCG-vaccinated infant at 3 weeks (wks), 
27wks and 52wks of age. Changes in differentiation phenotypes of T cells within the 
(B) total CD4+ T cell compartment and (D) Ki67+CD4+ T cells. Whole blood was 
analysed directly ex vivo following lysis of red blood cells The horizontal line 
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Differentiation kinetics of CD8 T cells was comparable to that observed for 
CD4+ T cells. Among CD8+ T cells, CD27+CD28+ T cells were predominant 
between 3 (median, 87.91%) and 6 weeks (median, 78.65%) of age (Figure 
7A and B). In contrast to CD4+ T cells, which predominantly retained CD28 
expression over the follow-up period, a subset of CD8+ T cells progressively 
lost expression of both CD27 and CD28. By 52 weeks of age virtually all 
CD8+ T cells expressed an intermediate (CD27-CD28+; median, 70.84%) or 
late (CD27-CD28-; median, 28.90%) differentiation phenotype (Figure 7B). 
Changes in the differentiation phenotype of CD8+ T cells undergoing cycling 
(Ki67+) were similar to those observed for the total T cell compartment 
(Figure 7C and D). Longitudinal data were consistent with results obtained by 
cross-sectional analysis (data no shown). 
These data show that the proportions of circulating CD4+ and CD8+ T cells 
with an intermediate and late differentiation phenotype appear at 10 weeks of 
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Figure 7. Changes in CD8+ T cell differentiation phenotype. (A) Longitudinal 
changes in the differentiation phenotypes of CD8+ T cells based on CD27 and CD28 
expression within the (A) total CD8+ T cell compartment and for (C) Ki67+CD8+ T 
cells. Dotplots are from a representative BCG-vaccinated infant at 3 weeks (wks), 
27wks and 52wks of age. Changes in differentiation phenotypes of T cells within the 
(B) total CD8+ T cell compartment and (D) Ki67+CD8+ T cells. Whole blood was 
analysed directly ex vivo following lysis of red blood cells The horizontal line 
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5.5. Discussion 
During the first year of life the neonatal immune system is continuously 
exposed to foreign antigens, both pathogenic and benign, resulting in marked 
alterations of the T cell compartment. Studies in infants are important for 
assessing the modulatory effects of environmental exposure, infection and/or 
vaccination on T cell function and phenotype.  
In this chapter, in vivo T cell turnover was examined by assessing the 
expression of the nuclear antigen, Ki67, which is expressed by all cycling T 
cells (Gerdes et al., 1984). The data presented here show that T cells remain 
in a constant state of turnover over the first year of life, which may result from 
the high demand for lymphopoiesis in infants. The generation of naïve T cells 
in infants is driven by two mechanisms, thymic output and peripheral T cell 
turnover (Schonland et al., 2003; Hazenberg et al., 2004; van Gent et al., 
2009). Thymopoiesis is required for the generation of a diverse set of naïve T 
cells, while peripheral turnover is required for generation of sufficiently large 
clonal pools of a particular specificity. The contribution of the thymus versus 
homeostatic mechanisms in the establishment of the naive T cell pool can be 
determined by measuring T-cell receptor excision circles (TRECS) 
(Hazenberg et al., 2004; Naylor et al., 2005). TRECS are episomal DNA by-
products generated through cleavage of DNA fragments during TCR α-chain 
rearrangement and are typically used as a marker of recent thymic emigrants 
(Hazenberg et al., 2000). Since TRECS are not replicated during cellular 
division, the frequency of naïve T cells in the periphery generated either in the 
thymus or through homeostatic proliferation can be determined (Al-Harthi et 










Chapter 5. Longitudinal characterisation of CD4+ and CD8+ T cells directly ex vivo. 
 124 
infancy, previous studies in young children have shown that TREC numbers 
remain relatively stable despite increasing numbers of naïve T cells. This data 
shows that post-thymic homeostatic proliferation contributes significantly to 
the establishment and maintenance of the naïve T cell pool in children 
(Schonland et al., 2003; Hazenberg et al., 2004; van Gent et al., 2009).  
In addition, neonatal T cells are highly sensitive to common γc cytokines 
required for homeostatic proliferation, relative to adult T cells. In the absence 
of TCR triggering, naïve CD4+ and CD8+ T cells isolated from cord blood 
have greater proliferative capacity in response to IL-7 and IL-15, compared 
with adult T cells (Schonland et al., 2003). However, it is important to note that 
the high concentrations of common γc cytokines used in in vitro studies may 
not represent in vivo physiological levels. Nevertheless, neonatal naïve T cells 
express high levels of the IL-7R and higher levels of IL-7 are detected in 
serum compared with adults (Bolotin et al., 1999). Therefore the high demand 
for T cell generation and the intrinsic sensitivity of neonatal T cells to common 
γc cytokines potentially accounts for the fraction of Ki67+ T cells observed 
throughout the first year of life.  
In addition to homeostatic mechanisms, exposure of naïve T cells to antigens 
through vaccination, infection and/or the environment are thought to 
contribute markedly to in vivo proliferation. Ex vivo levels of Ki67 expression 
in T cells increase transiently following immunisation of adults with vaccines 
that are effectively cleared (Cellerai et al., 2007; Miller et al., 2008). During 
chronic viral infections such as HIV, Ki67 is also elevated compared to healthy 
controls (Sachsenberg et al., 1998). For example, in healthy adults mean Ki67 
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during HIV infection a mean 6.5% of CD4+ T cells and 4.3% of CD8+ T cells 
express Ki67 (Sachsenberg et al., 1998). Infants with known chronic medical 
conditions were excluded from this study; however, we cannot exclude all 
possible co-variants. For example, mothers and infants were not screened for 
CMV infection. Previous studies in both young and elderly subjects have 
shown that CMV-specific T cells do not continuously cycle or show increased 
proliferative capacity in vivo (Wallace et al., 2010). Therefore, CMV infection 
would not explain the high Ki67 expression observed over the first year of life. 
Instead, the 6 scheduled EPI vaccines administered at 6, 10 and 14 weeks of 
age are likely to contribute significantly to the continuous turnover of T cells in 
an antigen-dependent manner. Alternatively, high Ki67 expression may be a 
consequence of other vaccine-related factors such as inflammation. 
Interestingly, Ki67 expression revealed different in vivo turnover kinetics for 
CD4+ and CD8+ T cells, suggesting that homeostatic or antigen driven 
turnover of these two subsets may be different. This is supported by studies 
showing that CD8+ T cells express higher levels of Ki67 than CD4+ T cells in 
early childhood and that accumulation of highly differentiated CD8+ T cells, 
but not CD4+ T cells, is observed in the elderly (Schonland et al., 2003; Saule 
et al., 2006; van Gent et al., 2009).  
An increase in the frequency of both CD4+ and CD8+ T cells to express 
cytotoxic molecules was also observed over time.  Although the frequency of 
CD4+ T cells expressing cytotoxic molecules increased with age, qualitative 
analysis revealed that the majority of CD4+ T cells do not express cytotoxic 
molecules. By contrast, a large proportion of CD8+ T cells within the total T 
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cytotoxic molecules at 52 weeks. These data suggest that cytotoxic molecule 
expression is a dominant feature of CD8+ T cells and that CD4+ T cells are 
likely to mediate their effector functions through the expression of cytokines or 
other effector molecules not measured in this study.  
The expression of cytotoxic molecules such as perforin and Grm has been 
shown to be predominantly restricted to CD4+ and CD8+ T cells with an 
effector or effector memory phenotype, whereas naïve T cells do not express 
these molecules (Appay et al., 2002a; Appay et al., 2002c; Takata and 
Takiguchi 2006). Therefore, the gradual increase in the frequency of T cells 
expressing cytotoxic molecules is most likely associated with an increase in 
the proportion of differentiated or antigen-experienced T cells over time. This 
observation is supported by the analysis of CD27 and CD28 expression, 
which showed an increase in T cells expressing intermediate and late 
differentiation phenotypes over time. The loss of CD27 and CD28 expression 
has been associated with the capacity of T cells to express cytotoxic 
molecules (Appay et al., 2002a; Appay et al., 2002c; Tomiyama et al., 2004; 
Takata and Takiguchi 2006; Makedonas et al., 2010).  
Almost all T cells in the newborn have a naïve phenotype (Schonland et al., 
2003; van Gent et al., 2009) and co-express CD27 and CD28 (Hamann et al., 
1997; McFarland et al., 2000; van Gent et al., 2009). However a progressive 
loss of both molecules is observed from childhood to adulthood as T cells 
become more differentiated (Tsegaye et al., 2003; Saule et al., 2006; van 
Gent et al., 2009). In addition to TCR triggering, proliferation of T cells 
induced through homeostatic cytokines further contributes to T cell 
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express a CD45RO+ memory phenotype after several rounds of antigen-
independent replication induced by IL-15 (Kim et al., 2002; Schonland et al., 
2003; Chiu et al., 2006). Importantly, neonatal CD4+ and CD8+ T cells retain 
a naïve CD45RO- phenotype following IL-7 dependent proliferation. Since IL-
15 preferentially drives the proliferation of CD8+ T cells, the contribution of 
homeostatic turnover to CD4+ T cell differentiation may not be significant. 
Despite the contribution of these mechanisms to T cell differentiation, one of 
the surprising findings of this study was the high proportion of T cells 
expressing an intermediate or late differentiation phenotype after 6 weeks of 
age. An accumulation of highly differentiated T cells has been observed in the 
elderly or under conditions of chronic infection and inflammation (Marchant et 
al., 2003; Tsegaye et al., 2003; Saule et al., 2006; Miles et al., 2008). 
Congenital CMV infection affects up to 3% of all infants born in developing 
countries and may have contributed to the differentiation of T cells observed 
in this study. Significantly higher proportions of both CD4+ and CD8+ T cells 
are observed in CMV-infected infants compared with healthy infants 
(Marchant et al., 2003; Miles et al., 2008). However, the EPI vaccines infants 
receive at 6 weeks of age is also likely to contribute significantly to the 
dramatic switch in T cell differentiation stage observed at 10 weeks of age. 
Booster vaccines administered at the scheduled EPI time points would further 
contribute to the progressive differentiation of T cells observed over the first 
year of life. Since T cells transiently down-regulate CD27 and CD28 after TCR 
triggering and in response to inflammatory and homeostatic cytokines, a 
proportion of T cells expressing this phenotype may represent a transient 
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al., 2001; Kim et al., 2002; Ochsenbein et al., 2004; Chiu et al., 2006). 
Unfortunately the contribution of homeostatic cytokines and antigen-driven 
mechanisms to the differentiation of T cells could not be completely discerned 
in this study as CD27 and CD28 does not allow complete separation of naïve 
and memory T cells. In addition, the influence of vaccine antigens versus 
exposure of infants to environmental antigens on the functional and 
phenotypic differentiation of T cells could also not be discerned.  
A statistical limitation was introduced into this study due to the small volumes 
of blood that could be safely drawn from infants over a specified period of 
time. As a result of this restriction, data was only collected at three to four of 
the seven scheduled time-points. Therefore we were unable to reliably apply 
traditional statistical methods to analyse longitudinal data due to loss of power 
and potential introduction of bias associated with missing data points. 
However, sample size determinations for each time point was such that 
reliable analysis of data could be completed both cross-sectionally (at each 
specific time point) and longitudinally for each infant while taking variability 
into account (chapter 2, section 2.7.2). More appropriate and advanced 
statistical methods which are unaffected by missing data, such as mixed 
effects models, will be carried out by a statistician at a later stage. Despite this 
statistical limitation, longitudinal trends were consistent with those obtained by 
cross-sectional analysis and the data presented here extends onto previously 

















Novel application of Ki67 as a marker of antigen-specific in 
vitro lymphoproliferation.  
6.1. Introduction 
Proliferation and clonal expansion of antigen-specific T cells are critical 
functions for the mediation of protective immunity and immunological memory 
(Rosenberg et al., 1997). In vitro proliferation of antigen-specific human T 
cells is most commonly assessed by detecting incorporation of specific tags 
into actively dividing cells during long-term culture of whole blood or PBMC 
with antigen (Gratzner, 1982; Lyons and Parish, 1994; Mehta and Maino, 
1997; Fulcher and Wong, 1999; Lyons, 2000; Magg and Albert, 2007). 
Measuring this important T cell function has numerous applications, including 
monitoring of vaccine immunogenicity (Davids et al., 2006; Beveridge et al., 
2007; Miller et al., 2008), drug toxicity screening (Elattar and Virji, 2000; 
Hideshima et al., 2000) and exploring immune regulation in disease (Woo et 
al., 2002; Jagannathan et al., 2009; Sharma et al., 2009).  
Until recently the standard method for detection of antigen-specific T cell 
proliferation was through incorporation of 3H-thymidine during DNA replication 
of dividing cells (Payan et al., 1983; Marchant et al., 1999). This technique 
has largely been replaced by more powerful assays that do not require 
radioactive materials and rely on assessment of cell cycling by flow cytometry. 
Fluorescent dye dilution assays, utilising dyes such as 5,6-carboxyfluorescein 
diacetate, succinimidyl ester (CFSE) or its derivative, Oregon Green (OG) 














use of the DNA intercalating agent, 5-bromo-2’-deoxyuridine (BrdU), detected 
by fluorochrome-conjugated antibody staining (Dolbeare et al., 1983; Houck 
and Loken, 1985; Rosato et al., 2001), are typical examples of these. These 
flow cytometry based proliferation assays also allow co-staining of other 
cellular markers, enabling cell sub-populations to be delineated by 
multiparameter analysis (Precopio et al., 2007). This includes 
immunophenotyping of antigen-responsive cells and assessment of other T 
cell functions following antigen stimulation (Lyons, 2000; Bachmann et al., 
2005; Davids et al., 2006).  
Ki67 is a nuclear protein that plays a role in the regulation of cell division and 
is used conventionally in cancer biology as an indicator of tumour cell 
proliferation (Gerdes, 1990; Scholzen and Gerdes, 2000). This protein is 
expressed during all active phases of cell division but is absent in quiescent 
cells and during DNA repair (Gerdes et al., 1984). Assessment of intracellular 
Ki67 expression directly ex vivo or after short-term cell culture has been 
utilised in a number of studies to monitor induction of specific T cell responses 
upon vaccination (Stubbe et al., 2006; Cellerai et al., 2007; Miller et al., 2008), 
or to measure T cell turnover in individuals with chronic viral infections, such 
as HIV (Sachsenberg et al., 1998; Doisne et al., 2004).  
In this chapter, we determine whether antigen-specific lympho-proliferation, 
after long-term culture, can be identified through the analysis of Ki67 















Proliferation of T cells if required to expand effector T cells of a particular 
specificity and is often used as a measure of TCM cell responses following 
vaccination. Proliferation assays are often technically difficult and require the 
incorporation of dyes or DNA intercalating agents, which are toxic to cells. In 
this chapter, Ki67 was explored as a specific and quantitative indicator of in 
vitro T cell proliferation by establishing the following aims: 
1. Determine the kinetics of Ki67 expression in T cells following long-term 
culture with antigen. 
2. Compare Ki67 as an indicator of antigen-specific T cell proliferation 
with standard proliferation assays. 
3. Compare the functional profiles of Ki67 expressing T cells with other 
markers of proliferation. 















6.3. Materials and methods 
6.3.1. Study participants 
Healthy adult donors were recruited as described in chapter 2 (section 2.1.1.) 
Healthy, 18 month old toddlers were recruited at SATVI clinic sites in the 
Western Cape, South Africa, before, and 11-13 days after their routine 18 
month vaccination against TT. Enrolled toddlers had received all routine 
childhood vaccinations as set out by the WHO EPI. Heparinised venous blood 
from adults and toddlers was collected into BD Vacutainer CPT tubes (BD 
Biosciences) and immediately processed as outlined below. Blood was 
collected by qualified phlebotomists within the guidelines f written consent. 
 
6.3.2. Whole blood BrdU incorporation assay 
Whole blood (125µL diluted 1:10 in warm RPMI 1640) was incubated with 
antigens for 6 days at 37°C with 5% CO2. Antigens were used at the following 
final concentrations: 1 x 105cfu/mL Danish BCG (Danish strain 1331; Statens 
Serum Institut), 1µg/mL TB10.4 protein (kindly provided by Tom Ottenhoff, 
Leiden University, Leiden, Netherlands), 2µg/mL M.tb PPD (Statens Serum 
Institut) and 0.16IU TT (Tetavax, Sanofi Pasteur). On day 6 (day 3 for PHA), 
10µmol/L BrdU (Sigma-Aldrich) was added for the last 5 hours of culture. 
When intracellular cytokine expression was assessed, 10ng/mL phorbol 12-
myristate 13-acetate (PMA, Sigma-Aldrich), 1.5µg/mL ionomycin (Sigma-
Aldrich) and 1.5µg/mL Brefeldin A were also added during the last 5 hours of 
culture. Control antigens included 1µg/mL PHA (positive control, Sigma-
Aldrich), medium only (unstimulated, NIL, negative control) or, for intracellular 














were harvested with 2mM EDTA and red blood cells lysed. White cells were 
stained with a viability dye (ViViD, LIVE/DEAD Fixable Violet Dead Cell Stain 
Kit, Invitrogen), fixed in BD FACS lysing solution according to manufacturer’s 
instructions and cryopreserved until analysis. 
 
6.3.3. PBMC isolation and the OG assay 
PBMC were isolated by density gradient centrifugation and immediately 
stained with 10µg/mL of CellTrace Oregon Green 488 (Molecular Probes, 
Invitrogen) per 1X107 cells and rested overnight at 37oC, 5% CO2. Cells were 
either incubated with medium or stimulated with 1 x 105cfu/mL Danish BCG, 
0.5µg/mL PPD, 1µg/mL TB10.4 protein or 0.05µg/mL SEB (positive control, 
Sigma-Aldrich), for 6 days at 37oC with 5% CO2. On day 6 for some assays, 
PBMC were restimulated with 50ng/mL PMA, 250ng/mL ionomycin and 
10µg/mL Brefeldin A for a further 5 hours. Finally, PBMC were stained with 
ViViD, fixed with BD FACS lysing solution and cryopreserved until analysis. 
 
6.3.4. Antibodies  
The following monoclonal antibodies were used for kinetic analysis of Ki67 
expression by T cells:  
CD3-QDot 605, CD4-PerCP, Ki67-PE.  
 
The following monoclonal antibodies were used for phenotypic and/or 
intracellular cytokine staining:  
CD3-QDot 605, CD8-PerCP-Cy5.5, Ki67-PE, IFN-γ-Alexa Fluor 700, TNF-α-














All antibodies were obtained from BD Biosciences except for CD3-QDot 605, 
which was from Invitrogen.  
 
6.3.5. Data analysis 
Cell doublets were excluded using forward scatter-area versus forward 
scatter-height parameters. Live T cells were selected using a ViVid versus 
CD3 parameters. In some experiments CD4+ T cells were gated as CD3+ 
CD8- lymphocytes, because PMA and ionomycin stimulation strongly down-
regulates CD4 expression on T cells. Boolean gating analysis was carried out 
once positive gates were established for cytokine expression. Single-stained 
or unstained mouse κ beads were used to calculate compensations for every 
run. Data were analysed with FlowJo software v.8.8.6, Pestle v 1.6.2 and 
Spice v 4.3.2 software. Statistical analyses were calculated using GraphPad 
















6.4.1. Ki67 is a specific marker of in vitro lymphoproliferation 
Ki67 is expressed by all cells undergoing cycling (Lopez et al., 1991; 
Scholzen and Gerdes, 2000). To investigate the kinetics of Ki67 expression in 
T cells cultured over 6 days, whole blood was either cultured in the absence 
of antigen (unstimulated, NIL), or in the presence of PPD or anti-CD3 and 
anti-CD28 (αCD3/αCD28). Expression of Ki67 was quantified each day. Ki67 
expression was low in unstimulated CD4+ T cells on day 1 (24 hours, median, 
0.62%), and by day 6, had decreased to <0.1% of CD4+ T cells (median, 
0.08%, Figure 1A). PPD stimulation resulted in Ki67 expression levels above 
those in unstimulated cells between days 2 and 4; expression peaked on day 
6 (Figure 1A and B). High expression of Ki67 following polyclonal T cell 
stimulation with αCD3/αCD28; Ki67 responses were high on day 1 already, 
peaked on day 3, and declined thereafter (Figure 1A and C). 
Next, proliferation by Ki67 detection was assessed in whole blood from 15 
healthy donors, after 6-day culture with no antigen (unstimulated, NIL), or with 
PPD. All donors had undetectable or very low frequencies of Ki67+CD4+ T 
cells in unstimulated blood (median, 0.07%). PPD stimulation resulted in 
















Figure 1. Ki67 as a specific marker of in vitro lymphoproliferation. Whole blood 
from healthy donors was incubated with the indicated antigens and Ki67 expression 
quantified on a daily basis over 6 days. (A) Representative example showing the 
frequencies of Ki67 expression by CD4+ T cells after incubation of whole blood with 
medium only (NIL), PPD or αCD3/αCD28 over 6 days. Dotplots were gated on live, 
CD3+ CD4+ lymphocytes. Ki67+ CD4+ T cell frequencies after (B) PPD stimulation 
or (C) αCD3/αCD28 stimulation in 4 donors. Data are expressed as a percentage of 
the maximum response. The frequency of Ki67+CD4+ T cells is indicated in each 
plot. (D) Frequencies of Ki67 expressing CD4+ T cells in whole blood from 15 donors 
after 6-day culture with medium only (NIL) or PPD. (E) Frequencies of Ki67+CD4+ T 
cells in PBMC from 14 donors. Differences were calculated using the Wilcoxon 














Ki67 expression was also assessed in PBMC. Again, Ki67 expression 
identified in vitro CD4+ T cell proliferation; frequencies of Ki67+ cells after 
PPD stimulation consistently exceeded those in unstimulated PBMC, at a 
median of 21.7% (Figure 1E). 
These data suggest that in 6-day PBMC or whole blood culture with antigen, 
Ki67 expression is up-regulated in T cells undergoing in vitro proliferation. 
 
6.4.2. Comparison of Ki67 expression with BrdU and OG assays 
To determine how Ki67 performs in relation to traditional in vitro proliferation 
assays, detection of antigen-specific T cell proliferation by Ki67 expression in 
whole blood was compared with BrdU incorporation, and in PBMC with the 
dye dilution of OG (Figure 2). 
BrdU is typically added during the last 2 to 24 hours of a proliferation assay; in 
this study BrdU was added for the last 5 hours of the 6-day culture. This 
marker is thus only incorporated into cells undergoing DNA synthesis at this 
stage of the culture period. Compared with the frequency of BrdU+ cells the 
frequency of Ki67+CD4+ T cells was significantly higher after whole blood 
stimulation with PPD or TB10.4 protein (Figure 2A, B and C). Importantly, all 
BrdU+ cells co-expressed Ki67, while Ki67 consistently identified a prominent 
population of proliferating, but BrdU-negative CD4+ T cells. 
In contrast to BrdU, the OG and Ki67 assays yielded remarkably similar 
frequencies of proliferating, specific T cells; Ki67+ and OGlow CD4+ T cell 
frequencies were not significantly different in PPD or TB10.4-stimulated 















Figure 2. Comparison of the Ki67 proliferation assay with the BrdU and OG 
proliferation assays. (A) Representative dotplots showing Ki67 versus BrdU 
expression by CD4+ T cells in whole blood. Dotplots are gated on live, CD3+CD8- 
lymphocytes. Frequencies of (B) PPD- and (C) TB10.4-specific CD4+ T cell 
proliferation as detected by Ki67 expression or BrdU incorporation (n=15). CD4+ T 
cells are defined as CD3+CD8- T cells (see methods: Data analysis). (D) 
Representative dotplots showing Ki67 and dye dilution of OG by CD4+ T cells in 
PBMC. Dotplots are gated on live, CD3+CD8- lymphocytes. Frequencies of (E) PPD- 
and (F) TB10.4-specific CD4+ T cell proliferation as detected by Ki67 expression or 
dye dilution of OG (OGlow) in 14 donors. CD4+ T cells are defined as CD3+CD8- T 
cells (see methods: Data analysis). Differences were calculated using the Wilcoxon 















Frequencies of Ki67+CD4+ T cells correlated strongly with BrdU+CD4+ T cell 
frequencies (PPD: r = 0.8036, p=0.0003; TB10.4 protein: r=0.9308, p<0.0001) 
(Figure 3A and B). Similarly, a strong correlation was found between 
frequencies of antigen-specific Ki67+ and OGlow CD4+ T cells (PPD: 




Figure 3. Correlations between Ki67+CD4+ T cell expression and BrdU 
incorporation or dye dilution of OG (OGlow). Whole blood was incubated with (A) 
PPD or (C) TB10.4 for 6 days (n=15). PBMC were incubated with (B) PPD or (D) 
TB10.4 for 6 days (n=14). Correlations were calculated using a Spearman’s rank 
correlation coefficient. 
 
These data show that intracellular Ki67 expression allows quantitative 














proliferating T cells detected by Ki67 expression correlate strongly with 
frequencies detected with conventional proliferation assays. 
 
6.4.3. Cytokine expression profiles of proliferating CD4+ T cells 
The functional capacity of cells that have expanded during the 6-day culture 
can be assessed by short-term polyclonal re-stimulation with PMA and 
ionomycin on day 6. This allows detection of cytokine expression by 
intracellular cytokine staining. The expression of IFN-γ, IL-2 and TNF-α by 
Ki67+CD4+ T cells was compared with BrdU+ or OGlow CD4+ T cell 
populations. Similar expression of IFN-γ and TNF-α was observed in 
proliferating CD4+ T cell populations identified by BrdU and Ki67 (Figure 4A 
and B). However, expression of IL-2 was different amongst the distinct 
subsets. The highest proportion of IL-2 expressing cells was BrdU+, while 
CD4+ T cells positive for Ki67 only comprised the lowest proportion of IL-2 
expressing cells (Figure 4B). When comparing the cytokine profiles of Ki67+ 
and OGlow CD4+ T cells, very similar expression profiles of IFN-γ, IL-2 and 















Figure 4. Cytokine expression profiles of proliferating CD4+ T cells. Whole 
blood or PBMC were cultured for 6 days with no antigen (NIL) or PPD. On day 6, 
cells were restimulated with PMA and ionomycin for 4 hours in the presence of 
Brefeldin A to detect cytokine expression by proliferating T cells. Representative 
dotplots of the cytokine expression profiles of (A) Ki67+ or BrdU+ CD4+ T cells and 
(C) Ki67+ or OGlow CD4+ T cells. (B) Proportions of BrdU+, Ki67+ or Ki67+BrdU- 
CD4+ T cells expressing IFN-γ, IL-2 or TNF-α (n=15). (D) Proportions of Ki67+ or 















6.4.4. Intra-assay variability of Ki67 proliferation assay 
To test the reproducibility of the Ki67 proliferation assay, we performed 5 
proliferation assays per donor on whole blood from 3 healthy adult volunteers. 
Intra-assay CV values for PPD-specific Ki67+CD4+ T cells were ≤ 4,33% and 
for Ki67+CD8+ T cells ≤ 16,14%. Even lower CV values were observed for 
PHA-stimulated blood (Table 1). This indicates that the Ki67 prolieration 
assay is highly reproducible. 
 
Table 1. Intra-assay CV values for T cell frequencies of Ki67 expression after 
PPD or PHA stimulation. 
PPD stimulation  
 Donor 1 Donor 2 Donor 3 
subset Ki67+CD4+ Ki67+CD8+ Ki67+CD4+ Ki67+CD8+ Ki67+CD4+ Ki67+CD8+ 
Mean 66.2 10.31 79.82 8.3 62.79 3.03 
SD 1.88 1.66 1.46 0.86 1.33 0.34 
CV 2.84 16.14 1.83 10.42 2.12 11.17 
       
PHA stimulation 
 Donor 1 Donor 2 Donor 3 
subset Ki67+CD4+ Ki67+CD8+ Ki67+CD4+ Ki67+CD8+ Ki67+CD4+ Ki67+CD8+ 
Mean 94.5 91.26 94.7 91.7 76.65 74.54 
SD 0.87 1.14 0.81 1.11 3.32 2.4 
















6.4.5. Monitoring of vaccine-induced T cell proliferation 
It is well established that vaccination-induced T cell proliferation results in 
increased in vivo and, thus, ex vivo expression of Ki67 (Cellerai et al., 2007; 
Miller et al., 2008). To determine whether these “background” expression 
levels of Ki67 affect the specificity of detecting antigen-specific proliferation of 
T cells in vitro, 6-day antigen-specific T cell proliferation was assessed before 
and 11-13 days after TT vaccination of healthy, 18 month old toddlers. This 
post-vaccination time point was selected because it coincides with the peak 
TT-specific CD4+ T cell response in healthy adults (Cellerai et al., 2007). 
As expected, the frequency of in vitro proliferating, Ki67+CD4+ T cells 
observed pre-vaccination was low (median, 0.15%). After vaccination, TT-
specific CD4+ T cell proliferation increased significantly (median, 3.77%, 
Figure 5A and B). To control for possible non-specific up-regulation of Ki67 
after TT vaccination, we also quantified BCG-specific T cell proliferation pre- 
and post- vaccination. Frequencies of BCG-specific Ki67+CD4+ T cells before 
and after TT vaccination were not different (Figure 5A and C). We also 
compared the relative TT-induced increase in T cell proliferation between TT 
and BCG-specific Ki67+CD4+ T cells. TT vaccine boosting of TT-specific 
Ki67+CD4+ T cells was significantly higher than BCG-specific Ki67+CD4+ T 















Figure 5. Monitoring of vaccine-induced T cell proliferation. (A) Dotplots 
showing Ki67 expression by CD4+ T cells from a representative 18 month old toddler 
before (pre-TT) and after TT vaccination (post-TT). Dotplots are gated on live, CD3+ 
lymphocytes. Values in each dotplot represent the frequency of  Ki67+ T cells within 
the CD3+CD8- T cell population. Frequencies of (B) TT-specific and (C) BCG-
specific CD4+ T cells pre- and post-TT vaccination in  11 toddlers. CD4+ T cells are 
defined as CD3+CD8- T cells (see methods: Data analysis). (D) Relative increase in 
TT-specific or BCG-specific CD4+ T cells pre- and post-TT. The lines represent the 
medians. (E) Dotplots depicting frequencies of Ki67+CD4+ T cells in whole blood 
directly ex vivo or after culture in the absence of antigen (unstim.) for 6 days. Values 
in each dotplot represent the frequency of  Ki67+ T cells within the CD3+CD8- T cell 
population. (F) Frequencies of  Ki67+ CD4+ T cells directly ex vivo or after culture for 
6 days with medium (n=11). CD4+ T cells are defined as CD3+CD8- T cells (see 
methods: Data analysis). Differences were calculated using the Wilcoxon matched 














To further examine the effects of vaccination-induced T cell proliferation on 
the Ki67 proliferation assay, Ki67 expression was quantified directly ex vivo in 
whole blood from toddlers before and 11-13 days after TT-vaccination. High 
ex vivo frequencies of Ki67+CD4+ T cells were readily detected before and 
after vaccination in all toddlers (Figure 5E and F). Importantly, after 6 days of 
culture with no antigen, Ki67 expression decreased markedly in all toddlers to 
background levels (Figure 5E and F). 
These data show that in vivo T cell proliferation does not interfere with the 
specificity of the Ki67 proliferation assay. This assay therefore sensitively 















Proliferation is commonly measured as one of the critical indicators of T cell 
function. Intracellular Ki67 expression was assessed as a marker of in vitro 
proliferation in whole blood- or PBMC-based assays. This study shows that 
the Ki67 assay provides an alternative approach to measuring antigen-driven 
T cell proliferation, and compared this assay system to other proliferation 
assays currently in use.  
Monitoring vaccine-induced T cell proliferative potential is important for 
determining vaccine take, memory function and long-term persistence of 
vaccine-specific responses. Previous studies have quantified Ki67 expression 
directly ex vivo either as a measure of the vaccine-induced proliferative 
response (Miller et al., 2008), or in combination with markers of activation to 
identify antigen-specific T cells (Stubbe et al., 2006). To detect increases in 
Ki67, these studies relied on low-level Ki67 expression before vaccination in 
healthy adults. Ex vivo detection of specific Ki67 expression may thus be 
challenging in individuals with high levels of in vivo T cell proliferation such as 
those resulting from recent vaccinations or infections. We observed high ex 
vivo frequencies of Ki67+CD4+ T cells in toddlers, suggesting elevated levels 
of in vivo T cell turnover, which are likely driven by the high number and 
frequency of routine childhood vaccines given to toddlers. Culture of whole 
blood in the absence of antigen for 6 days reduced Ki67 expression to low 
levels, presumably due to cells reverting to a quiescent state during culture. 
Therefore, this assay proved to be sufficiently specific and sensitive for the 
identification of rare, antigen-specific T cells following vaccination in the 














The development of fluorescent dyes and tracking markers has enabled 
combined analysis of antigen-specific T cell proliferation, phenotyping and 
cytokine expression by flow cytometry (Johannisson and Festin, 1995; Mehta 
and Maino, 1997; Lyons and Doherty, 2004; Wallace et al., 2008). To date, 
whole blood BrdU and PBMC dye dilution assays have been the preferred 
flow cytometry based methods to assess lymphocyte proliferation.  
Ki67 expression identified approximately double the frequency of proliferating 
CD4+ T cells detected by BrdU incorporation. The classical BrdU assay 
involves addition of BrdU during the last 2 to 24 hours of cell culture. During 
this time BrdU, a synthetic thymidine analog, is incorporated into newly 
synthesised DNA of actively dividing cells in the S-phase (Gratzner, 1982; 
Dolbeare et al., 1983). Incubation of cells with BrdU is limited to 24 hours or 
less because incorporated BrdU inhibits cell cycle progression. Therefore a 
major limitation of this assay is that it only detects cells that have progressed 
through the S-phase during this short period of time on the last day of culture. 
By contrast, Ki67 is expressed by cells in all active phases of the cell cycle, 
including the S-phase. Therefore, Ki67 is a more sensitive marker for the 
detection of rare T cell responses and reflects the extent of in vitro antigen-
specific proliferation more accurately than BrdU incorporation.  
Higher proportions of IL-2 expressing BrdU+ CD4+ T cells were observed 
compared with IL-2 expressing Ki67+ CD4+ T cells. We propose that BrdU 
and Ki67 identify T cell populations in different states of cellular differentiation. 
CD4+ T cells that recently incorporated BrdU are actively dividing at the time 
of Brefeldin A-mediated cytokine accumulation and presumably express 














higher proportion of Ki67+CD4+ T cells may have completed multiple cell 
cycles and differentiated into an effector phenotype (Schwendemann et al., 
2005) characterized by low IL-2 expression (Sallusto et al., 1999; Harari et al., 
2005).  
Cellular proliferation in PBMC is routinely evaluated by dye dilution methods, 
such as CFSE or derivatives thereof, such as OG (Robinson and Amara, 
2005). The advantage of PBMC-based assays is the ability to perform the 
assay after PBMC cryopreservation, a practical strategy utilised in large-scale 
clinical settings. Limitations of many protein reactive dye compounds include 
cellular toxicity and sensitivity to pH and light (Wallace et al., 2008). The Ki67 
proliferation assay provides remarkably similar outcomes to the dye dilution 
assays, while it requires no incubation or washing steps prior to or during the 
culture and exposure of cells to toxic compounds is eliminated. Additionally, 
since labelling of cells before antigen stimulation is not required, detection of 
Ki67 by flow cytometry can be performed on antigen-stimulated cells after 
cryopreservation. 
A limitation of Ki67 as a proliferation marker is its inability to resolve the 
number of proliferation cycles that cells have undergone. Dye dilution assays 
allow enumeration of cell cycles because the mean fluorescence intensity of 
the dye is halved between daughter cells after each cell division (Parish, 
1999; Lyons and Doherty, 2004). Enumeration of cell cycles enables 
calculation of the original precursor frequency of specific cells, since the 
number of cells and their respective number of divisions are known (Givan et 
al., 1999). Since Ki67 expression does not allow differentiation of individual 














Overall, these data show that outcomes of the Ki67 assay correlate strongly 
with current flow based whole blood and PBMC proliferation assays. This 
assay is highly reproducible, versatile, and presents several practical 
advantages over current techniques. We propose Ki67 as a marker for 
quantifying antigen-specific T cell proliferation, and incorporating the Ki67 
assay as a practical tool for monitoring T cell responses in large field studies 
or pediatric studies based on limited blood volumes. This assay will be 
implemented in a future longitudinal study that aims to assess changes in 
BCG-specific T cell proliferative capacity and cytokine expression over the 
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Longitudinal changes in BCG-specific T cell cytotoxic 
molecule expression and differentiation phenotype over the 
first year of life. 
7.1. Introduction 
CTL contribute to mycobacteria-specific immunity through their capacity to 
recognise and kill M.tb infected target cells (Lalvani et al., 1998a; Stenger et 
al., 1998; Hussey et al., 2002; Stegelmann et al., 2005; Murray et al., 2006; 
Bastian et al., 2008; Klucar et al., 2008). Numerous in vitro studies have 
shown that CTL from healthy TST positive individuals and TB patients inhibit 
M.tb growth in vitro and lyse infected target cells (Tan et al., 1997; Lalvani et 
al., 1998a; Canaday et al., 2001; Stegelmann et al., 2005; Bastian et al., 
2008). Killing and inhibition of M.tb growth is mediated through cytotoxic 
effector molecules, such as granulysin and perforin, which are expressed by 
both CD4+ and CD8+ T cells (Stenger et al., 1998; Klucar et al., 2008; Bruns 
et al., 2009). Additionally, clinical data suggests that CTL may be critical for 
maintaining latency in M.tb infected individuals (Bruns et al., 2009).  
In vaccinated adults and infants, BCG-specific CTL up-regulate multiple 
cytotoxic effector molecules, degranulate (Smith et al., 1999; Murray et al., 
2006) and lyse M.tb infected cells (Hussey et al., 2002). Murray et al. 
demonstrated that BCG-specific CD8+ T cells from 10-week old vaccinated 
infants up-regulate granulysin, perforin and Grm. Granulysin, a saposin like 
lipid-binding protein, can directly trigger apoptosis and in combination with 
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correlates with CTL lytic capacity as is required for the optimal induction of 
perforin dependent apoptosis (Pardo et al., 2002; Harari et al., 2009). 
Therefore, the induction of CTL through BCG vaccination may provide an 
important component to vaccine induced host responses.  
All antigen-experienced CTL store cytotoxic effector molecules in cytoplasmic 
granules. Therefore, measuring up-regulation of cytotoxic molecules in 
antigen-specific T cells from pre-formed molecules by flow cytometry is 
challenging (Appay et al., 2002c; Harari et al., 2009; Makedonas et al., 2010). 
To overcome this limitation previous studies have combined CTL analysis with 
measurement of activation markers, tetramers or ICS to identify antigen-
specific up-regulation or de novo synthesis of cytotoxic molecules (Murray et 
al., 2006; Harari et al., 2009; Makedonas et al., 2010).  
Characterisation of T cells in different viral models has shown that the 
expression of cytotoxic effector molecules is closely related to cellular 
differentiation and maturity (Appay et al., 2002a; Marchant et al., 2003; Harari 
et al., 2009). In this chapter, CD27 and CD28 expression was analysed to 
monitor the differentiation of BCG-specific T cells over the first year of life and 
to assess the relationship between cytotoxic molecule expression and 
differentiation phenotype. As described in chapter 5, co-stimulatory molecules 
CD27 and CD28 identify functionally discordant T cell populations. T cells with 
proliferative capacity pre-dominantly have an early differentiation phenotype 
(CD27+CD28+) and express low levels of perforin (Appay et al., 2002a; 
Kovaiou et al., 2005). T cells expressing a late differentiation phenotype 
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cytotoxic molecules (Appay et al., 2002a; Appay et al., 2002c; Marchant et al., 
2003; Tomiyama et al., 2004).  
While cross-sectional studies have shown that BCG-vaccination of infants 
induces CTL (Hussey et al., 2002; Murray et al., 2006), longitudinal studies 
are needed to describe the kinetics of T cell responses following vaccination. 
This type of data is critical for evaluating novel TB vaccine candidates and for 
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The kinetics of BCG-specific T cell responses following vaccination of infants 
has not been studied. Infants are a likely target population for novel TB 
vaccines, which aim to boost BCG-specific T cell responses therefore this 
type of data is critical for determining when to boost BCG-induced responses. 
The objective of this study was to determine kinetic changes in the expression 
of cytotoxic effector molecules and differentiation stage of specific T cells 
following BCG vaccination. Ki67, a nuclear protein expressed during cell 
cycling, was used to detect BCG-specific cells following incubation of whole 
blood with BCG for 3 days, followed by measurement of BCG-specific 
induction of perforin, granulysin and GrmB in Ki67+ cells. Progressive loss of 
CD27 and CD28 was assessed as a proxy for T cell differentiation. To 
achieve the objective of this study, blood was collected from infants at multiple 
time points over a one year period and the following sub-aims were set: 
1. Characterise BCG-specific T cell cytotoxic molecule expression during 
the first year of life. 
2. Monitor differentiation markers within the total T cell compartment and 
for BCG-specific T cells. 
3. Assess the relationship between T cell differentiation stage and the 
expression of cytotoxic molecules. 











Chapter 7. Longitudinal changes in BCG-specific T cell cytotoxic molecule expression and 
differentiation phenotype over the first year of life. 
 
 154 
7.3. Materials and methods 
7.3.1. Study participants and recruitment 
The infants studied in this chapter were selected from the longitudinal cohort 
described in chapter 2. Infants were selected based on those with the most 
complete longitudinal data sets. Cross-sectional and longitudinal analyses 
were completed on samples from 68 infants selected from a cohort of 90. 
 
7.3.2. Cytotoxicity assay 
Whole blood was stimulated with antigens for 3 days as described previously 
in chapter 2 (section 2.3.2). 
 
7.3.3. Antibodies 
BCG-specific T cell cytotoxic molecule expression and differentiation 
phenotypes were assessed using the “Cytotoxicity Panel” optimised in chapter 
3 (section 3.4.8). 
 
7.3.4. Data analysis 
T cells were identified by a SSC vs. CD3 dotplot. Cell doublets were excluded 
using forward scatter-area versus forward scatter-height parameters. Dead 
cells and debris were excluded from analysis using a Ki67-PE vs. granulysin-
Alexa Fluor 488 dotplot. CD4+ and CD4- T cells were identified on a dotplot 
showing CD4 vs. Ki67. CD8+ T cells were selected out of the CD4- T cell 
population using a CD4 vs. GrmB dotplot. A skewed gate was used to select 
for CD8+ T cells due to data spread between the APC-H7 and Alexa Fluor 
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once positive gates were established for functional (Figure 1 Panel B-C) and 
phenotypic (Figure 1 Panel D) parameters.  
The expression of cytotoxic molecules and differentiation phenotypes are 
reported as a frequency of BCG-specific T cells, defined as Ki67+, and for the 
total T cell compartment (comprising Ki67+/- populations). Evaluation of Ki67 
as a marker of antigen-specific T cells after stimulation of whole blood with 
BCG is described in chapter 3 (section 3.4.7). T cell phenotyping and 
monitoring of qualitative changes over time (pie charts) was carried out on 
samples which had at least 50 Ki67+ events and in which the frequency of 
Ki67+ T cells after stimulation with BCG was at least three times above 
background Ki67 expression (NIL). Samples were excluded from analysis if 
the frequency of Ki67+ T cells after incubation with PHA was <3 median 
absolute deviations above median background (NIL) expression. Reported 
data have been corrected for background except for the phenotypic results. 
Single-stained mouse  beads were used to calculate compensations for 
every run. Data were analysed with FlowJo software v 9.0.1, Pestle v 1.6.2 
and Spice v 5.1 software. Statistical analyses were calculated using 
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Figure 1. Flow cytometric analysis of T cell cytotoxic molecule expression and 
differentiation phenotypes. (A) Gating strategy from a representative infant donor. 
Whole blood was incubated with BCG for 3 days and then stained for (B) Ki67, GrmB 
(C) granulysin, perforin and differentiation markers (D) CD27 and CD28. Boolean 
gates for each condition were determined using unstimulated (NIL) controls. The 
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7.4.1. Longitudinal changes in Ki67 expression in CD4+ and CD8+ T 
cells following BCG vaccination of newborns 
To determine the kinetics of BCG-specific T cell responses after vaccination, 
Ki67 expression was assessed cross-sectionally at multiple time points in 
CD4+ and CD8+ T cells from 3 weeks to 52 weeks of age, following 
incubation of whole blood with BCG for 3 days.  
The frequency of Ki67+ T cells 3 weeks after BCG vaccination was low for 
CD4+ (median, 1.619%; Figure 2A) and CD8+ T cells (median, 0.5681%; 
Figure 2B). At 6 weeks, a significant expansion of Ki67+CD4+ T cells was 
observed (median, 7.198%), this was followed by the gradual contraction in 
the frequency of Ki67+ T cells (Figure 2A). At 52 weeks, Ki67+CD4+ T cell 
frequencies were significantly lower compared to 3 weeks (median, 0.2380%).  
The kinetics of Ki67+CD8+ T cells was similar to that of Ki67+CD4+ T cells. 
Ki67+CD8+ T cell responses peaked 6 weeks after vaccination (median, 
0.8448%) and gradually waned with age (Figure 2B). At 6 weeks, the 
frequency of Ki67+CD8+ T cells was significantly higher compared to 52 
weeks (median, 0.1183%; Figure 2B). Overall, the magnitude of the 
Ki67+CD8+ T cell response was lower at all time points compared with 
Ki67+CD4+ T cell responses. Longitudinal data for individual infants 
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Figure 2. Changes in Ki67 expression in T cells over the first year of life. Cross-
sectional analysis of Ki67 expression in (A) CD4+ and (B) CD8+ T cells after 
stimulation of whole blood for 3 days with BCG. The horizontal line indicates the 
median and the whiskers the interquartile range. Differences were calculated using 
the Kruskal-Wallis test followed by a Mann Whitney U test. Longitudinal changes in 
Ki67 expression in (C) CD4+ and (D) CD8+ T cells for individual infants. Each line 
represents a different infant. Statistical analyses were not performed on these data. 




These data show that vaccination of infants with BCG predominantly drives 
the proliferation of CD4+ T cells and that T cell responses peak 6 weeks post 
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7.4.2. Functional characterisation of cytotoxic T cell responses 
following BCG vaccination 
To characterise T cell cytotoxic molecule expression after vaccination GrmB, 
perforin and granulysin expression by BCG-specific T cells were measured 
(Figure 3A and B). BCG-specific T cells were defined as Ki67+.  
 
 
Figure 3. T cells up-regulate Ki67 and cytotoxic molecules in response to BCG. 
Representative dotplots showing Ki67, GrmB, granulysin and perforin expression in 
(A) CD4+ and (B) CD8+ T cells. Whole blood was stimulated for 3 days with medium 
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Cross-sectional analysis showed that granulysin and GrmB expression by 
Ki67+CD4+ T cells was detectable at low levels as early as 3 weeks after 
vaccination (Figure 4A).  
 
 
Figure 4. Changes in BCG-specific T cell cytotoxic molecule expression. Kinetic 
changes in GrmB, granulysin and perforin expression in BCG-specific (A) CD4+ and 
(B) CD8+ T cells. Summary data are reported as a frequency of CD4+ and CD8+ T 
cells. The horizontal line indicates the median and the whiskers the interquartile 
range. Differences were calculated using the Kruskal-Wallis test followed by the 
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Perforin expressing Ki67+CD4+ T cells remained below the sensitivity level of 
the assay for most of the follow-up period. The frequencies of BCG-specific T 
cells expressing GrmB, perforin and granulysin peaked 6 weeks after 
vaccination and gradually waned over time. Only frequencies of Ki67+CD4+ T 
cells expressing GrmB were significantly higher at 6 weeks compared with 3 
weeks (Figure 4A). 
Ki67+CD8+ T cells displayed similar kinetics to Ki67+CD4+ T cells. 
Expression of cytotoxic molecules by specific cells peaked 6 weeks after BCG 
vaccination and gradually waned over time (Figure 4B). 
No significant changes in the frequency of BCG-specific CD8+ T cells 
expressing perforin, granulysin or GrmB were observed over time (Figure 
4B).   
GrmB expression at 6 weeks was significantly lower in Ki67+CD8+ T cells 
compared with Ki67+CD4+ T cells (p=0.223; Mann Whitney U test). BCG-
specific CD8+ T cells expressed significantly more perforin than specific 
CD4+ T cells from 27 to 52 weeks of age (27 weeks, p=0.0003; 40 weeks, 
p=0.0368; 52 weeks, p=0.0281; Mann Whitney U test).  
Longitudinal comparisons of cytotoxic profiles supported cross-sectional 
observations (Figure 5A and B), however changes in cytotoxic molecule 












Chapter 7. Longitudinal changes in BCG-specific T cell cytotoxic molecule expression and 




Figure 5. Longitudinal changes in BCG-specific T cell cytotoxic molecule 
expression. Longitudinal changes in GrmB, granulysin and perforin expression in 
BCG-specific (A) CD4+ and (B) CD8+ T cells for individual infants. Each line 
represents a different infant. Statistical analyses were not performed on these data. 




These data show that BCG vaccination up-regulates the expression of 
cytotoxic molecules in CD4+ and CD8+ T cells. BCG-specific cytotoxic T cell 
responses peak 6 weeks post-vaccination and gradually decline with age.  
 
7.4.3. Qualitative changes in BCG-specific T cell populations 
To determine changes in the qualitative nature of the BCG-specific T cell 
response, the proportions of Ki67+ T cells expressing cytotoxic molecules 
was monitored over time. Cross-sectional analysis showed that three weeks 
after vaccination approximately 20% of Ki67+CD4+ T cells expressed one 
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cells expressing GrmB only and co-expressing GrmB and granulysin gradually 
increased over time and by 52 weeks of age approximately 45% of 
Ki67+CD4+ T cells expressed cytotoxic molecules (Figure 6B). Ki67+CD4+ T 




Figure 6. Changes in the proportion of BCG-specific CD4+ T cells expressing 
cytotoxic molecules over time. (A) Representative flow cytometric plots show 
changes in GrmB, perforin and granulysin expression by BCG-specific CD4+ T cells 
over time. Ki67+ T cells (blue events) were overlaid onto a density plot (grey 
shading) of the total CD4+ T cell population. Frequencies within specific quadrants 
reflect expression of cytotoxic molecules as a percentage of Ki67+CD4+ T cells. (B) 
Pie charts representing the proportions of the total Ki67+CD4+ response expressing 
a given number of cytotoxic molecules. Responses are grouped and colour-coded 
according to the number of cytotoxic molecules expressed. The contribution of each 
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Overall, a greater proportion of Ki67+CD8+ T cells expressed cytotoxic 
molecules compared with CD4+Ki67+ T cells (Figure 7A and B).  
 
 
Figure 7. Changes in the proportion of BCG-specific CD8+ T cells expressing 
cytotoxic molecules over time. (A) Representative flow cytometric plots show 
changes in GrmB, perforin and granulysin expression by BCG-specific CD8+ T cells 
over time. Ki67+ T cells (blue events) were overlaid onto a density plot (grey 
shading) of the total CD8+ T cell population. Frequencies within specific quadrants 
reflect expression of cytotoxic molecules as a percentage of Ki67+CD8+ T cells. (B) 
Pie charts representing the proportions of the total Ki67+CD8+ response expressing 
a given number of cytotoxic molecules. Responses are grouped and colour-coded 
according to the number of cytotoxic molecules expressed. The contribution of each 
cytotoxic molecule to each pie slice is depicted by the outer, colour-coded arcs. 
 
At 3 weeks of age, approximately 70% of CD8+Ki67+ T cells expressed 
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cells dominating the response (Figure 7B). The proportion of Ki67+CD8+ T 
cells expressing 1+ or 2+ cytotoxic molecules increased with age. By 52 
weeks of age, approximately 50% of CD8+Ki67+ T cells expressed 2+ or 3+ 
cytotoxic molecules (Figure 7B). This was mainly attributable to an increase 
in Ki67+CD8+ T cell expression of perforin and granulysin over time. Perforin 
and granulysin was mostly co-expressed by CD8+ T cells expressing other 
cytotoxic molecules. Longitudinal data were consistent with results obtained 
by cross-sectional analysis (data no shown). 
These data show that the proportion of BCG-specific CD4+ and CD8+ T cells 
expressing cytotoxic molecules increases with age. Additionally, BCG-specific 
CD8+ T cells become progressively more polyfunctional (expressing multiple 
cytotoxic molecules) during the first year of life as they acquire the capacity to 
express granulysin and perforin. 
 
7.4.4. Differentiation of BCG-specific T cells over time 
To examine T cell maturation over time, surface expression of CD27 and 
CD28 was measured. The total CD4+ T cell population predominantly 
expressed both CD27 and CD28 (total CD4+ T cell population; 3 week 
median, 97.6%) and retained this phenotype throughout the follow-up period 
(52 week median, 95.9%; Figure 8A and B) The same phenotypic profile was 
observed for CD4+ T cells stimulated with medium only (NIL, data not shown). 
BCG-specific T cells were CD27+CD28+ 3 weeks after vaccination (median, 
81.9%; Figure 8A and C). The proportion of Ki67+CD4+ T cells expressing 
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median, 58.72%) and an increase in T cells expressing an intermediate 
phenotype (CD27-CD28+) was observed (Figure 8C).  
 
 
Figure 8. Changes in BCG-specific T cell differentiation phenotype over time. 
(A) Changes in the differentiation phenotypes of BCG-specific T cells (Ki67+, blue) 
based on CD27 and CD28 expression over time. Ki67+ T cells were overlaid onto a 
density plot of the total CD4+ T cell population (grey shading). Frequencies reflect 
the percentage of Ki67+CD4+ T cells within specific quadrants. Changes in 
differentiation phenotypes of (B) total CD4+ T cells and (C) Ki67+CD4+ T cells 
following stimulation of whole blood with BCG for 3 days. The horizontal line 
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At 3 weeks, total CD8+ T cells were CD27+CD28+ (3 week median, 97.6%) 
and the proportion of cells expressing this phenotype gradually decreased 
over time (Figure 9A and B).  
 
 
Figure 9. Changes in BCG-specific T cell differentiation phenotype over time. 
(A) Changes in the differentiation phenotypes of BCG-specific T cells (Ki67+, blue) 
based on CD27 and CD28 expression over time. Ki67+ T cells were overlaid onto a 
density plot of the total CD8+ T cell population (grey shading). Frequencies reflect 
the percentage of Ki67+CD8+ T cells within specific quadrants. Changes in 
differentiation phenotypes of (B) total CD8+ T cells and (C) Ki67+CD8+ T cells 
following stimulation of whole blood with BCG for 3 days. The horizontal line 
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A small population of CD8+ T cells expressed a CD27+CD28- or CD27-CD28- 
phenotype increased throughout the first year (Figure 9B).  
Changes in the differentiation phenotype of BCG-specific CD8+ T cells was 
similar to that observed for the total T cell compartment (Figure 9A and C). 
However, the increase in the proportion of cells expressing intermediate 
(CD27+CD28-, CD27-CD28+) and late (CD27-CD28-) differentiation 
phenotypes was more pronounced compared with the total CD8+ T cell 
compartment (Figure 9B and C). The increase in the proportion of 
Ki67+CD8+ T cells expressing more mature phenotypes was predominantly 
due to the gradually loss of CD28 expression. Longitudinal data were 
consistent with results obtained by cross-sectional analysis (data no shown). 
These data show that the proportion of BCG-specific CD4+ and CD8+ T cells 
expressing intermediate and late differentiation phenotypes progressively 
increase with age. 
 
7.4.5. Relationship between cytotoxic granule profiles and 
differentiation phenotype of BCG-specific T cells 
Having observed an increase in the proportion of BCG-specific T cells 
expressing cytotoxic molecules and changes in differentiation phenotype of 
these cells over time, we next examined the relationship between different 
cytotoxic profiles and differentiation phenotypes. The down-regulation of 
CD27 and CD28 is associated with acquisition of cytotoxic molecule 
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Figure 10. Loss of CD27 and CD28 and the acquisition of cytotoxic molecule 
expression. Representative dotplots showing the (A) loss of CD27 and acquisition of 
GrmB expression over time in CD4+ T cells (total CD4+ T cell compartment) and (B) 
the loss of CD28 and acquisition of granulysin expression in CD8+ T cells (total 
CD8+ T cell compartment). 
 
A weak positive correlation was observed between frequencies of BCG-
specific CD27-CD28+ cells and GrmB expressing CD4+ T cells (Figure 11A 
and Table 1). Perforin expressing CD4+ T cells were not analysed as 
expression levels for this molecule was low. The subset of CD4+ T cells 
expressing a late differentiation phenotype (CD27-CD28-) was small and 
therefore also not analysed.  
For BCG-specific CD8+ T cells, CD27+CD28- and CD27-CD28- T cell 
populations positively correlated with granulysin (Figure 11B and Table 2) 
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Figure 11. Correlations between BCG-specific (A) CD4+ and (B) CD8+ T cell 
subsets expressing cytotoxic molecules and an intermediate differentiation 
phenotype. Data included for analysis are from all time points. Correlations were 
calculated using a Spearman’s rank correlation co-efficient. 
 
An inverse relationship was found between the early differentiation stage 
CD27+CD28+ populations and GrmB and perforin expressing Ki67+CD4+ T 
cells (Table 1) and granulysin and perforin expressing Ki67+CD8+ T cells 
(Table 2). 
 
Table 1. Relationship between the proportions of BCG-specific CD4+ T cells 
expressing cytotoxic molecules and differentiation phenotype. 
 GrmB Granulysin 
 r p r p 
CD27+CD28+ -0.3474 <0.0001 -0.101 0.2625 
CD27-CD28+ 0.3604 < 0.0001 0.1264 0.1601 
CD27+CD28- -0.1095 0.2241 -0.15 0.095 
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Table 2. Relationship between the proportions of BCG-specific CD8+ T cells 
expressing cytotoxic molecules and differentiation phenotype. 
 GrmB Granulysin Perforin 
 r p r p r p 
CD27+CD28+ -0.1742 0.0638 -0.3201 0.0005 -0.3598 <0.0001 
CD27-CD28+ 0.07854 0.4062 0.05633 0.5517 0.05486 0.5621 
CD27-CD28- 0.1191 0.2069 0.2479 0.0078 0.3046 0.001 
CD27+CD28- 0.1146 0.2249 0.2539 0.0064 0.3156 0.0006 
A Spearman test was used to assess correlations. 
 
These data suggest that the differentiation of BCG-specific T cells into more 
mature phenotypes over time is associated with an increase in the capacity of 
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A number of novel TB vaccine candidates that have entered clinical trials are 
based on boosted BCG-primed T cell responses. Since infants are a likely 
target population for heterologous prime-boost regimens, determining the 
kinetics of T cell responses following BCG vaccination is critical for future 
vaccination strategies. In this study, the kinetics and magnitude of BCG-
specific T cell responses following vaccination of infants were monitored over 
the first year of life. BCG-specific expression of Ki67 and cytotoxic effector 
molecules, GrmB, perforin and granulysin by T cells peaked 6 weeks after 
vaccination. This observation is highly significant for the rational design and 
optimisation of heterologous prime boost regimens based on BCG-primed T 
cell responses. Highly activated effector T cells are more susceptible to 
activation induced cell death (AICD), compared with naïve or resting memory 
T cells (Lynch et al., 1995). Therefore, vaccine boosting of BCG-specific T cell 
responses during the peak effector phase may result in increased apoptosis 
of vaccine-specific cells. The data presented here suggest that BCG-specific 
responses should ideally be boosted after 14 weeks of age following the 
contraction of specific T cells. 
The number of detailed kinetic studies of mycobacteria-specific T cell 
responses following vaccination with BCG is limited and have predominantly 
been done in adults (McShane et al., 2004; Nabeshima et al., 2005). In these 
studies, T cell kinetic changes were monitored by measuring IFN-γ responses 
to M.tb PPD by ELISA or cultured ELISPOT. McShane et al. showed that 
antigen-specific IFN-γ secreting T cells peaked 4 weeks after BCG 
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8 weeks after BCG re-vaccination of tuberculin skin test negative health care 
workers. Unlike adult participants in these studies, the infants recruited into 
this study were mycobacterially naïve when immunised with BCG (Hussey et 
al., 2002). Since pre-existing immunity to mycobacteria modulates T cell 
responses to BCG (Fine, 1995; Black et al., 2002), the differences in peak 
responses between this study and those done in adults may be related to 
prior exposure to mycobacteria. Different assay systems and antigens used 
for re-stimulation may also contribute to the discrepancy between results.  
However, a common observation between all studies is that the peak BCG-
specific T cell response is delayed relative to that following vaccination with 
live viral vaccines (Miller et al., 2008). Murine TB a rosol models suggest that 
the late onset of mycobacteria-specific T cell responses is attributed to 
delayed transport of mycobacteria from the site of challenge to the site of T 
cell priming, the lymph nodes (Gallegos et al., 2008; Wolf et al., 2008). 
Delayed adaptive immunity is also evident in humans as measured by TST, 
which is only detectable 4 – 8 weeks after BCG vaccination of mycobacteria 
naïve individuals (Menzies, 2000).  
Multiple reports have demonstrated that CTL contribute to mycobacteria-
specific protective immunity through their capacity to recognise and kill 
infected target cells. BCG vaccination of infants induces CTL, which kill and 
lyse M.tb infected target cells (Hussey et al., 2002; Murray et al., 2006), 
however detailed characterisation of BCG-specific CTL has not been done.  
This study shows that BCG vaccination of infants up-regulates the expression 
of cytotoxic effector molecules in both CD4+ and CD8+ T cells. Previous 
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mycobacteria-specific antigens, to target and lyse M.tb infected cells (Bastian 
et al., 2008; Klucar et al., 2008). Bastian et al. showed that CD4+ T cells from 
BCG vaccinated (PPD+ESAT6-) and latently infected (PPD+ESAT6+) healthy 
adults respond to crude M.tb cell wall extract, which contains a broad 
spectrum of mycobacterial glyco-lipids and lipo-peptides (Bastian et al., 2008). 
When stimulated with a chloroform-methanol extract (CME) of M.tb, CD4+ T 
cells proliferated, expressed Th1 cytokines and up-regulated the expression 
of perforin, granulysin and GrmB. In addition, CME expanded CD4+ T cells 
recognised and killed M.tb infected macrophages. Klucar et al. generated 
CD4+ T cell clones specific for a single CFP-10 epitope from healthy PPD 
reactive donors and analysed anti-mycobacterial effector function. CFP-10 
epitope specific clones targeted H37Rv infected autologous dendritic cells. 
This was dependent on granlysin and perforin because neutralising these 
cytotoxic molecules partially inhibited killing capacity (Klucar et al., 2008). 
These in vitro studies demonstrate that CD4+ T cells from BCG vaccinated 
and M.tb infected individuals play a role in cytotoxic mediated killing of 
intracellular M.tb and that this mechanism is dependent on cytotoxic effector 
molecules such as granulysin and perforin. The increased incidence of latent 
TB reactivation, a major complication in individuals treated with anti-TNF 
therapy for inflammatory rheumatic diseases (Gardam et al., 2003), has also 
provided clinical data that supports the role of CTL in mediating control of M.tb 
infection. Bruns et al. demonstrated that lymphocyte expression of perforin 
and granulysin decreased significantly within two weeks of rheumatoid 
arthritis and ankylosing spondylitis patients starting anti-TNF therapy. 
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a loss of CD8+ TEMRA cells, which had the highest lysing capacity against M.tb 
infected monocytes. These data suggest that CTL play a role in maintaining 
latent infection in healthy M.tb infected individuals and that induction of CTL 
through vaccination contributes to protective immunity.   
Qualitative analysis of Ki67+ T cells revealed that the proportion of BCG-
specific T cells with the capacity to express cytotoxic effector molecules 
increases with age. Despite this, a large subset of BCG-specific CD4+ T cells 
did not express cytotoxic molecules throughout the follow-up period. This 
subset most likely represents a population of T cells that express Th1 
cytokines or effector/regulatory molecules not measured in this study. 
Although the majority of CD4+ T cells did not expr ss perforin, the proportion 
of CD8+ T cells expressing this cytolytic protein increased with age. It has 
previously been shown that the expression of perforin correlates directly with 
CTL lysing capacity (Harari et al., 2009). The secretion of serine proteases or 
granulysin together with perforin, which facilitates the delivery of these 
molecules into target cells, is required for maximum cytotoxic activity (Stenger 
et al., 1998; Shi et al., 2005). An important question that was not addressed in 
this study was whether BCG-specific CTL can degranulate and if the 
observed increase in cytotoxic molecule expression over time is associated 
with improved killing capacity.  
It is important to note that a novel mechanism of perforin-mediated killing 
independent of the granule exocytosis pathway was recently described 
(Makedonas et al., 2009). Makedonas et al. demonstrated that following 
degranulation, perforin is up-regulated in the absence of T cell proliferation 
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can be detected by using an antibody (δG9 clone) that detects both granule-
associated and granule-independent forms of perforin (Hersperger et al., 
2008). The antibody (B-D48 clone) used in this study only detects granule-
associated perforin and not newly synthesised perforin, which may define a 
novel correlate of cytotoxic capacity (Hersperger et al., 2008; Hersperger et 
al., 2010; Makedonas et al., 2010).  
Previous studies, which combined phenotypic classification of T cells with the 
analysis of cytotoxic molecule expression, have shown a relationship between 
expression of cytotoxic molecules and T cell differentiation. Expression of 
cytotoxic molecules was associated with T cells of a more mature phenotype, 
whereas naïve T cells did not express cytotoxic molecules (Kovaiou et al., 
2005; Chowdhury and Lieberman, 2008; Chattopadhyay et al., 2009). In 
agreement with previous studies, the expression of cytotoxic molecules in our 
study was associated with the loss of CD27 and CD28. Early after vaccination 
most BCG-specific T cells did not express cytotoxic effector molecules. 
Together these data imply that changes in cytotoxic expression profiles over 
time are related to a phenotypic shift from an early to a more mature 
differentiation stage.  
As discussed in chapter 5, differentiation of T cells is driven by numerous 
mechanisms including TCR triggering, co-stimulation, cytokine levels, 
homeostatic turnover and inflammation. Memory T cell populations specific to 
antigens that are efficiently cleared, such as influenza and TT, predominantly 
retain an early differentiation phenotype (Stubbe et al., 2008; Harari et al., 
2009). T cells specific to antigens that persist or to viruses that are poorly 
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differentiation) phenotype (Appay et al., 2002a; Marchant et al., 2003; Stubbe 
et al., 2008; Harari et al., 2009). The accumulation of highly differentiated 
CD4+ and CD8+ T cells within the total T cell compartment is also observed in 
infants infected with CMV compared to healthy controls (Marchant et al., 
2003; Miles et al., 2008). These data suggest that one of the main factors 
driving T cell differentiation is antigen persistence. Thus, the question arises 
whether the observation of BCG-specific T cells with a more differentiated 
phenotype is driven by continuous TCR triggering, either through the 
persistence of BCG or through exposure to cross-reactive environmental 
mycobacteria. This question is still difficult to address as all infants in South 
Africa are BCG vaccinated within 48 hours of birth. Therefore an unvaccinated 
control cohort in which environmental mycobacteria can be studied is not 
available. Interestingly, the accumulation of differentiated T cells was 
observed within the total CD8+ T cell compartment in addition to BCG–
specific T cells. This observation suggests that other factors such as 
homeostatic T cell turnover, inflammation, exposure to other vaccine or 
environmental antigens and age-associated accumulation of more 
differentiated CD8+ T cells contribute to this observation (Geginat et al., 2003; 
Schonland et al., 2003; Chiu et al., 2006; van Gent et al., 2009). 
Numerous studies have characterised the BCG-specific T cell response in 
humans, however this is the first comprehensive study monitoring quantitative 
and qualitative longitudinal changes following vaccination of infants. The 
results presented here provide novel insights into the kinetic of cytotoxic 
effector molecule expression and differentiation phenotypes of T cells 
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Chapter 8 
8.1. General discussion  
BCG is the most widely administered vaccine on the EPI schedule. Despite 
this, our knowledge of T cell responses induced after BCG vaccination of 
infants is limited. Since infants will be targets of novel TB vaccines a better 
understanding of the immune response induced by BCG is critical for 
developing novel strategies to improve vaccination against TB. Previous 
studies that have characterised BCG-specific T cell responses in infants have 
been limited, often because the methodologies employed did not allow for 
detailed characterisation of specific T cell responses. For example, the 
memory phenotype of BCG-specific Th1 cells was not known (Vekemans et 
al., 2001; Ota et al., 2002; Davids et al., 2006). The availability of new 
fluorescent dyes and development of PFC has facilitated detailed dissection 
of cell-mediated immunity induced through vaccination and infection (Harari et 
al., 2004; Harari et al., 2005; Beveridge et al., 2007; Precopio et al., 2007). 
Based on these studies it has become clear that previous methods used to 
assess T cell function have underestimated the complexity of antigen-specific 
responses. To characterise T cell responses following BCG vaccination in 
detail, we developed and optimised novel PFC reagent panels to address 
many gaps in our knowledge of T cell mediated immune responses. These 
included BCG-induced T cell cytokine and cytotoxic molecule expression, T 
cell memory phenotype and differentiation stage. These methodologies were 
also applied to characterising kinetics of specific T cell responses over the 
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As described in chapter 4, cross-sectional analysis of a 10-14 week old infant 
cohort showed that BCG vaccination induces distinct T cell subsets that co-
express Th1 cytokines in multiple combinations. This is an important finding 
because IFN-γ production is typically measure to diagnose latent infection via 
IFN-γ release assays (Mahomed et al., 2006; Janssens et al., 2007) or to 
describe human immune responses to novel TB vaccines (McShane et al., 
2004). Furthermore, previous studies have shown that polyfunctional T cells 
display enhanced effector functions and are associated with slow progression 
of disease or no progression in individuals with chronic viral infections (Betts 
et al., 2006; Kannanganat et al., 2007b). Despite these observations, recent 
studies in mice and humans have shown that the frequency of mycobacteria-
specific polyfunctional Th1 cells in peripheral blood does not correlate with 
protection against TB (Tchilian et al., 2009; Kagina et al., 2010). The findings 
in our study strongly support measurement of additional T cell cyokines and 
functions that may contribute to vaccine-mediated protection (Combadiere et 
al., 2004; Murray et al., 2006).  
In addition to Th1 cytokines, T cells with cytolytic capacity contribute to 
mycobacteria-specific protective immunity through their capacity to kill 
infected target cells and have been suggested to play a role in maintaining 
latent infection in healthy M.tb infected individuals (Andersson et al., 2007; 
Bruns et al., 2009). The data in chapter 7 confirm previous findings that BCG 
vaccination of infants induces CTL that have the capacity to up-regulate 
GrmB, granulysin and perforin. In addition, the proportion of BCG-specific T 
cells expressing cytotoxic molecules increased over time and this was 
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phenotype. These findings are consistent with previous reports showing that 
the expression of cytotoxic effector molecules positively correlates with 
cellular differentiation and maturity (Appay et al., 2002a; Marchant et al., 
2003; Chattopadhyay et al., 2009; Harari et al., 2009; Cellerai et al., 2010). An 
important question still to be addressed is whether BCG-specific CTL are 
functional and if the observed increase in cytotoxic molecule expression over 
time translates into improved killing capacity. As discussed in chapter 7, 
higher expression of perforin and GrmB correlates with the enhanced ability of 
virus-specific T cells to lyse infected target cells (Migueles et al., 2002; Harari 
et al., 2009; Hersperger et al., 2010).  
Based on the data discussed above we can conclude that BCG vaccination 
induces cytokines and cytotoxic molecules which have been shown to control 
M.tb, and are thus likely to contribute to protective efficacy of BCG observed 
during infancy. However, most adults vaccinated during infancy will not be 
protected against pulmonary TB suggesting that protection mediated by BCG-
specific memory T cells gradually wanes with age (Donald et al., 2010). The 
primary goal of vaccination is to induce long-lived antigen-specific T cells that 
respond rapidly upon pathogen re-encounter. Many factors influence the 
development of long-lived memory T cells, antigen load and duration of 
antigen exposure may be the most significant (Iezzi et al., 1998; Wherry et al., 
2004). The development and stability of long-lived memory T cell populations 
following transient antigen exposure has been clearly demonstrated in 
experimental models of infection and following immunisation of humans with 
live viral vaccines (Hammarlund et al., 2003; Wherry et al., 2003; Wherry et 
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Miller et al., 2008). Studies from three highly effective vaccines against 
tetanus, yellow fever and smallpox have shown that a stable long-lived 
memory T cell population may be established as early as 30 days after 
vaccination (Cellerai et al., 2007; Miller et al., 2008). The work completed in 
chapter 4 showing that BCG-specific T cells express a pre-dominantly TEM 
phenotype 10-14 weeks after vaccination suggests that antigen may persist. 
We hypothesise that mycobacteria-specific T cell responses measured at 10-
14 weeks of age are likely to be BCG-specific, because exposure to 
environmental mycobacteria is typically low before 10-14 weeks of age 
(Kagina et al., 2009). In mice, BCG induces a chronic infection that results in 
persistent immune activation (Dudani et al., 2002). Persistence of BCG in the 
murine host thus establishes a mycobacteria-specific CD4+ and CD8+ T cell 
response that expresses a predominantly TEM phenotype. Only a small 
proportion of specific cells express a TCM phenotype in this model (Dudani et 
al., 2002; Henao-Tamayo et al., 2010). Therefore, we propose that the low 
protective efficacy of BCG against pulmonary disease in adults may relate to 
diminished memory T cell quality and/or population size. Orme and 
colleagues have proposed that the primary TEM pool established following 
BCG vaccination is able to confer protection to the host for a few decades 
(Orme, 2010). However, age-related TEM attrition or exhaustion, driven by 
BCG persistence or through repeated exposure to cross-reactive 
mycobacteria, leads to a gradual decline in vaccine-mediated protection 
(Henao-Tamayo et al., 2010; Orme 2010). These effects are thought to be 
one of the contributing factors that result in ineffective immunity against M.tb 
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kinetic studies reported in chapter 7 support this “repeated antigen exposure” 
hypothesis. BCG-specific T cells clearly differentiated towards a more mature 
phenotype over the first year of life. This has important implications for prime-
boost strategies, because differentiation of TCM or TEM subsets are governed 
by antigen load and duration of antigen exposure (Masopust et al., 2006; 
Wirth et al., 2010). TCM are typically established following a brief period of 
antigenic stimulation during priming (Cellerai et al., 2007; Miller et al., 2008). 
By contrast, excessive antigenic stimulation favours commitment of TEM and 
impairs the development of long-lived memory cells (Champagne et al., 2001; 
Kaech et al. 2002; Wherry et al., 2004; Golden-Mason et al., 2006; Wherry et 
al., 2007; Lv et al., 2010). Whether the accumulation of differentiated T cells 
over the first year of life is driven by persistence of BCG or through cross-
reactive environmental mycobacteria is not known.  
Other mechanisms such as homeostatic proliferation and vaccine-induced or 
infection mediated inflammation are likely to contribute to the differentiation of 
T cells. The direct ex vivo studies of T cell differentiation in chapter 5 suggest 
that these mechanisms contribute substantially to the marked functional and 
phenotypic alterations of T cells over the first year of life. Direct ex vivo 
analysis of CD27 and CD28 expression revealed that after 6 weeks of age a 
large proportion of T cells in infants expressed a highly differentiated 
phenotype. The 6 EPI vaccines infants receive at 6 weeks is likely to 
contribute significantly to the dramatic shift in T cell differentiation phenotype 
at 10 weeks of age. These results contrast with a previous report showing that 
>80% of all CD4+ and CD8+ T cells retain CD27 expression during infancy 
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PBMC therefore differences between our study and van Gent et al. may be 
attributed to cryo-preservation of cells which modulates the expression of 
cellular surface markers (Costantini et al., 2003).  As shown in chapter 7, a 
large proportion of T cells re-express CD27 and CD28 after 3-days in culture. 
Re-expression of CD27 and CD28 was antigen-independent suggesting that 
in vitro conditions and manipulation of cells substantially influences 
expression of these molecules. Thus, the direct ex vivo analysis of fixed whole 
blood in our study is likely to be a more accurate representation of T cell 
phenotypes in vivo. 
Since the onset of mycobacteria-specific T cell responses following 
vaccination or infection is relatively delayed compared to live viral vaccines, 
the transition of TEM into TCM may occur after 10-14 weeks of age (Miller et al., 
2008; Wolf et al., 2008). Additional longitudinal studies are currently underway 
in our group to establish if and when a long-lived memory T cell pool is 
established following BCG vaccination. Whole blood samples from the same 
cohort were stimulated and cryo-preserved to assess changes in T cell 
proliferative capacity, cytokine expression and memory phenotype over the 
first year of life. The Ki67 assay described in chapter 6 was specifically 
optimised to assess longitudinal changes in T cell proliferation, a hallmark of 
memory T cells and mechanism of vaccine-mediated protection (Sallusto et 
al., 1999; Combadiere et al., 2004). Markers of activation and those 
associated with long-lived memory T cells will be analysed in whole blood 
following short-term stimulation with BCG and TT. In addition to the classical 
memory T cell markers, CCR7 and CD45RA, other markers associated with 
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rationale for this is based on the observation that CCR7 and CD45RA 
expression may not accurately define a true memory T cell population. For 
example, Cellerai and colleagues assessed CD45RA and CCR7 in addition to 
BCL-2 and CD127 following re-immunisation of adults with TT. Based on 
CD45RA and CCR7, 1-2 years after vaccination equal proportions of IL-2 
expressing TT-specific cells displayed TEM and TCM phenotypes whilst IFN-γ 
expressing cells predominantly displayed a TEM phenotype. By contrast, 
analysis of IL-2 and IFN-γ expressing T cells using BCL-2 and CD127 
revealed that all cytokine expressing TT-specific T cells displayed a long-lived 
memory phenotype, based on dual expression of BCL-2 and CD127 (Cellerai 
et al., 2007).  
Heterologous prime-boost vaccination regimens aim to boost the BCG-primed 
response with novel subunit vaccines. These approaches aim to enhance 
vaccine mediated protective efficacy. Boosting T cell responses during the 
effector phase of the vaccine response may lead to T cell exhaustion and 
death or may drive the generation of predominantly short-lived antigen-
specific effector cells. Expansion of a long-lived TCM population under 
conditions of excessive antigenic stimulation and inflammation is unlikely 
(Wherry 2003; Dey et al., 2009). Antigen-specific responses should ideally be 
boosted after a stable memory T cell population has been established 
(Wherry et al., 2004; Wrammert et al., 2009). In chapter 7, longitudinal 
analysis of the frequency of BCG-specific cells and cytotoxic molecule 
expression showed that the expansion and contraction of primary BCG-
specific T cell responses occurs within the first 3 months of life and that 
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TEM into TCM was not measured, the kinetic data discussed above suggest 
that we can reasonably conclude that BCG-specific responses could ideally 
be boosted with heterologous vaccines after 14 weeks of age, following the 
contraction phase (Figure 1). McShane and colleagues reported that the 
magnitude of the specific T cell response in adults is not influenced by the 
time interval between BCG-prime and MVA85A-boost (Pathan et al., 2007). 
Vaccine-specific responses were measured by IFN-γ ELISPOT only therefore, 
the effects of boosting BCG-primed responses at different intervals on the 
expression of other relevant cytokines and on differentiation of appropriate 
memory T cell subsets could not be determined.  
 
 
Figure 1. Proposed model describing specific T cell kinetics based on a BCG-
prime novel vaccine-boost strategy. 
 
A potential caveat in the interpretation of the BCG-speific kinetic data in our 
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3 days. In chapter 6, quantification of the kinetics of Ki67 expression following 
antigen-stimulation demonstrated that a small subset of T cells began to cycle 
and express Ki67 after 3 days. The observed T cell kinetics may be different if 
a different assay system, such as a short-term whole blood assay, was used. 
The kinetics of vaccine-specific T cell responses in adults have been 
previously measured by assessing markers of activation and Ki67 directly ex 
vivo (Cellerai et al., 2007; Miller et al., 2008), as shown in chapter 5. However, 
using a similar approach to monitor antigen-specific T cell responses in 
infants is challenging due to increased in vivo T cell turnover over the first 
year of life.  
Collectively, the data presented in this thesis serves as a basis for 
understanding the development of BCG-specific immunity in humans. These 
data provide a framework for optimising prime-boost vaccination strategies 
and are useful as a comparative model for assessing T cell responses 
following immunisation with novel TB vaccine candidates. Importantly, 
longitudinal changes in BCG-specific T cell differentiation phenotype suggest 
that low-level antigen exposure through persistence of BCG, or exposure to 
cross-reactive mycobacteria, results in continuous activation of specific T 
cells. This mimics chronic infection, which prevents the development of long-
lived memory T cells. These observations support the hypothesis recently 
proposed by Orme and colleagues, suggesting that BCG vaccination is a poor 
inducer of long-lived memory T cells (Henao-Tamayo et al., 2010; Orme, 
2010) and have important implications for optimising BCG-based vaccination 
strategies. A potential solution for this limitation would be to treat infants with 
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thus promoting the transition of TEM into long-lived TCM (Kamath et al., 2006). 
Colleagues from SATVI recently proposed a novel vaccination regimen based 
on priming with non-replicating viral-vectored or subunit vaccines and 
boosting with BCG at a later time point (Figure 2) (Hatherill et al., 2010).  
 
 
Figure 2. Proposed model describing specific T cell kinetics based on a novel 
TB vaccine-prime BCG-boost strategy. 
 
This approach represents a safer option for HIV infected infants who have an 
increased risk of developing BCG-disease and other complications following 
BCG vaccination (Hesseling et al., 2007). These vaccination strategies based 
on priming with a novel subunit vaccine confer a similar level of protection in 
experimental TB challenge models compared with BCG-prime heterologous 
boost (Skinner et al., 2005; Romano et al., 2006). This alternative approach 
not only represents a feasible strategy to circumvent complications arising 
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solution for the induction of long-lived mycobacteria-specific immunity 
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Appendix A  
Instrument configuration. Fluorochromes assigned to each laser line and PMT on the SATVI LSR II. Fluorochrome 
Maximum emission wavelengths of fluorochromes, filter and mirror combinations for each PMT. 
 
Laser excitation 
line (nm) Fluorochrome 
Maximum emission 
wavelength (nm) Detector Bandpass filter 
Dichroic longpass 
mirror 
488 (Blue) PE-Cy7 785 A 780/60 735 
 PerCP-Cy5.5 694 B 695/40 685 
 PerCP 675 C 670/14 635 
 Alexa 610 PE 628 D 610/20 600 
 PE 578 E 575/26 550 
 FITC 520 F 530/30 505 
 Alexa Fluor 488 520 F 530/30 505 
 SSC  G 488/10 Blank 













Appendix A (continued) 
Instrument configuration. Fluorochromes assigned to each laser line and PMT on the SATVI LSR II. Fluorochrome 
Maximum emission wavelengths of fluorochromes, filter and mirror combinations for each PMT. 
Laser excitation 
line (nm) Fluorochrome 
Maximum emission 
wavelength (nm) Detector Bandpass filter 
Dichroic longpass 
mirror 
633 (Red) APC-Cy7 767 A 780/60 735 
 Alexa Fluor 700 723 B 720/40 690 
 APC 660 C 660/20 Blank 
 Alexa Fluor 647 660 C 660/20 Blank 
405 (Violet) QDot 655 655 A 655/8 630 
 QDot 605 605 B 605/12 505 
 Amcyan 491 C 525/50 Blank 












Weeks Frequency Percentage Cumulative 
3 + 6 6 9.09 9.09 
3 + 10 16 24.24 33.33 
3 + 14 16 24.24 57.58 
6 + 10 6 9.09 66.67 
6 + 14 16 24.24 90.91 
10 + 14 6 9.09 100.00 
Total 66 100  
 
Weeks Frequency Percentage Cumulative 
27 + 40 22 33.33 33.33 
27 + 52 22 33.33 66.67 
40 + 52 22 33.33 100 












The following tables outline the random allocation of infant participants to specific bleeding schedules (time given in weeks) and 





















1 3 6 14 10 40 30 52 30 76 
2 3 6 10 6 40 30 52 30 72 
3 6 6 10 6 27 21 40 30 63 
4 3 6 10 6 27 21 40 30 63 
5 3 6 6 6 27 21 52 30 63 
6 3 6 10 6 40 30 52 30 72 
7 6 6 14 10 27 21 40 30 67 
8 3 6 10 6 27 21 52 30 63 
9 3 6 6 6 27 21 40 30 63 
10 3 6 10 6 40 30 52 30 72 
11 10 6 14 10 40 30 52 30 76 
12 3 6 14 10 27 21 52 30 67 
13 6 6 14 10 27 21 52 30 67 
14 6 6 14 10 27 21 40 30 67 
15 10 6 14 10 27 21 52 30 67 






























17 6 6 14 10 27 21 52 30 67 
18 3 6 14 10 40 30 52 30 76 
19 3 6 14 10 27 21 40 30 67 
20 6 6 14 10 27 21 52 30 67 
21 3 6 14 10 27 21 40 30 67 
22 6 6 14 10 27 21 52 30 67 
23 3 6 6 6 27 21 52 30 63 
24 6 6 14 10 40 30 52 30 76 
25 3 6 10 6 27 21 52 30 63 
26 3 6 14 10 40 30 52 30 76 
27 6 6 14 10 27 21 52 30 67 
28 6 6 10 6 27 21 52 30 63 
29 3 6 14 10 27 21 40 30 67 
30 3 6 10 6 27 21 40 30 63 
31 10 6 14 10 27 21 40 30 67 
32 3 6 10 6 40 30 52 30 72 
33 3 6 10 6 27 21 40 30 63 
34 6 6 14 10 27 21 52 30 67 
35 3 6 10 6 40 30 52 30 72 






























37 6 6 14 10 27 21 40 30 67 
38 3 6 6 6 27 21 40 30 63 
39 3 6 14 10 27 21 40 30 67 
40 10 6 14 10 40 30 52 30 76 
41 3 6 14 10 40 30 52 30 76 
42 6 6 10 6 27 21 52 30 63 
43 6 6 14 10 27 21 52 30 67 
44 6 6 14 10 40 30 52 30 76 
45 3 6 14 10 40 30 52 30 76 
46 3 6 10 6 27 21 52 30 63 
47 6 6 14 10 40 30 52 30 76 
48 3 6 10 6 40 30 52 30 72 
49 3 6 10 6 40 30 52 30 72 
50 6 6 10 6 40 30 52 30 72 
51 6 6 14 10 27 21 40 30 67 
52 6 6 14 10 27 21 40 30 67 
53 10 6 14 10 27 21 52 30 67 
54 3 6 14 10 27 21 40 30 67 
55 3 6 14 10 27 21 40 30 67 































58 3 6 14 10 27 21 52 30 67 
59 3 6 14 10 27 21 40 30 67 
60 6 6 14 10 27 21 52 30 67 
61 3 6 14 10 27 21 40 30 67 
62 6 6 10 6 40 30 52 30 72 
63 10 6 14 10 27 21 52 30 67 
64 3 6 14 10 27 21 40 30 67 
65 3 6 6 6 27 21 52 30 63 
66 6 6 10 6 27 21 40 30 63 
67 3 6 14 10 40 30 52 30 76 
68 3 6 10 6 40 30 52 30 72 
69 6 6 10 6 27 21 40 30 63 
70 3 6 10 6 27 21 40 30 63 
71 3 6 6 6 27 21 52 30 63 
72 3 6 10 6 40 30 52 30 72 
73 6 6 14 10 27 21 40 30 67 
74 3 6 10 6 27 21 52 30 63 
75 3 6 6 6 27 21 40 30 63 































78 3 6 10 6 27 21 52 30 63 
79 3 6 6 6 27 21 40 30 63 
80 3 6 10 6 40 30 52 30 72 
81 10 6 14 10 40 30 52 30 76 
82 3 6 14 10 27 21 52 30 67 
83 6 6 14 10 27 21 52 30 67 
84 6 6 14 10 27 21 40 30 67 
85 10 6 14 10 27 21 52 30 67 
86 3 6 10 6 40 30 52 30 72 
87 6 6 14 10 27 21 52 30 67 
88 3 6 14 10 40 30 52 30 76 
89 3 6 14 10 27 21 40 30 67 
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Bacillus Calmette-Guérin Vaccination of Human Newborns
Induces T Cells with Complex Cytokine and
Phenotypic Profiles1
Andreia P. Soares,* Thomas J. Scriba,* Sarah Joseph,* Ryhor Harbacheuski,†
Rose Ann Murray,† Sebastian J. Gelderbloem,* Anthony Hawkridge,* Gregory D. Hussey,*
Holden Maecker,‡ Gilla Kaplan,† and Willem A. Hanekom2*
The immune response to vaccination with bacillus Calmette-Guérin (BCG), the only tuberculosis vaccine available, has not been
fully characterized. We used multiparameter flow cytometry to examine specific T cell cytokine production and phenotypic
profiles in blood from 10-wk-old infants routinely vaccinated with BCG at birth. Ex vivo stimulation of whole blood with
BCG for 12 h induced expression of predominantly IFN-, IL-2, and TNF- in CD4 T cells in seven distinct cytokine
combinations. IL-4 and IL-10 expression was detected in CD4 T cells at low frequencies and only in cells that did not
coexpress type 1 cytokines. Specific CD8 T cells were less frequent than CD4 T cells and produced mainly IFN- and/or
IL-2 and less TNF-, IL-4, and IL-10. Importantly, many mycobacteria-specific CD4 and CD8 T cells did not produce
IFN-. The predominant phenotype of BCG-specific type 1 T cells was that of effector cells, i.e., CD45RACCR7CD27,
which may reflect persistence of Mycobacterium bovis BCG in infants until 10 wk of age. Among five phenotypic patterns of
CD4 T cells, central memory cells were more likely to be IL-2 and effector cells were more likely to be IFN-. We
concluded that neonatal vaccination with BCG induces T cells with a complex pattern of cytokine expression and phenotypes.
Measuring IFN- production alone underestimates the magnitude and complexity of the host cytokine response to BCG
vaccination and may not be an optimal readout in studies of BCG and novel tuberculosis vaccination. The Journal of
Immunology, 2008, 180: 3569 –3577.
N early one-third of the global population is latently in-fected with Mycobacterium tuberculosis and 2 millionpeople die of tuberculosis (TB)3 disease every year (Tu-
berculosis Fact Sheet, 2005, World Health Organization, Geneva,
Switzerland). Bacillus Calmette-Guérin (BCG), the only vaccine
against TB currently available, has variable efficacy in preventing
pulmonary disease (1), but 80% efficacy in preventing childhood
miliary disease and meningitis (2). Our knowledge of immunity
induced by BCG vaccination is incomplete, particularly after hu-
man newborn vaccination. However, infants will be targets of
novel, safer, and more efficacious TB vaccines in the future and a
better understanding of the immune response induced by newborn
BCG vaccination is likely to facilitate development of improved
vaccines.
Experimental evidence suggests that both CD4 and CD8 T
cells are important for protection against mycobacteria (3–6). In
humans, the role of CD4 T cells has been highlighted by a in-
creased risk of disease after infection with M. tuberculosis when
CD4 T cell numbers decline in HIV-infected persons (7). A pri-
mary function of both CD4 and CD8 T cells is to produce the
type 1 cytokine IFN-. The critical role of this cytokine has been
demonstrated by characteristic severe mycobacterial disease in pa-
tients with mutations of the IFN- receptor (8, 9). Other type 1
cytokines, such as TNF- and IL-2, may also be important in pro-
tection against TB: the role of TNF- has been underscored by
high rates of reactivation of latent TB following treatment of rheu-
matoid arthritis patients with specific inhibitors of this cytokine
(10, 11); T cell IL-2 expression has been associated with long-term
memory (12, 13), which is the aim of protective immunity. BCG
vaccination of human newborns does indeed induce specific CD4
and CD8 T cells capable of producing IFN- (14–16) Previous
studies have also shown that BCG vaccination of infants induces
TNF-, which is detectable in plasma by ELISA (17). However,
the pattern of production of all type 1 cytokines, on a single cell
basis, has not been delineated.
Our aim was to also describe expression of type 2 cytokines
such as IL-4, thought to reflect a suboptimal immune response to
mycobacteria (18, 19). Although BCG vaccination of infants has
been shown to induce low levels of type 2 cytokines (15, 16, 20),
the detection was in plasma, and cell-associated expression has not
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been reported. We also wished to assess T cell IL-10 expression,
since this cytokine is likely to be an important regulator of effector
T cell responses against TB (21) and is induced by newborn BCG
vaccination (15, 16, 22).
The memory phenotype of T cells induced by BCG vaccination
of newborns has not been described. Ag-experienced cells may be
categorized based on expression of surface markers (13, 23–26).
Central memory cells express CCR7 but not CD45RA and are
likely to represent a long-lived population, which expands rapidly
in lymph nodes following subsequent Ag encounter (23, 27). In
contrast, effector cells are both CCR7 and CD45RA and act
immediately following Ag exposure, but have limited proliferative
capacity (13, 23). A third subset, terminally differentiated memory
cells are CD45RA and CCR7 and the most differentiated sub-
population, based on short telomere length and function (26, 28).
Naive or non-Ag-experienced T cells characteristically express
both CD45RA and CCR7 (13, 26, 28). Combination of markers
other than CCR7 and CD45RA may also differentiate subsets of
Ag-experienced cells. Fritsch et al. (26) recently proposed the
phenotypic classification of CD4 T cell populations based on
expression of CD27 and CCR7. Central memory T cells were
defined as CD27 and CCR7, effectors as CD27 and
CCR7, and terminally differentiated T cells as CD27 and
CCR7. Our aim was to evaluate expression of all of these
markers among Ag-experienced T cells induced by BCG. Al-
though several investigators have characterized mycobacteria-
specific immune responses by four-color flow cytometry (29 –
31), these studies could only measure two cytokines or
phenotypic markers at a time and thus most likely underesti-
mated the complexity of the response.
Our hypothesis was that BCG vaccination of newborns would
induce both CD4 and CD8 T cells capable of producing mul-
tiple cytokines and that a central memory phenotype of specific
cells would be dominant 10 wk after vaccination. We used an
intracellular cytokine assay with multiparameter flow cytometry to
comprehensively characterize these variables. To achieve our
goals, we established clinical structures and optimized techniques
(32) to overcome hurdles common to investigation of immunity in
infants.
Materials and Methods
Study participants and blood collection
Healthy 10-wk-old infants, routinely vaccinated intradermally with BCG
(Statens Serum Institut, Copenhagen, Denmark) at birth, were enrolled in
the Cape Town region of South Africa. This area has a very high TB
disease incidence in children 5-year old and younger, exceeding 2% per
year in certain areas (32). Infants born to HIV-positive mothers, infants
known to be HIV positive, infants with suspected or confirmed TB disease,
infants with possible exposure to TB disease and infants with any other
active or chronic illnesses at the time of enrollment were excluded. Human
participation was according to the U.S. Department of Health and Human
Services and good clinical practice guidelines. This included protocol ap-
proval by the University of Cape Town Research Ethics Committee and
written informed consent. Sodium heparinized blood was collected from
each infant. Two different cohorts were enrolled to preserve blood volume
collected for assessment with two different flow cytometric protocols (see
below): 29 infants to assess cytokine expression of T cells and 27 infants
to assess the phenotype of IFN-- and IL-2-expressing T cells.
Ags and Abs
BCG was reconstituted from the vaccine vial (SSI) at 1.8  106 organ-
isms/ml as previously described (32). The positive control streptococcal
enterotoxin B (SEB; Sigma-Aldrich) was used at 10 g/ml. The costimu-
latory Abs anti-CD28 and anti-CD49d (both from BD Biosciences) were
each used at 1 g/ml. Cytokine profiles of BCG-specific T cells were
examined using the following conjugated Abs: anti-CD3 Amcyan (SK7)
and anti-IL-2 Alexa 610-PE (5344.111), both custom-conjugated at BD
Biosciences; and anti-CD4 Alexa Fluor 700 (RPAT4), anti-CD8 Cy5.5-
PerCP (SK1), anti-IL-4 FITC (MP4-25D2), anti-IFN- PE (25723.11), anti-
IL-10 allophycocyanin (JES3-19F1), and anti-TNF- Cy7-PE (MAb11),
all obtained from BD Biosciences. A separate protocol was used for as-
sessing T cell phenotypes using the following conjugated Abs: anti-CD3
PacBlu (UCHT1), anti-CD4 Cy5.5PerCP (SK3), anti-CD8 Cy5.5PerCP
(SK1), anti-CD45RA Cy7PE (L48), anti-CD27 PE (MT271), anti-IFN-
AlexaFluor 700 (B27) and anti-IL-2 FITC (5344.111), all obtained from
BD Biosciences, and anti-CCR7 allophycocyanin (150503), obtained from
R&D Systems.
Whole blood intracellular cytokine detection assay
To determine cell-associated cytokine production, 1 ml of heparinized
whole blood was incubated with BCG and anti-CD28 and anti-CD49d as
described before (32). Blood incubated with SEB and costimulants, or with
costimulatory Abs alone (UNS), served as positive and negative controls,
respectively. Brefeldin A (10 g/ml; Sigma-Aldrich) was added during the
last 5 h of incubation to capture cytokines intracellularly. After a total
FIGURE 1. Flow cytometric detection of
CD4 T cell cytokine expression in whole blood
incubated with BCG for 12 h from a single 10-
wk-old BCG-vaccinated infant. The cutoff gates
for cytokine expression were determined using
unstimulated T cells from whole blood incu-
bated with costimulants only (A). Cytokine ex-
pression in CD4 T cells from whole blood in-
cubated with BCG (B) and with SEB (C) is
shown. IL-2/TNF- subset gating was based on
patterns of cytokine expression in SEB-stimu-
lated whole blood. Dot plots are gated on CD3
CD4 T cells and are representative of 29
infants.
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incubation of 12 h, RBC were lysed and white blood cells were fixed with
FACS Lysing Solution (BD Biosciences), followed by cryopreservation.
Cell staining and flow cytometric analysis
To detect intracellular cytokines, cryopreserved cells were thawed, washed
in PBS, permeabilized with Perm/Wash solution (BD Biosciences), and
incubated at 4°C with fluorescence-conjugated Abs for 1 h. To assess T cell
memory phenotypes, a two-step staining method, resulting in optimal stain-
ing, was used: cells were thawed, washed in PBS, and permeabilized with
Perm/Wash solution and then incubated with surface marker Abs for 1 h at
4°C, followed by an additional hour with Abs specific for intracellular
cytokines. Flow cytometric acquisition was completed on a LSRII flow
cytometer (BD Biosciences) configured for 3 lasers and 12 detectors. All of the
cells in the tube were acquired. Analysis was performed using FACSDiva
software (BD Biosciences). Although automated compensation with mouse
IgG  beads was applied, compensation settings were assessed manually
after acquisition and adjusted if necessary. Multiparameter panel develop-
ment (data not shown) included evaluation of appropriate staining controls
of Ab and fluorochrome interactions and of spectral overlap using control
blood samples (33, 34).
Cutoffs to determine positive cytokine expression in CD4 and CD8 T
cells from blood incubated with BCG were set using cells from blood
incubated with costimulatory Abs alone (negative control) (Fig. 1A). An-
gled cutoff lines were necessary for some fluorochromes, because of data
spread at higher fluorescence intensities, following instrument compensa-
tion (e.g., Fig. 1). SEB was an excellent positive control for induction of all
cytokines, except IL-4. IL-4-expressing HICK-2 cells (BD Biosciences),
processed per the manufacturer’s protocol, were used as positive control
for IL-4. Where distinction between positive and negative surface marker
populations was not clear, isotype-matched control Ab staining was used to
set cutoffs for phenotypic markers.
Plasma cytokine detection
Plasma was collected from the stimulated whole blood after 7 h and cryo-
preserved. Later, thawed plasma was used to measure levels of IL-2, IL-4,
IL-10, and IFN- with multiplex beads according to the manufacturer’s
instructions (Bio-Rad) and read on a luminometer (Luminex). The range of
detection for all cytokines was 1.95–32,000 pg/ml. The optimal plasma
dilution for our assay, determined in pilot experiments, was 1/4. Back-
ground cytokine levels measured in plasma harvested from unstimulated
blood were subtracted from BCG-stimulated blood.
Statistical considerations
Negative control (background) values for cytokine expression were not
subtracted from BCG-induced responses, because the median backgrounds
for all CD4 T cell subsets was 0.001% (range, 0.000–0.01%) and for
CD8 T cell subsets was 0.000% (range, 0.000–0.01%). We used an em-
piric cutoff value of 0.01% as positive: given that a median of 508,509
CD4 T cells and 188,498 CD8 T cells was collected, this cutoff was
predicted to be 90% different from background, at an  of 0.05 (35). IL-4
and IL-10 expression was reported with backgrounds (see below). Non-
parametric tests were used to compare differences in cytokine expression
and phenotypic profiles between CD4 and CD8 T cells. Associations
between cellular expression of cytokines and plasma levels of these were
assessed by the nonparametric Spearman test. Data were considered sta-
tistically significant when p  0.05. Statistical analysis was performed
using GraphPad Prism 4 software.
FIGURE 2. Cytokine profiles of
BCG-specific T cells in 10-wk-old in-
fants vaccinated at birth. A, Fre-
quency of CD4 and of CD8 T cells
expressing individual type 1 cyto-
kines following incubation of blood
with BCG for 12 h in 29 infants. Re-
sponses above 0.01% were consid-
ered positive. The horizontal line in-
dicates the median and the whiskers
indicate the interquartile range. B,
Frequency of BCG-specific CD4 T
cells expressing different combina-
tions of type 1 cytokines. C, Fre-
quency of BCG-specific CD8 T
cells expressing different combina-
tions of type 1 cytokines. D, Repre-
sentative staining of intracellular type
1 cytokines in BCG-specific CD4 T
cells and CD8 T cells from a single
10-wk-old infant. Cutoff gates for cy-
tokine expression were determined
using unstimulated T cells from
whole blood incubated with costimu-
lants only. IL-2/TNF- subset gating
was based on patterns of cytokine ex-
pression in SEB-stimulated whole
blood. E, Comparison of frequency of
CD4 and of CD8 T cells express-
ing IFN- (dark bars) with frequency
of T cells expressing IL-2 and/or
TNF- without IFN- (light bars) in
29 BCG-vaccinated infants.
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BCG-specific CD4 and CD8 T cell type 1 cytokine
production
Intracellular expression of three type 1 cytokines thought to be
critical for protective immunity against mycobacteria, IFN-, IL-2
and TNF- (36, 37), was evaluated by incubating blood from 29
BCG-vaccinated infants with BCG for 12 h (Fig. 1). The me-
dian frequencies of CD4 T cells expressing either IFN- or
IL-2 or TNF- were similar (Fig. 2A). Lower frequencies of
CD8 T cells expressed IFN-, IL-2 ( p  0.05), or TNF-
( p  0.0001), compared with CD4 T cells (Fig. 2A). There
was a strong positive correlation between the frequencies of
IFN-- or IL-2- or TNF--expressing CD4 and CD8 T cells
(r  0.770, r  0.879, r  0.760, respectively, all p  0.0001,
Spearman test).
Analysis of simultaneous expression of IFN-, IL-2, and TNF-
on a single cell level revealed seven distinct type 1 cytokine-ex-
pressing CD4 T cell populations (Fig. 2B). Among CD8 T
cells, the dominant population expressed IFN- only; three
other populations were discernable (Fig. 2C). Importantly, a
substantial proportion of CD4 T cells expressing IL-2 and/or
TNF- did not coexpress IFN- (Fig. 2D). Similarly, among
CD8 T cells, a proportion of IL-2-expressing T cells also did
not coexpress IFN- (Fig. 2D). Total type 1 T cell responses
were dominated by IFN- expression; however, measuring
IFN- alone did not detect all type 1 cytokine-expressing T
cells (Fig. 2E).
All three type 1 cytokines could also be detected in plasma (data
not shown). There was a significant correlation between plasma
levels of IFN-, IL-2, and TNF- and frequencies of CD4 T cells
producing these cytokines (Table I). Plasma IFN- and IL-2 also
correlated with frequencies of CD8 T cells producing IFN- and
IL-2, respectively (Table I).
Taken together, we concluded that BCG vaccination of new-
borns induces multiple type 1 T cell subsets defined by expression
of distinct cytokine combinations.
BCG-specific IL-10 and type 2 cytokine production
The frequency of T cells expressing IL-10 or IL-4 following in-
cubation of whole blood with BCG was low (Fig. 3). Few donors
had responses above 0.01%, our cutoff for a positive response, but
IL-10 and IL-4 production was consistently above the background
expression levels found in blood not incubated with BCG (Fig. 3,
B and D). CD4 T cell expression of both cytokines was slightly
higher than that of CD8 T cells (CD4 T cell expression
shown in Fig. 3; CD8 T cells: median, 0.004%; range, 0.001–
0.024%, expressed IL-10 and median, 0.005%; range, 0.000 –
0.011%, expressed IL-4). IL-10 and IL-4 were never coex-
pressed by cells making type 1 cytokines (Fig. 3, A and C).
Intracellular IL-4 could be readily detected in HICK-2 cyto-
kine-expressing cells, which served as positive control (Fig.
3C). IL-4 and IL-10 were detected at low levels in plasma of
whole blood incubated with BCG (Fig. 4).
We concluded that BCG vaccination of newborns induces low
levels of IL-4 and IL-10 expression.
Phenotypic profiles of specific type 1 T cell subsets
Studies in other infectious disease models have shown that distinct
populations of Ag-experienced T cells may be associated with
long-lived protection (38). We therefore examined the phenotypic
FIGURE 3. Expression of IL-10 (A) and IL-4 (C) in CD4 T cells from
whole blood from a single, vaccinated infant incubated with costimulants
(UNS), BCG, or SEB. Frequency of CD4 T cells expressing IL-10 (B)
and IL-4 (D) following incubation of blood with costimulants only (light
bars) and BCG (dark bars) for 12 h in 29 infants.
Table I. Association between type 1 cytokine levels in plasma and
frequencies of CD4 or CD8 T cells expressing these cytokines after





r p r p
Plasma IFN- 0.6793 0.0001 0.6305 0.0004
Plasma IL-2 0.6441 0.0003 0.6013 0.0009
Plasma TNF- 0.4034 0.01 0.3187 0.1052
a A Spearman test was used to assess correlation in 29 infants.
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profiles of BCG-induced T cells. Specific CD4 T cells were de-
fined as either IFN-- or IL-2-expressing (Fig. 5, A–D); frequen-
cies of cells expressing other cytokines were too low to reliably
delineate the phenotype. Five major and distinct Ag-experienced
CD4 T cells subsets could be discerned, based on expression of
CD45RA, CCR7, and CD27 (Fig. 6, A–C). By far the most com-
mon phenotype of both IFN-- and IL-2-expressing CD4 T
cells was CD45RACCR7CD27 (Fig. 6A), a phenotype that
has been reported to be characteristic of effector T cells (13).
The second most common phenotype among IFN--expressing
CD4 T cells was CD45RACCR7CD27, also characteristic
of effector T cells (Fig. 6A). Among IL-2-expressing CD4 T
cells, the latter population was significantly less frequent (Fig.
6A), while central memory phenotypes were more common:
IL-2 cells were more likely to be CD45RACCR7CD27,
CD45RACCR7CD27, or CD45RACCR7CD27, com-
pared with IFN--expressing CD4 T cells (Fig. 6A). CD4 T
cells that expressed both IFN- and IL-2 were predominantly
effector memory cells (CD45RACCR7CD27 or CD45RA
CCR7CD27; Fig. 6B). As a comparison, the expression of
phenotypic markers among cytokine-negative CD4 T cells are
depicted in Fig. 6C.
Phenotypes of BCG-specific CD8 T cells could reliably be
detected only for IFN--producing cells, because the frequencies
of IL-2-producing CD8 T cells were too low. CD8IFN- T
cells also displayed a predominant CD45RACCR7CD27 ef-
fector phenotype (Fig. 6D). Unlike CD4IFN- T cells, a central
memory population (CD45RACCR7CD27) was the second
FIGURE 4. Levels of IL-4 and IL-10 in plasma from whole blood in-
cubated with BCG for 7 h. The horizontal line represents the median.
Background cytokine levels were subtracted.
FIGURE 5. Phenotype of BCG-
specific CD4 T cells in 10-wk-old
infants vaccinated at birth. Ag-spe-
cific CD4 T cells were identified by
expression of intracellular IFN- (A),
IL-2 (B), or both cytokines (C), and
the expression of CD45RA, CCR7,
and CD27 was determined in each
case. The plots illustrate the distribu-
tion of cytokine-expressing cells (in
color; foreground) in relation to the
entire CD4 T cell population (gray;
background, also shown in D).
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most common. The expression of phenotypic markers among cy-
tokine-negative CD8 T cells are depicted in Fig. 6E.
We concluded that the majority of specific T cells induced by
BCG vaccination of newborns has an effector phenotype and that
IL-2 expression is more likely to be associated with a central mem-
ory phenotype.
Discussion
We showed that BCG vaccination of human newborns induces a
diverse set of T cells, delineated by distinct cytokine production
and phenotypic profiles. BCG-specific T cells produced mainly
type 1 cytokines, as has been demonstrated before (14–16, 20, 22).
However, we showed that not only IFN- is produced. A consid-
erable number of IFN--negative CD4 T cells were present, ex-
pressing the other type 1 cytokines IL-2 and TNF-. Similarly,
many CD8 T cells produced IL-2 in the absence of IFN-. The
most commonly used measure of mycobacteria-induced immunity
today is IFN- production, be this to diagnose latent infection via
IFN- release assays (39, 40) or to describe human immune re-
sponses to novel TB vaccines (41). Recent experimental data sug-
gest that measuring IFN- may not correlate with vaccination-
induced protection against TB (42–44). This strongly supports
measurement of all three cytokines on a cellular level to delineate
a mycobacteria-specific type 1 response. This is further supported
by our observation that diversity in the T cell cytokine response
was predominant in our study population, e.g., in some infants
cells that produced one cytokine dominated, whereas in others
cells that produced three cytokines dominated. Measuring a single
component of the immune response may underestimate the mag-
nitude and complexity of BCG-induced immunity.
A BCG-induced CD8 T cell response was readily detectable,
as type 1 cytokine-producing cells. Murine studies suggest that
FIGURE 6. Frequency of different
subsets of BCG-specific CD4 T
cells, based on expression of
CD45RA, CCR7, and CD27 among
IFN- and IL-2 (A) and IFN-
IL-2 (B), expressing CD4 T
cells. C, Frequency of these cells
among cytokine-negative, i.e., mostly
mycobacteria-nonspecific, CD4 T
cells. D, Frequency of different sub-
sets of BCG-specific CD8 T cells
among IFN- expressing cells. E,
Frequency of these cells among my-
cobacteria-nonspecific CD8 T cells.
The horizontal line represents the me-
dian and the whiskers the interquartile
range. , p  0.05; ns, p  0.05.
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CD8 T cells play an important role in control of M. tuberculosis
infection and contribute substantially to total IFN- production (4).
Although a BCG-induced CD8 T cell response has been de-
scribed before (14, 45), we now show that the response is charac-
terized by both IFN--and IL-2-producing subsets. An interesting
observation was that CD8 T cells produced very little TNF-.
Smith et al. (45) detected similar frequencies of CD8 T cells
expressing TNF- and IFN- following incubation of PBMC with
BCG for 6 days. The contrasting low frequency of TNF- expres-
sion observed in our study could be due to differences in assays,
since we measured cytokine expression 12 h after incubation of
whole blood with BCG. In longer term assays such as those per-
formed by Smith et al. (45), TNF- production may be derived
from newly differentiated effector T cells, whereas our short-term
assay measures cytokine-producing potential directly ex vivo. Our
results also contrast with data from HIV-infected adults, whose
HIV-specific CD8 T cells readily express TNF- in short-term
intracellular cytokine assays (46, 47), implying that BCG-specific
CD8 T cells in newborns express little TNF-.
The memory phenotype of BCG-induced T cells has not been
reported. We identified five phenotypically distinct subsets within
BCG-specific type 1 T cells, based on expression of CD45RA,
CCR7, and CD27. The predominant phenotype of both IFN-- and
IL-2-expressing CD4 and CD8 T cells was CD45RACCR7
CD27. CCR7 effector cells are characteristic of persistent acti-
vation of T cells seen in chronic viral infections where Ag is not
cleared (48–50). Similarly, increased numbers of effector T cells
are observed in children with active TB (51). It is possible that M.
bovis BCG had persisted up to 10 wk of age, the time at which
blood was collected from infants, resulting in this predominant
phenotype.
Distinct differences in phenotypes were observed among CD4
IFN-- and IL-2-expressing cells. IL-2-expressing cells were sig-
nificantly more likely to have a central memory phenotype, e.g.,
CD45RACCR7CD27, compared with IFN--expressing cells.
IL-2-expressing T cells induced by BCG vaccination therefore fol-
lows patterns similar to those previously described for purified
human central memory populations, which are likely to express
IL-2 (13). However, our results, from 10 wk after vaccination with
BCG, contrast with results obtained 8 wk after vaccination with
tetanus toxoid; specific IL-2-expresing central memory cells were
present but in a relatively small population, whereas this popula-
tion was predominant after tetanus vaccination (52). Tetanus tox-
oid is not a persistent Ag; we therefore hypothesize that viable M.
bovis BCG persisted following vaccination, driving differentiation
predominantly into IFN--expressing effector cells and preventing
differentiation into IL-2-expressing central memory cells. An al-
ternate hypothesis is that continuous exposure to environmental
mycobacteria may contribute to chronic immune activation and
therefore a predominance of effector T cells. The infants in this
study were from a region with high rates of environmental myco-
bacteria and unpublished data suggest that exposure may occur
even within the first 10 wk of life. It has been proposed that ex-
posure to environmental mycobacterial Ags in tropical regions
may undermine protective immunity induced by BCG (53). A third
hypothesis is that the time point at which we measured the host
response was too early for full differentiation into the central mem-
ory phenotype. A central memory/IL-2 phenotype has been asso-
ciated with improved prognosis of chronic human viral infections
such as HIV (49) and in experimental settings of chronic intracel-
lular bacterial infection with long-lived protection (38). It remains
to be determined whether a central memory phenotype is also as-
sociated with successful vaccination against TB.
We found that a significant amount of specific CD4 and CD8
T cells had a phenotype traditionally regarded as naive, i.e.,
CD45RA and CCR7. In a recent study of children with TB,
Caccamo et al. (54) also described this population, identified as
specific by MHC class I pentamers of Ag-85A. We propose that
this CD45RACCR7 population reflects early differentiation
into Ag-specific cells, before loosing CD45RA expression.
We could detect very low intracellular expression of the type 2
cytokine IL-4 above background values. Expression of type 2 cy-
tokines has been associated with a suboptimal immune response to
mycobacteria (55). For example, Ordway et al. (56) showed that
long-term control of latent M. tuberculosis infection in humans
appeared to be associated with optimal type 1 cytokine production
and absence of detectable type 2 cytokine production. They
showed that high percentages of IL-4-expressing CD8 and  T
cells soon after M. tuberculosis infection were associated with ul-
timate development of TB disease. The IL-4-expressing cells were
detected after incubation of PBMC for 6 days, which contrasted
with our 12-h assay; longer term assays may be required to detect
these cells in the setting of BCG vaccination of the newborn. In-
tracellular expression of IL-10 could also be detected in our cohort,
was low, and, like IL-4 expression, was never coexpressed with
any type 1 cytokine. We propose that the IL-10-expressing T cells
were induced regulatory T cells, which are expected to be present
at low frequencies. Regulatory T cells control conventional effec-
tor immune responses, are induced by infections (57) and likely
also by vaccination with BCG.
Our results clearly demonstrate the advantages of complex mul-
tiparameter flow cytometric analysis for deciphering a vaccination-
induced immune response. However, this technology is not readily
available. It is therefore important to note, from our findings, that
when detection of IFN- or IL-2 is the aim and flow cytometry is
not available, plasma levels may serve as surrogates of T cell cy-
tokine production. We showed that plasma levels of type 1 cyto-
kines correlated strongly with intracellular expression despite the
fact that non-T cells also have the ability to make these cytokines
(58, 59). When only four-color flow cytometry is available, inclu-
sion of all three type 1 cytokines in one-color channel for detecting
the total type 1 response may be the most useful. This proposal is
supported by observations in HIV infection, where the presence of
“polyfunctional” CD8 T cell populations, i.e., HIV-specific
CD8 T cells that coexpress multiple cytokines, was associated
with better clinical outcome (46). The observation in a mouse
model of Leishmania major infection that polyfunctional T cell
induction is also associated with the best outcome (60) suggests
that measurement of these cells may also be important following
BCG vaccination, since the mechanisms of immune protection are
very similar for Leishmania and mycobacteria. Regardless, mea-
surement of all three type 1 cytokines in one color would still not
delineate the complexity of cytokine expression profiles. This may
be important, since other studies of HIV infection showed that IL-2
expression, rather than IFN- or dual expression, correlated with
the best clinical outcome (49). We therefore propose that delinea-
tion of multiple cytokine-expressing subsets, individually, will be
important to investigate protective immunity against TB, either
following natural infection or following vaccination.
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2001. Neonatal bacillus Calmette-Guérin vaccination induces adult-like IFN-
production by CD4 T lymphocytes. Eur. J. Immunol. 31: 1531–1535.
23. Sallusto, F., J. Geginat, and A. Lanzavecchia. 2004. Central memory and effector
memory T cell subsets: function, generation, and maintenance. Annu. Rev. Im-
munol. 22: 745–763.
24. Kaech, S. M., J. T. Tan, E. J. Wherry, B. T. Konieczny, C. D. Surh, and
R. Ahmed. 2003. Selective expression of the interleukin 7 receptor identifies
effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4:
1191–1198.
25. Song, K., R. L. Rabin, B. J. Hill, S. C. De Rosa, S. P. Perfetto, H. H. Zhang,
J. F. Foley, J. S. Reiner, J. Liu, J. J. Mattapallil, et al. 2005. Characterization of
subsets of CD4 memory T cells reveals early branched pathways of T cell
differentiation in humans. Proc. Natl. Acad. Sci. USA 102: 7916–7921.
26. Fritsch, R. D., X. Shen, G. P. Sims, K. S. Hathcock, R. J. Hodes, and P. E. Lipsky.
2005. Stepwise differentiation of CD4 memory T cells defined by expression of
CCR7 and CD27. J. Immunol. 175: 6489–6497.
27. Huster, K. M., M. Koffler, C. Stemberger, M. Schiemann, H. Wagner, and
D. H. Busch. 2006. Unidirectional development of CD8 central memory T cells
into protective Listeria-specific effector memory T cells. Eur. J. Immunol. 36:
1453–1464.
28. Geginat, J., A. Lanzavecchia, and F. Sallusto. 2003. Proliferation and differen-
tiation potential of human CD8 memory T-cell subsets in response to antigen or
homeostatic cytokines. Blood 101: 4260–4266.
29. Sester, M., U. Sester, P. Clauer, G. Heine, U. Mack, T. Moll, G. W. Sybrecht,
A. Lalvani, and H. Kohler. 2004. Tuberculin skin testing underestimates a high
prevalence of latent tuberculosis infection in hemodialysis patients. Kidney Int.
65: 1826–1834.
30. Hughes, A. J., P. Hutchinson, T. Gooding, N. J. Freezer, S. R. Holdsworth, and
P. D. Johnson. 2005. Diagnosis of Mycobacterium tuberculosis infection using
ESAT-6 and intracellular cytokine cytometry. Clin. Exp. Immunol. 142: 132–139.
31. Tesfa, L., F. W. Koch, W. Pankow, H. D. Volk, and F. Kern. 2004. Confirmation
of Mycobacterium tuberculosis infection by flow cytometry after ex vivo incu-
bation of peripheral blood T cells with an ESAT-6-derived peptide pool. Cytom-
etry B Clin. Cytom. 60: 47–53.
32. Hanekom, W. A., J. Hughes, M. Mavinkurve, M. Mendillo, M. Watkins,
H. Gamieldien, S. J. Gelderbloem, M. Sidibana, N. Mansoor, V. Davids, et al.
2004. Novel application of a whole blood intracellular cytokine detection assay
to quantitate specific T-cell frequency in field studies. J. Immunol. Methods 291:
185–195.
33. Maecker, H. T., T. Frey, L. E. Nomura, and J. Trotter. 2004. Selecting fluoro-
chrome conjugates for maximum sensitivity. Cytometry A 62: 169–173.
34. Perfetto, S. P., P. K. Chattopadhyay, and M. Roederer. 2004. Seventeen-colour
flow cytometry: unravelling the immune system. Nat. Rev. Immunol. 4: 648–655.
35. Motulsky, H. 1995. Choosing an appropriate sample size. In Intuitive Biostatis-
tics. Oxford Univ. Press, New York, pp. 199–200.
36. Flynn, J. L. 2004. Immunology of tuberculosis and implications in vaccine de-
velopment. Tuberculosis 84: 93–101.
37. Kaufmann, S. H. 2005. Recent findings in immunology give tuberculosis vac-
cines a new boost. Trends Immunol. 26: 660–667.
38. Zaph, C., J. Uzonna, S. M. Beverley, and P. Scott. 2004. Central memory T cells
mediate long-term immunity to Leishmania major in the absence of persistent
parasites. Nat. Med. 10: 1104–1110.
39. Mahomed, H., E. J. Hughes, T. Hawkridge, D. Minnies, E. Simon, F. Little,
W. A. Hanekom, L. Geiter, and G. D. Hussey. 2006. Comparison of mantoux skin
test with three generations of a whole blood IFN- assay for tuberculosis infec-
tion. Int. J. Tuberc. Lung Dis. 10: 310–316.
40. Janssens, J. P., P. Roux-Lombard, T. Perneger, M. Metzger, R. Vivien, and
T. Rochat. 2007. Quantitative scoring of a -interferon assay for differentiating
active from latent tuberculosis. Eur. Respir. J. 30 : 722–728.
41. McShane, H., A. A. Pathan, C. R. Sander, S. M. Keating, S. C. Gilbert,
K. Huygen, H. A. Fletcher, and A. V. Hill. 2004. Recombinant modified vaccinia
virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired
antimycobacterial immunity in humans. Nat. Med. 10: 1240–1244.
42. Hovav, A. H., J. Mullerad, L. Davidovitch, Y. Fishman, F. Bigi, A. Cataldi, and
H. Bercovier. 2003. The Mycobacterium tuberculosis recombinant 27-kilodalton
lipoprotein induces a strong Th1-type immune response deleterious to protection.
Infect. Immun. 71: 3146–3154.
43. Majlessi, L., M. Simsova, Z. Jarvis, P. Brodin, M. J. Rojas, C. Bauche, C. Nouze,
D. Ladant, S. T. Cole, P. Sebo, and C. Leclerc. 2006. An increase in antimyco-
bacterial Th1-cell responses by prime-boost protocols of immunization does not
enhance protection against tuberculosis. Infect. Immun. 74: 2128–2137.
44. Hope, J. C., M. L. Thom, B. Villarreal-Ramos, H. M. Vordermeier,
R. G. Hewinson, and C. J. Howard. 2005. Vaccination of neonatal calves with
Mycobacterium bovis BCG induces protection against intranasal challenge with
virulent M. bovis. Clin. Exp. Immunol. 139: 48–56.
45. Smith, S. M., A. S. Malin, P. T. Lukey, S. E. Atkinson, J. Content, K. Huygen,
and H. M. Dockrell. 1999. Characterization of human Mycobacterium bovis ba-
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e TAntigen-specific proliferation is a critical function of memory T cells that is often utilised tomeasure vaccine immunogenicity and T cell function. We proposed that measurement of
intracellular expression of the nuclear protein, Ki67, could reliably assess specific T cell
proliferation in vitro.
Ki67 was expressed in CD4+ and CD8+ T cells that had undergone in vitro proliferation after
6-day culture of human whole blood or PBMC with antigens. T cells cultured with no antigen
did not express Ki67. When compared to current flow cytometry based proliferation assays,
Ki67 detected proliferating cells with greater sensitivity than BrdU incorporation, whereas its
sensitivity was similar to dye dilution of Oregon Green (OG), a CFSE derivative. Overall, the
magnitude and cytokine expression profile of proliferating T cells detected by Ki67 expression
correlated strongly with T cells detected with BrdU or OG. The intra-assay variability of Ki67
proliferation was 2–3% for CD4+ T cells, and 10–16% for CD8+ T cells. Finally, we demonstrate
that the Ki67 assay detects tetanus toxoid-specific CD4+ T cell proliferation after infant
vaccination with tetanus toxoid (TT).
Overall our data suggest that intracellular Ki67 expression provides a specific, quantitative and
reproducible measure of antigen-specific T cell proliferation in vitro.







Proliferation and clonal expansion of antigen-specific T cells
are critical functions for mediating protective immunity and
immunological memory (Rosenberg et al., 1997; Combadiere
et al., 2004). Previously, the most widely used method forT, tetanus toxoid; OG,
n, Faculty of Health
rn Cape, South Africa.
Hanekom).
equally to this manu-
All rights reserved.detection of antigen-specific T cell proliferation has involved
incorporation of 3H-thymidine into DNA of dividing cells
(Payan et al., 1983; Marchant et al., 1999). This technique has
largely been replaced by flow cytometric assays of prolifera-
tion. Examples include fluorescent dye dilution assays, using
CFSE or its derivative, Oregon Green (OG) (Magg and Albert
2007; Wallace et al., 2008; MacMillan et al., 2009), and assays
that detect the DNA intercalating agent, 5-bromo-2′-deoxyur-
idine (BrdU), detected by fluorochrome-conjugated antibody
staining (Dolbeare et al., 1983; Houck and Loken 1985; Rosato
et al., 2001). The advantages of these assays are that they allow
co-stainingwith othermarkers, enabling delineation of cellular
sub-populations according to phenotype and functional char-
acteristics, such as cytokine production (Lyons, 2000; Bach-
mann et al., 2005; Precopio et al., 2007).
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Ki67 is a nuclear protein that plays a role in the regulation
of cell division. This marker has been used extensively in
cancer biology to indicate tumour cell proliferation (Gerdes,
1990; Scholzen and Gerdes, 2000). The protein is expressed
during all active phases of cell division, but is absent in
quiescent cells and during DNA repair (Gerdes et al., 1984).
Intracellular Ki67 expression directly ex vivo, or after in vitro
cell culture, has been used to measure specific T cell
responses induced by vaccination (Stubbe et al., 2006;
Cellerai et al., 2007; Miller et al., 2008), or turnover of these
cells in individuals with chronic viral infections, such as HIV
infection (Sachsenberg et al., 1998; Doisne et al., 2004).
In this study, we show that Ki67 expression in T cells is a
specific and quantitative indicator of proliferation, and that
results are comparable to those when proliferation is
measured by other methods. We also show that measure-
ment of Ki67 may be applied to longitudinal monitoring of
vaccine-specific T cell responses. Overall, the Ki67 assay offers
a reliable, versatile and simple method for detection of
antigen-specific T cell proliferation.
2. Materials and methods
2.1. Study subjects
Healthy adult donors were recruited at the Institute of
Infectious Disease and Molecular Medicine, University of
Cape Town. Healthy, 18 month old toddlers were recruited at
the South African Tuberculosis Vaccine Initiative clinic sites in
the Western Cape, South Africa, before, and 11–13 days after
their routine 18 month vaccination with TT. Enrolled toddlers
had received all routine childhood vaccinations as set out by
the WHO Expanded Programme on Immunisation. Hepar-
inised venous blood from adults and toddlers was collected
into BD Vacutainer CPT tubes (BD Biosciences) and immedi-
ately processed as outlined below. Participation of all
participants was in accordance with the Declaration of
Helsinki, the US Department of Health and Human Services
guidelines, and good clinical practice guidelines. This includ-
ed protocol approval by the Research Ethics Committee of the
University of Cape Town, and written informed consent by all
adults or parents of the toddlers.
2.2. Whole blood BrdU incorporation assay
Whole blood (125 μL diluted 1:10 in warm RPMI 1640)
was incubated with antigens for 6 days at 37 °C with 5% CO2.
Antigens were used at the following final concentrations:
1×105 cfu/mL Danish BCG (Danish strain 1331; Statens
Serum Institut), 1 μg/mL TB10.4 protein (kindly provided
by Tom Ottenhoff, Leiden University, Leiden, Netherlands),
2 μg/mL M. tuberculosis purified protein derivative (PPD,
Statens Serum Institut) and 0.16 IU TT (Tetavax, Sanofi
Pasteur). On day 6 (day 3 for PHA), 10 μmol/L BrdU (Sigma-
Aldrich) was added for the last 5 h of culture. When
intracellular cytokine expression was assessed, 10 ng/mL
phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich),
1.5 μg/mL ionomycin (Sigma-Aldrich) and 1.5 μg/mL Brefel-
din A (Sigma-Aldrich) were also added during the last 5 h of
culture. Control antigens included 1 μg/mL phytohaemagglu-




(unstim., negative control) or, for intracellular cytokine
assays, medium with PMA and ionomycin (unstim-PI). On
day 6, cells were harvested with 2 mM EDTA (Sigma-Aldrich)
and red blood cells lysed. White cells were stained with a
viability dye (LIVE/DEAD Fixable Violet Dead Cell Stain Kit,
Invitrogen), fixed in BD FACS Lysing Solution (BD Bios-
ciences) according to manufacturer's instructions and cryo-
preserved until analysis.
2.3. PBMC isolation and the OG assay
PBMC were isolated by density gradient centrifugation
and immediately stained with 10 μg/mL of CellTrace Oregon
Green 488 (Molecular Probes, Invitrogen) per 1×107
cells and rested overnight at 37 °C, 5% CO2. Cells were
either incubated with medium or 1×105 cfu/mL Danish
BCG, 0.5 μg/mL PPD, 1 μg/mL TB10.4 protein or 0.05 μg/mL
staphylococcal enterotoxin B (SEB, positive control, Sigma-
Aldrich), for 6 days at 37 °C with 5% CO2. On day 6 for
some assays, PBMC were restimulated with 50 ng/mL PMA,
250 ng/mL ionomycin and 10 μg/mL Brefeldin A for a further
5 h. Finally, PBMC were stained with LIVE/DEAD Fixable
Violet Dead Cell Stain, fixed with BD FACS Lysing Solution (BD
Biosciences) and cryopreserved until analysis.
2.4. Antibodies and flow cytometry
The following monoclonal antibodies were used for
phenotypic and/or intracellular cytokine staining: CD3-QDot
605 (UCHT1), CD4-PerCP (SK3), CD8-PerCP-Cy5.5 (SK1), Ki67-
PE (B56), IFN-γ-Alexa Fluor 700 (B27), TNF-α-PE-Cy7
(MAb11), IL-2-APC (MQ1-17H12), and anti-BrdU-FITC (B44).
All antibodies were from BD Biosciences except for CD3-QDot
605, which was from Invitrogen. Samples were acquired on a
BD LSRII flow cytometer (BD Biosciences, San Jose, CA).
2.5. Data analysis
Cell doublets were excluded using forward scatter-area
versus forward scatter-height parameters. Single-stained or
unstained mouse κ beads were used to calculate compensa-
tions for every run. In some experiments CD4+ T cells were
gated as CD3+ CD8− lymphocytes, because PMA and
ionomycin stimulation strongly down-regulates CD4 expres-
sion on T cells. Data were analysed with FlowJo software
v.8.8.6 (Treestar Inc.), Pestle v 1.6.2 and Spice v 4.3.2 software
(provided by M. Roederer, National Institutes of Health,
Bethesda, MD). Statistical analyses were calculated using
GraphPad Prism v 4.0.
3. Results
3.1. Ki67 is a specific marker of in vitro lymphoproliferation
Ki67 is expressed by all cells undergoing cycling (Lopez
et al., 1991; Scholzen and Gerdes, 2000). We investigated the
kinetics of Ki67 expression in T cells cultured over 6 days.
Whole blood was either cultured in the absence of antigen
(unstimulated), or in the presence of purified protein
derivative (PPD) or anti-CD3 and anti-CD28 (αCD3/αCD28).
Expression of Ki67 was quantified each day. Ki67 expression
45A. Soares et al. / Journal of Immunological Methods 362 (2010) 43–50was low in unstimulated CD4+T cells on day 1 (24 h,median,
0.62%), and by day 6, had decreased to b0.1% of CD4+ T cells
(median, 0.08%, Fig. 1A). PPD stimulation resulted in Ki67
expression levels above those in unstimulated cells between
days 2 and 4; expression peaked on day 6 (Fig. 1A and B). High
expression of Ki67 was observed following polyclonal T cell
stimulation with αCD3/αCD28; Ki67 was observed responses
were high on day 1 already, peaked on day 3, and declined
thereafter (Fig. 1A and C).
Next, we assessed proliferation by Ki67 detection in whole





Fig. 1. Ki67 as a specific marker of in vitro lymphoproliferation. Whole blood from he
quantified on a daily basis over 6 days. (A) Representative example showing the fre
with medium only (unstim.), PPD or αCD3/αCD28 over 6 days. Dotplots were gat
(B) PPD stimulation or (C) αCD3/αCD28 stimulation in 4 donors. Data are expressed
cells is indicated in each plot. (D) Frequencies of Ki67 expressing CD4+ T cells in wh
PPD. (E) Frequencies of Ki67+ CD4+ T cells in PBMC from 14 donors. Differences wantigen, or with PPD. All donors had undetectable or very low
frequencies of Ki67+ CD4+ T cells in unstimulated blood
(median, 0.07%). PPD stimulation resulted in higher frequen-
cies of Ki67+ CD4+ T cells in all donors (median, 46.1%,
Fig. 1D).
We also determined whether proliferation could be
detected by assessing Ki67 expression in PBMC. Again, Ki67
expression identified in vitro CD4+ T cell proliferation;
frequencies of Ki67+ cells after PPD stimulation consistently
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as a percentage of the maximum response. The frequency of Ki67+ CD4+ T
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Fig. 2. Comparison of the Ki67 proliferation assay with the BrdU and Oregon
Green proliferation assays. (A) Representative dotplots showing Ki67
versus BrdU expression by CD4+ T cells in whole blood. Dotplots are gated
on live, CD3+ CD8− lymphocytes. Frequencies of (B) PPD- and (C) TB10.4-
specific CD4+ T cell proliferation as detected by Ki67 expression or BrdU
incorporation (n=15). CD4+ T cells are defined as CD3+ CD8− T cells (see
Data analysis). (D) Representative dotplots showing Ki67 and dye dilution o
OregonGreenbyCD4+Tcells inPBMC.Dotplots are gatedon live, CD3+CD8−
lymphocytes. Frequencies of (E) PPD- and (F) TB10.4-specific CD4+ T cel
proliferation as detected by Ki67 expression or dye dilution of Oregon Green
(OGlow) in 14 donors. CD4+T cells are defined as CD3+CD8− T cells (seeData
analysis). Differences were calculated using the Wilcoxon matched pairs test.





These data suggest that in 6-day PBMC or whole blood
culture with antigen, Ki67 expression is up-regulated in T
cells undergoing in vitro proliferation.
3.2. Comparison of Ki67 expression with BrdU and Oregon
Green assays
Next, we compared our Ki67-based proliferation assay
with more traditional flow cytometric proliferation assays,
i.e., those measuring BrdU incorporation and dye dilution of
OG (Fig. 2).
BrdU is incorporated into cells undergoing DNA synthesis,
and is typically added during the last 2 to 24 h of a proliferation
assay; in this study we added BrdU for the last 5 h of the 6-day
culture. The frequency of Ki67+ CD4+ T cells was higher than
the frequency of BrdU+ cells after whole blood stimulation
with PPD or TB10.4 protein (Fig. 2A, B and C). Importantly, all
BrdU+ cells co-expressed Ki67 (Fig. 2A).
The OG assay requires uniform labelling of cells prior to
long-term culture. In contrast to results from the BrdU assay,
the OG and Ki67 assays yielded remarkably similar frequen-
cies of proliferating, specific T cells; Ki67+ and OGlow CD4+ T
cell frequencies were not different in PPD or TB10.4-
stimulated PBMC (Fig. 2D, E and F).
Frequencies of Ki67+CD4+T cells correlated stronglywith
BrdU+ CD4+ T cell frequencies (Fig. 3A and B). Similarly, a
strong correlation was found between frequencies of antigen-
specific Ki67+ and OGlow CD4+ T cells (Fig. 3C and D).
These data show that frequencies of proliferating T cells
detected by Ki67 expression agree with frequencies detected
with conventional proliferation assays.
3.3. Cytokine expression profiles of proliferating CD4+ T cells
The functional capacity of cells that have expanded during
the 6-day culture may be assessed by short-term polyclonal
re-stimulation with PMA and ionomycin on day 6. This
induces cytokine production, which can be measured by
intracellular staining. We compared expression of IFN-γ, IL-2
and TNF-α by Ki67+ CD4+ T cells with expression of these
cytokines in BrdU+ or OGlow CD4+ T cells. When Ki67
and BrdU assay results were compared, similar expression of
IFN-γ and TNF-α was observed in proliferating CD4+ T cells.
BrdU+CD4+T cells yielded higher proportions of IL-2+ cells
than Ki67+ CD4+ T cells but these differences were small
(Fig. 4A and B). Similar expression profiles of IFN-γ, IL-2 and
TNF-α were observed when comparing Ki67+ and OG
dilution (Fig. 4C and D).
3.4. Intra-assay variability of Ki67 proliferation assay
To test the reproducibility of theKi67proliferation assay,we
performed 5 proliferation assays per donor on whole blood
from 3 healthy adult volunteers. Intra-assay coefficient of
variation (CV) values for PPD-specificKi67+CD4+Tcellswere
between 2% and 3%, and for Ki67+ CD8+ T cells, which were
present at lower frequencies than Ki67+ CD4+ T cells,
between 10 and 16%. Even lower CV values were observed for
PHA-stimulated blood, which induced the highest frequencies
of Ki67+ T cells (Table 1). These results indicate that the Ki67
proliferation assay generates highly reproducible findings.f
l
3.5. Measurement of vaccination-induced T cell proliferation
To establish if Ki67 can be used to measure vaccine-
specific T cell proliferation, we determined Ki67 expression
in T cells before and 11–13 days after tetanus toxoid (TT) re-
immunisation of healthy, 18 month old infants. This post-
vaccination time point was selected because it coincides with
the peak TT-specific CD4+ T cell response in healthy adults
(Cellerai et al., 2007).
The frequency of proliferating, Ki67+ CD4+ T cells observed
pre-vaccination, following in vitro incubation of whole blood
with TT, was low (median, 0.15%). After vaccination, TT-specific
CD4+ T cell proliferation increased markedly (median, 3.77%,
of
Fig. 3. Correlations between Ki67+ CD4+ T cell expression and BrdU
incorporation or dye dilution of Oregon Green (OGlow). Whole blood was
incubated with (A) PPD or (C) TB10.4 for 6 days (n=15). PBMC were
incubated with (B) PPD or (D) TB10.4 for 6 days (n=14). Correlations were
calculated using a Spearman's rank correlation coefficient.




Fig. 5A and B). To control for possible non-specific up-regulation
of Ki67 after TT vaccination in vitro, we also quantified BCG-
specific T cell proliferation pre- and post-vaccination. Frequen-
ciesofBCG-specificKi67+CD4+Tcellswerenotdifferentbefore
and after TT vaccination (Fig. 5A, C and D).
It is well established that vaccination-induced T cell
proliferation results in increased in vivo and, thus, ex vivo
expression of Ki67 (Cellerai et al., 2007; Miller et al., 2008). To
determine whether “background” expression levels of Ki67,
reflecting in vivo T cell turnover, affected the detection of
antigen-specific T cell proliferation in vitro, we quantified
Ki67 expression directly ex vivo in whole blood from toddlers
before and 11–13 days after TT vaccination. High ex vivo
frequencies of Ki67+ CD4+ T cells were readily detected in
all toddlers before and after TT vaccination (Fig. 5E and F).
Importantly, after 6 days of culture in the absence of antigen,
Ki67 expression decreased markedly to background levels
(Fig. 5E and F).
These data suggest that in vivo T cell turnover does not
interfere with the specificity of the Ki67 proliferation assay.
This assay is therefore specific for the detection of antigen-
specific T cell proliferation in vitro.4. Discussion
Proliferation is a commonly measured indicator of T cell
function. We assessed intracellular Ki67 expression as a
marker of in vitro proliferation in whole blood or PBMC-based
assays. We show that the Ki67 assay provides an alternative
approach to measuring antigen-driven T cell proliferation,
and found that results obtained were very similar to those





The development of fluorescent dyes and tracking markers
has enabled combined analysis of antigen-specific T cell
proliferation, phenotyping and cytokine expression by flow
cytometry (Johannisson and Festin, 1995; Mehta and Maino,
1997; Lyons and Doherty, 2004; Wallace et al., 2008). To date,
whole blood BrdU and PBMC dye dilution assays have been the
preferred flow cytometry based methods to assess lymphocyte
proliferation. In comparison, Ki67 expression identified ap-
proximately double the frequency of proliferating CD4+T cells
detected byBrdU incorporation. Incubationof cellswith BrdU is
limited to 24 h or less because incorporated BrdU inhibits cell
cycle progression. Therefore a major limitation of the BrdU
assay is that only cells that have progressed through the S-
phase during this short incubation period may be detected. In
contrast, cells express Ki67 in all active phases of the cell cycle.
Therefore, Ki67 appears to be a more sensitive marker for the
detection of rare T cell responses, and may reflect the extent of
in vitro antigen-specific proliferation more accurately than
BrdU incorporation.
Cellular proliferation in PBMC samples is routinely evaluat-
ed by dye dilution methods, using CFSE or derivatives such as
OG (Robinson and Amara, 2005). A recent non-human primate
studyhas proposedmeasurementof in vitroproliferationby the
combined analysis of Ki67 and side scatter properties of cells
(Shedlock et al., 2010). The authors demonstrate a correlation
between this assay and theCFSE dilution assay. In this study,we
show that the proliferation events detected by loss of OG dye
are virtually identical to the Ki67+ events. From this we
reasoned that Ki67 expression is an accurate measure of T cell
proliferation as only cells that have completed cycling display a
decrease in OG fluorescence intensity. Limitations of many
protein reactive dye compounds include cellular toxicity
(Last'ovicka et al., 2009; Shedlock et al., 2010) and sensitivity
to pH and light (Wallace et al., 2008). The Ki67 proliferation
assay requires no incubation orwashing stepsprior to or during
the culture, and exposure of cells to toxic compounds is
eliminated. Additionally, since labelling of cells is not required
before antigen stimulation, detection of Ki67 byflowcytometry
can be performed on antigen-stimulated cells after cryopres-
ervation. A limitation of Ki67 as a proliferation marker is its
inability to resolve the number of proliferation cycles that cells
have undergone, as can be done with dye dilution assays
(Parish, 1999; Lyons and Doherty, 2004). Enumeration of cell
cycles enables calculation of the original precursor frequency of
specific cells, since the number of cells and their respective
number of divisions are known (Givan et al., 1999).
Monitoring vaccine-induced T cell proliferative potential is
important for determining vaccine take, memory function and
long-term persistence of vaccine-specific responses. Previous
studies have quantified Ki67 expression directly ex vivo as a
measure of the vaccine-induced proliferative response (Miller
et al., 2008), or in combination with activation markers to
identify antigen-specific T cells (Stubbe et al., 2006). To detect
increases in the expression of Ki67, these studies relied on low-
level Ki67 expression before vaccination in healthy adults.
Direct ex vivodetection of antigen-specific Ki67 expressionmay
thus be challenging in individuals with high levels of in vivo T
cell proliferation — such as those resulting from recent
vaccinations or infections. We observed high ex vivo frequen-
cies of Ki67+ CD4+ T cells in toddlers, suggesting elevated










Fig. 4. Cytokine expression profiles of proliferating CD4+ T cells. Whole blood or PBMC were cultured for 6 days with no antigen or PPD. On day 6, cells were
restimulated with PMA and ionomycin for 4 h in the presence of Brefeldin A to detect cytokine expression by proliferating T cells. Representative dotplots of
the cytokine expression profiles of (A) Ki67+ or BrdU+ CD4+ T cells and (C) Ki67+ or OGlow CD4+ T cells. (B) Proportions of BrdU+, Ki67+ or Ki67+ BrdU−
CD4+ T cells expressing IFN-γ, IL-2 or TNF-α (n=15). (D) Proportions of Ki67+ or OGlow CD4+ T cells expressing IFN-γ, IL-2 or TNF-α (n=14).
48 A. Soares et al. / Journal of Immunological Methods 362 (2010) 43–50driven by routine childhood vaccinations and exposure to
infections, common in this age group. Whole blood cultured in
the absence of antigen reduced Ki67 expression to barelyTable 1
Intra-assay CV values for T cell frequencies of Ki67 expression after PPD or PHA sti
Subset Donor 1 Donor 2
Ki67+ CD4+ Ki67+ CD8+ Ki67+ CD4+
PPD stimulation
Mean 66.2 10.31 79.82
SD 1.88 1.66 1.46
CV 2.84 16.14 1.83
PHA stimulation
Mean 94.5 91.26 94.7
SD 0.87 1.14 0.81
CV 0.92 1.25 0.86detectable levels byday6, presumably due to cells reverting to a
quiescent state. Therefore, this 6-day assay proved to be
sufficiently specific and sensitive for the identification of rare,mulation.
Donor 3
















Fig. 5.Monitoring of vaccine-induced T cell proliferation. (A) Dotplots showing Ki67 expression by CD4+ T cells from a representative 18 month old toddler before
(pre-TT) and after TT vaccination (post-TT). Dotplots are gated on live, CD3+ lymphocytes. Values in each dotplot represent the frequency of Ki67+ T cells within
the CD3+ CD8− T cell population. Frequencies of (B) TT-specific and (C) BCG-specific CD4+ T cells pre- and post-TT vaccination in 11 toddlers. CD4+ T cells are
defined as CD3+ CD8− T cells (see Data analysis). (D) Relative increase in TT-specific or BCG-specific CD4+ T cells pre- and post-TT. The lines represent the
medians. (E) Dotplots depicting frequencies of Ki67+ CD4+ T cells in whole blood directly ex vivo or after culture in the absence of antigen (unstim.) for 6 days.
Values in each dotplot represent the frequency of Ki67+ T cells within the CD3+ CD8− T cell population. (F) Frequencies of Ki67+ CD4+ T cells directly ex vivo or
after culture for 6 days with medium (n=11). CD4+ T cells are defined as CD3+ CD8− T cells (see Data analysis). Differences were calculated using theWilcoxon
matched pairs test.
49A. Soares et al. / Journal of Immunological Methods 362 (2010) 43–50antigen-specific T cells following vaccination in the context of
high ex vivo frequencies of Ki67+ T cells.
Overall, our data show that outcomes of the Ki67 assay
correlate strongly with current flow cytometry based whole
blood and PBMC proliferation assays. This assay is highly
reproducible, versatile, and presents several practical
advantages over current techniques. We propose Ki67 as a
marker for quantifying antigen-specific T cell proliferation,and utilising this assay to monitor T cell responses in large
field studies or paediatric studies based on limited blood
volumes.
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